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ABSTRACT 
Introduction:  
Obesity has been suggested to be one of the risk factors for erectile dysfunction 
(ED) and lower urinary tract symptoms (LUTS). Bariatric surgery has been used 
for the treatment of obesity and has been suggested to have a significant 
impact on obesity-related conditions such as diabetes mellitus, ED and LUTS. 
Previous studies have investigated the effect of bariatric surgery on erectile and 
urological function in obese men; however those studies used long-term time 
points post-operatively (more than 1 month). Since it is now known that bariatric 
surgery can potentially induce glycaemic improvement within one week 
independent of weight loss, this study aimed to investigate the short-term effect 
in order to test the hypothesis as to whether improvement in urogenital function 
after bariatric surgery is due to weight loss or whether it is due to glycaemic 
improvement.  
Aim:  
To evaluate the baseline characteristics of patients with erectile dysfunction and 
to determine the early effects of bariatric surgery on erectile and urological 
function in morbidly obese men. 
Method:  
This was a prospective study investigating the effect of BMI on urogenital 
function by conducting two separate clinical audits; the first audit was designed 
to investigate the baseline characteristics of patients with erectile dysfunction 
and determine if there were any correlations between urogenital function and 
obesity.  The audit was set up and conducted over a nine month period 
between June 2014 and March 2015, involving 60 patients with any urological 
condition. The second audit was designed to investigate the effect of bariatric 
surgery on male patients' body mass index (BMI), urological symptoms, and 
sexual function. The audit was set up and conducted over a thirty month period 
between February 2013 to July 2015, involving 30 patients aged 30 years and 
above with a body mass index of 35 kg/m2 and over undergoing bariatric 
surgery. Urogenital function was assessed in both audits using two validated 
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questionnaires: International Index of Erectile Function (IIEF) and International 
Prostate Symptom Score (IPSS). The second audit was completed before the 
surgery and four weeks, three months and six months after the surgery. The 
data were analysed using parametric and non-parametric tests for paired 
samples. The data were obtained from ongoing clinical audits at the UCL 
Hospitals. The study was approved by the Cranfield University Health Research 
Ethics Committee.  
Results:  
The analysis of 60 patients in the baseline characteristics audit 
indicates that 78.3% of the patients (n=47) suffered from being 
overweight and obese (BMI over 25 kg/m2). 80% of patients had ED 
(IIEF score less than 25). There was no significant difference between 
the ED and NO-ED group in respect of their IPSS scores. A significant 
correlation was found between sexual desire, overall satisfaction and 
BMI (p=0.01) but no correlation was found between any of the IPSS 
domains and BMI. A significant positive correlation was found between 
testosterone and IIEF domains (p<0.01) except overall satisfaction 
(p>0.05). Although there was no significant correlation between 
testosterone and obesity (BMI>30kg/m2), a significant correlation was 
found between free testosterone and overweightness (25kg/m2 ≤ BMI 
<30kg/m2). 
In the bariatric surgery audit, 18 patients reported ED (IIEF score <25) 
before the operation. BMI, IIEF, IPSS, fasting blood glucose and HbA1c 
all improved significantly starting at 1 month post-operatively and 
continued to improve throughout the study. 
Conclusions:  
The findings suggest that obesity could be an important risk factor for urogenital 
dysfunction in men. The results also highlight the role of testosterone in men 
with obesity on their urogenital function. Bariatric surgery leads to improvement 
in erectile and urinary function as well as glycaemic improvement within 1 
month post-operatively. Since the surgery-induced weight loss occurred at an 
unexpectedly early time point, it was not possible to ascertain whether the 
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improvement in urogenital dysfunction was due to weight loss or glycaemic 
improvement. Further studies with even shorter time points and greater patient 
numbers are required to address this question. 
 
 
Keywords:  
 
Erectile dysfunction, obesity, bariatric surgery, International index of erectile 
function (IIEF), International prostatic symptom score (IPSS) and Lower urinary 
tract symptoms (LUTS). 
 
 
v 
ACKNOWLEDGEMENTS 
First of all, I would like to express my sincere gratitude to my advisor Prof. Selim 
Cellek for the continuous support of my PhD and related research, for his 
patience, motivation, and immense knowledge. His guidance helped me all the 
time in research and writing of this thesis. 
 
I would like to express my deepest gratitude to my advisor, Dr. Nicola White, for 
her excellent guidance, I could not have imagined having a better advisor and 
mentor for my PhD. 
 
Besides my advisors, I would like to thank the rest of my external supervisors: 
Mr. Asif Muneer, Mr. David Ralph, and Mr. Majid Hashemi, for their insightful 
comments, encouragement, and for their eye openers which widened my 
research from various perspectives. 
 
I would especially like to thank the surgeons, nurses, nurse assistants and 
dieticians in the Urology and bariatric clinics at the University College London 
Hospital. All of you have been there to support me when I collected data for my 
PhD. 
 
My sincere thanks also goes out to King Faisal specialist hospital and research 
Centre; in particular, I am grateful to Dr. Sultan Alsudairy for enlightening me 
with the first glance of research and the Saudi cultural bureau in London-UK, 
who provided me the opportunity to continue my studies. Without their precious 
support it would not have been possible to achieve this PhD. 
 
I would like to thank my husband, Dr Hamad Albahili. He was always there 
cheering me up and stood by me through the good times and bad. Words 
cannot describe how lucky I am to have him in my life. He has selflessly given 
more to me than I ever could have asked for. I love you, and look forward to our 
lifelong journey together. 
 
vi 
A special thanks to my family. Words cannot express how grateful I am to my 
family for all of the sacrifices that you’ve made on my behalf. Your prayers for 
me were what sustained me thus far.  
 
I dedicate this thesis to the memory of my beloved mother, Mrs Suaad Alsabti. It 
is your shining example that I try to emulate in all that I do.  
 
Special thanks goes out to my father Mr. Mustafa I have been able to finish my 
PhD with his prayers, my two elder sisters Dr Weam and Mrs Ibtisam, and my 
two elder brothers Mr Mazin and Dr Hazim. They were always supporting me 
and encouraging me with their best wishes and prayers.  
 
Finally, I would like to thank all my friends for all their support, advice, and 
believing in me, in particular, Mr. Faris Abomelha for his IT support. 
 
Thank you God for everything 
 
vii 
TABLE OF CONTENTS 
ABSTRACT ......................................................................................................... i 
ACKNOWLEDGEMENTS................................................................................... v 
LIST OF FIGURES ............................................................................................. xi 
LIST OF TABLES ............................................................................................. xiii 
LIST OF EQUATIONS ...................................................................................... xvi 
LIST OF ABBREVATIONS ............................................................................. xviii 
1 INTRODUCTION ............................................................................................. 1 
1.1 Obesity ...................................................................................................... 1 
1.1.1 Definition and classification ................................................................ 1 
1.1.2 Epidemiology of obesity ..................................................................... 2 
1.1.3 Pathophysiology of obesity ................................................................. 3 
1.1.4 Obesity and co-morbidities ................................................................. 5 
1.1.5 Treatment ........................................................................................... 6 
1.1.5.1 Non-surgical treatment options .................................................... 6 
1.1.5.2 Surgical treatment options (bariatric surgery) ............................ 12 
1.1.6 Types of bariatric surgery ................................................................. 15 
1.1.6.1 Gastric band .............................................................................. 16 
1.1.6.2 Roux-en-Y gastric bypass .......................................................... 17 
1.1.6.3 Biliopancreatic diversion ............................................................ 19 
1.1.6.4 Sleeve gastrectomy ................................................................... 21 
1.1.6.5 Efficacy of types of bariatric surgery .......................................... 22 
1.1.7 Mechanisms of weight loss and metabolic improvement following 
bariatric surgery ........................................................................................ 26 
1.1.7.1 Glucagon like Peptide-1 ............................................................. 27 
1.1.7.2 Peptide YY ................................................................................. 27 
1.1.7.3 Ghrelin ....................................................................................... 28 
1.1.7.4 Adipose tissue ........................................................................... 28 
1.1.7.5 Change in food preference ........................................................ 29 
1.1.7.6 Change in appetite ..................................................................... 30 
1.1.8 Effects of bariatric surgery on diabetes ............................................ 30 
1.1.8.1 Hindgut hypothesis (changes in insulin secretions) ................... 32 
1.1.8.2 Foregut hypothesis (changes in hepatic insulin resistance) ....... 32 
1.1.8.3 Anti-incretin hypothesis .............................................................. 36 
1.1.8.4 Inflammation hypothesis ............................................................ 36 
1.1.8.5 Gluconeogenesis hypothesis ..................................................... 36 
1.2 Urogenital dysfunction ............................................................................ 38 
1.2.1 Definition of erectile dysfunction ....................................................... 39 
1.2.2 Epidemiology of erectile dysfunction ................................................ 40 
1.2.3 Physiology of penile erection ............................................................ 41 
1.2.4 Pathophysiology of erectile dysfunction ........................................... 43 
1.2.5 Diagnosis of erectile dysfunction ...................................................... 45 
1.2.6 Treatment of erectile dysfunction ..................................................... 47 
1.3 Lower urinary tract symptoms ................................................................. 50 
1.3.1 Anatomy of urinary function .............................................................. 50 
1.3.2 Symptoms and signs of lower urinary tract symptoms ..................... 51 
viii 
1.3.3 Epidemiology of urinary tract symptoms ........................................... 53 
1.3.4 Epidemiological studies in urinary tract symptoms ........................... 54 
1.3.5 Pathophysiology of urinary tract symptoms ...................................... 55 
1.3.6 Diagnosis and treatment of urinary tract symptoms ......................... 56 
1.3.6.1 Monotherapy .............................................................................. 58 
1.3.6.2 Combination therapy .................................................................. 59 
1.3.6.3 Associated medications ............................................................. 60 
1.3.7 Link between erectile dysfunction and urinary tract symptoms ........ 60 
1.3.7.1 Studies suggesting a link between ED and LUTS ...................... 61 
1.3.7.2 Risk factors associated with ED and LUTS ............................... 63 
1.4 Obesity and urogenital dysfunction ......................................................... 64 
1.4.1 Clinical correlation between obesity and urogenital dysfunction ...... 65 
1.4.1.1 Studies on obesity and sexual function ...................................... 65 
1.4.1.2 Studies on obesity and urological function ................................. 67 
1.4.2 Proposed mechanisms linking obesity to urogenital dysfunction ...... 68 
1.4.3 Effect of bariatric surgery on urogenital function .............................. 71 
1.4.3.1 Animal models ........................................................................... 71 
1.4.3.2 Clinical studies ........................................................................... 73 
1.5 Study rationale, aims and objectives ....................................................... 75 
1.5.1 Rationale .......................................................................................... 75 
1.5.2 Aims and objectives ......................................................................... 78 
1.5.2.1 Objectives .................................................................................. 78 
2 METHODS .................................................................................................... 80 
2.1 Audit of baseline characteristics of urogenital function ........................... 80 
2.1.1 Baseline characteristics audit design ............................................... 80 
2.1.2 Baseline characteristics audit setting ............................................... 81 
2.1.3 Patient recruitment ........................................................................... 81 
2.1.3.1 Study population ........................................................................ 81 
2.1.3.2 Recruitment of participants ........................................................ 82 
2.1.3.3 The patient recruitment process and data collection .................. 83 
2.1.3.4 Assessment of baseline blood chemistry and haematology ...... 84 
2.1.4 Ethical considerations ...................................................................... 85 
2.1.5 Statistics ........................................................................................... 86 
2.2 Bariatric surgery audit ............................................................................. 89 
2.2.1 Inclusion and exclusion criteria ........................................................ 89 
2.2.2 Patient recruitment process and data collection: .............................. 90 
2.2.3 Bariatric surgery audit design ........................................................... 91 
2.2.3.1 Assessments ............................................................................. 92 
2.2.3.2 Follow- up .................................................................................. 95 
2.2.4 Ethical considerations ...................................................................... 95 
2.2.5 Statistics ........................................................................................... 96 
3 RESULTS ...................................................................................................... 97 
3.1 Baseline characteristics of urogenital function audit ............................... 97 
3.1.1 Data distribution ............................................................................... 97 
3.1.2 Patient cohort profile: general demographics ................................... 99 
3.1.3 Multiple medical conditions ............................................................ 101 
3.1.4 Blood biochemistry and haematology............................................. 104 
3.1.5 International Index of Erectile Function (IIEF) results ..................... 108 
ix 
3.1.6 International Prostate Symptom Scale (IPSS) results .................... 108 
3.1.7 Correlations between different variables ........................................ 109 
3.1.7.1 Correlation between erectile function and obesity ................... 111 
3.1.7.2 Correlation between IPSS domains and obesity ...................... 112 
3.1.7.3 Correlation between IIEF and IPSS domains .......................... 113 
3.1.7.4 Correlation between age and IIEF/IPSS domains.................... 116 
3.1.7.5 Correlations among clinical biomarkers, ED, LUTS and obesity
 ............................................................................................................ 118 
3.2 Bariatric surgery audit ........................................................................... 122 
3.2.1 Analysis of variance ....................................................................... 124 
3.2.2 The patient cohort profile (bariatric surgery audit) .......................... 125 
3.2.3 Age range ....................................................................................... 127 
3.2.4 Bariatric surgery types .................................................................... 127 
3.2.5 Change in body weight associated with bariatric surgery. .............. 128 
3.2.5.1 BMI and EWL in the ED group ................................................. 128 
3.2.5.2 BMI and EWL in the NO-ED group .......................................... 129 
3.2.5.3 BMI and EWL according to surgery type ................................. 131 
3.2.6 Change in erectile function following bariatric surgery over time .... 135 
3.2.6.1 ED group: overall improvement ............................................... 135 
3.2.6.2 NO-ED group: overall improvement ......................................... 138 
3.2.7 Change in urological function following bariatric surgery over time 141 
3.2.7.1 ED group: overall improvement ............................................... 141 
3.2.7.2 NO-ED group: overall improvement ......................................... 145 
3.2.8 Change in metabolic biomarkers following bariatric surgery over time
 ................................................................................................................ 148 
4 DISCUSSION .............................................................................................. 153 
4.1 Baseline characteristics audit ............................................................... 154 
4.1.1 Correlations in the baseline characteristics audit ........................... 155 
4.1.1.1 Age .......................................................................................... 155 
4.1.1.2 Height ...................................................................................... 156 
4.1.1.3 Medical conditions ................................................................... 156 
4.1.1.4 Clinical biomarkers .................................................................. 157 
4.1.1.5 Sexual function (IIEF) .............................................................. 161 
4.1.1.6 Urological function (IPSS) ........................................................ 161 
4.1.1.7 Obesity (BMI) ........................................................................... 162 
4.1.1.8 IIEF and IPSS .......................................................................... 163 
4.1.2 Limitation of the audit ..................................................................... 164 
4.2 Bariatric surgery audit ........................................................................... 165 
4.2.1 Effect of surgery type, sexual function (IIEF) and obesity (BMI) ..... 166 
4.2.2 Effect of bariatric surgery on body weight (BMI) ............................. 167 
4.2.3 Effect of bariatric surgery on sexual function (IIEF) ........................ 168 
4.2.4 Effect of bariatric surgery on urological function (IPSS) ................. 174 
4.2.5 Effect of bariatric surgery on biomarkers ........................................ 180 
4.2.5.1 Fasting blood glucose .............................................................. 180 
4.2.5.2 HbA1c ...................................................................................... 181 
4.2.6 Limitation of the audit ..................................................................... 182 
5 CONCLUSION ............................................................................................ 187 
5.1 Future works ......................................................................................... 189 
x 
REFERENCES ............................................................................................... 193 
APPENDICES ................................................................................................ 215 
Appendix A: Supplementary information to Chapter 2 – Methods. ................. 215 
A.1 IIEF questionnaire .................................................................................... 216 
A.2 IPSS questionnaire .................................................................................. 218 
A.3 UCLH biochemistry and haematology request ......................................... 219 
Appendix B: Documentation relating to the ethical approval of this project. ... 220 
B.1 Baseline characteristics of urogenital function audit protocol submitted for 
ethics board approval. .................................................................................... 220 
B.2 Patient information sheet of baseline characteristics of urogenital function 
audit ............................................................................................................... 224 
B.3 Copy of approval letter from ethics board (Cranfield University Health 
Research Ethics Committee; CUHREC) ........................................................ 226 
B.4 Urogenital function following bariatric surgery audit protocol submitted for 
ethics board approval ..................................................................................... 227 
B.5 UCLH patient information sheet of urogenital function following bariatric 
surgery audit ................................................................................................... 231 
B.6 Copy of approval letter from ethics board (Cranfield University Health 
Research Ethics Committee; CUHREC) ........................................................ 233 
B.7 Copy of approval letter from Surgical Specialties at University College 
London Hospital ............................................................................................. 234 
B.8 Copy of honorary contract from Surgical Specialties at University College 
London Hospital (page1) ................................................................................ 235 
B.9 Copy of honorary contract first extension from Surgical Specialties at 
University College London Hospital (page1) .................................................. 236 
B.10 Copy of honorary contract of second extension from Surgical Specialties at 
University College London Hospital (page1) .................................................. 237 
B.11 Copy of honorary contract of third extension from Surgical Specialties at 
University College London Hospital ................................................................ 238 
Appendix C Supplementary data to Chapter 3 – Results ............................... 239 
C.1 Supplementary data to Section ‎3.1.7 ....................................................... 239 
C.2 Supplementary data to section ‎3.2 .......................................................... 247 
C.3 Supplement figures to section ‎3.2.8. ........................................................ 250 
Appendix D List of publications ...................................................................... 254 
 
 
xi 
LIST OF FIGURES  
Figure  1-1: Energy balance and the aetiology of obesity .................................... 5 
Figure  1-2: Various approaches to the treatment of obesity. .............................. 8 
Figure  1-3: Average weight loss of subjects completing a weight management 
intervention for at least one year. .............................................................. 10 
Figure  1-4: The process of weight assessment and management according to 
obesity surgery services of the NHS ......................................................... 13 
Figure  1-5: Gastric band ................................................................................... 17 
Figure  1-6: Roux-en-Y gastric bypass .............................................................. 18 
Figure  1-7: Biliopancreatic diversion ................................................................ 20 
Figure  1-8: Sleeve gastrectomy ........................................................................ 21 
Figure  1-9: Intestinal Gluconeogenesis Pathway ............................................. 37 
Figure  1-10: Male urogenital system anatomy.................................................. 39 
Figure  1-11: Molecular mechanism of penile smooth muscle relaxation. ......... 42 
Figure  1-12: Treatment algorithm for erectile dysfunction ................................ 49 
Figure  1-13: Diagram of the bladder ................................................................. 51 
Figure  1-14: Study rationale scheme. ............................................................... 78 
Figure  2-1: Examples of testing normality by histogram. .................................. 87 
Figure  2-2: The plan of bariatric surgery .......................................................... 93 
Figure  3-1: The patient cohort profile- age distribution. .................................. 100 
Figure  3-2: Patient distribution with ED and other medical conditions (N=48). 102 
Figure  3-3: An overview of all patients showing the frequencies of multiple 
chronic conditions (N=60). ...................................................................... 103 
Figure  3-4: Not true ED patient (example1). ................................................... 125 
Figure  3-5: Not true ED patient (example2). ................................................... 125 
Figure  3-6: Patient distribution chart ............................................................... 126 
Figure  3-7: Age distribution of patients for bariatric surgery audit. ................. 127 
Figure  3-8: Distribution of bariatric surgery type among patients groups. ...... 128 
Figure  3-9: Changes in BMI for the ED and NO-ED groups over time. .......... 129 
Figure  3-10: Changes in %EWL in the ED and NO-ED groups over time. ..... 130 
Figure  3-11: Changes in BMI comparing different surgery types across time 
points. ..................................................................................................... 132 
Figure  3-12: Changes in %EWL comparing different surgery types across time 
points. ..................................................................................................... 133 
Figure  3-13: Changes in erectile function and sexual desire domains- IIEF for 
ED group through time. ........................................................................... 136 
Figure  3-14: Changes in overall satisfaction, orgasmic function and intercourse 
satisfaction –IIEF domains for ED group through time ............................ 137 
Figure  3-15: Changes in erectile function and sexual desire- IIEF domains for 
the NO-ED group over time. .................................................................... 139 
Figure  3-16: Changes in orgasmic function, intercourse satisfaction and overall 
satisfaction- IIEF domains for the NO-ED group over time...................... 140 
Figure  3-17: Changes in frequency, intermittency and straining - IPSS domains 
for the ED group over time. ..................................................................... 142 
Figure  3-18: Changes in urgency, weak stream and Qol - IPSS domains for the 
ED group over time. ................................................................................ 142 
xii 
Figure  3-19: Changes in nocturia and incomplete emptying - IPSS domains for 
the ED group over time. .......................................................................... 143 
Figure  3-20: Changes in IPSS total score for the ED group over time. .......... 143 
Figure  3-21: Changes in intermittency, nocturia and Qol -IPSS domains for the 
NO-ED group over time. .......................................................................... 145 
Figure  3-22: Changes in straining, incomplete emptying and urgency -IPSS 
domains for the NO-ED group over time. ................................................ 146 
Figure  3-23: Changes in frequency and weak stream -IPSS domains for the 
NO-ED group over time. .......................................................................... 146 
Figure  3-24: Changes in IPSS total score domain for the NO-ED group over 
time. ........................................................................................................ 147 
Figure  3-25: Percentage of patients’ fasting blood glucose above or within the 
normal range. .......................................................................................... 149 
Figure  3-26: Changes in fasting blood glucose level in the ED and NO-ED 
groups over time. .................................................................................... 150 
Figure  3-27: Changes in HbA1c level in the ED and NO-ED groups over time.
 ................................................................................................................ 151 
Figure  5-1: Table of correlations between variables of the baseline 
characteristics audit ................................................................................ 240 
Figure  5-2: Differences between variables of ED and NO-ED groups at time 1 
(baseline) ................................................................................................ 250 
Figure  5-3: Differences between variables of ED and NO-ED groups at time 2
 ................................................................................................................ 251 
Figure  5-4: Differences between variables of ED and NO-ED groups at time 3
 ................................................................................................................ 252 
Figure  5-5: Differences between variables of ED and NO-ED groups at time 4
 ................................................................................................................ 253 
 
 
 
 
 
 
 
 
xiii 
LIST OF TABLES 
Table ‎1-1: Classification of body mass index (BMI) for obesity according to 
NICE guidelines .......................................................................................... 1 
Table ‎1-2: Symptoms and Consequences of Obesity ........................................ 3 
Table ‎1-3: The pharmacologic options of obesity treatment ............................... 9 
Table ‎1-4: Advantages and disadvantages lifestyle changes and weight loss 
medication. ................................................................................................ 11 
Table ‎1-5: Type of bariatric surgery performed between 2011 and 2013 
according to the UK-NBSR........................................................................ 15 
Table ‎1-6: Advantages and disadvantages several common types of bariatric 
surgery ...................................................................................................... 23 
Table ‎1-7: Summary of evidence for the effect of bariatric surgery on diabetes.
 .................................................................................................................. 33 
Table ‎1-8: IPSS Questionnaire Scores. ............................................................ 57 
Table ‎1-9: Examples of epidemiological evidence for the association between 
ED and LUTS ............................................................................................ 62 
Table ‎2-1: List of items that were investigated in the blood test. ...................... 85 
Table ‎2-2: Plan of the follow-up appointments of bariatric surgery patients. .... 95 
Table ‎3-1: Test of normality for baseline characteristics of urogenital function 
audit (N=60). ............................................................................................. 97 
Table ‎3-2: Descriptive statistics of the general demographic details of patients.
 ................................................................................................................ 100 
Table ‎3-3: General descriptive statistics of the ED and NO-ED groups. ........ 101 
Table ‎3-4: Medical diagnosis differences between the ED and NO-ED groups.
 ................................................................................................................ 104 
Table ‎3-5: Descriptive statistics of blood biochemistry tests for all patients. .. 105 
Table ‎3-6: Descriptive statistics of blood haematology tests for all patients 
(N=60). .................................................................................................... 106 
Table ‎3-7: Blood biochemistry tests:  Statistical comparison between the ED 
and NO-ED groups. ................................................................................. 106 
Table ‎3-8: Haematology tests:  Statistical comparison between the ED and NO-
ED groups. .............................................................................................. 107 
Table ‎3-9: Descriptive statistics of IIEF results for the ED and NO-ED groups.
 ................................................................................................................ 108 
Table ‎3-10: Descriptive statistics of IPSS results for the ED and NO-ED groups, 
with statistical comparison between groups using the Mann-Whitney U test.
 ................................................................................................................ 109 
Table ‎3-11: List of significant correlations between variables in baseline 
characteristics of urogenital function audit .............................................. 109 
Table ‎3-12: Correlation between IIEF domains and BMI (N=60). ................... 111 
Table ‎3-13: Correlation between BMI and IIEF domains in the ED and NO-ED 
groups. .................................................................................................... 111 
Table ‎3-14: Correlation between IPSS domains of and BMI (N=60). ............. 112 
Table ‎3-15: Correlation between BMI and IPSS domains in the ED and NO-ED 
groups. .................................................................................................... 112 
Table ‎3-16: Correlations between IIEF and IPSS domains (N=60). ............... 114 
xiv 
Table ‎3-17: Correlations between IIEF and IPSS domains in the ED (N=48) and 
NO-ED (N=12) groups. ............................................................................ 115 
Table ‎3-18: Correlation between age and IIEF domains (N=60). ................... 116 
Table ‎3-19: Correlation between age and IIEF domains within the ED group 
(N=48). .................................................................................................... 116 
Table ‎3-20: Correlation between age and IPSS domains (N=60) ................... 117 
Table ‎3-21: Correlation between age and IPSS domains in the ED and NO-ED 
groups. .................................................................................................... 117 
Table ‎3-22: Comparison of IIEF scores between smokers and non-smokers 
(N=60). .................................................................................................... 120 
Table ‎3-23: Comparison of IIEF scores between smokers and non-smokers 
within the ED group (N=48). .................................................................... 120 
Table ‎3-24: Comparison of IIEF scores between smokers and non-smokers 
within the NO-ED group (N=12). ............................................................. 120 
Table ‎3-25: Skewness test of the bariatric surgery audit (N=35). ................... 122 
Table ‎3-26: BMI and %EWL of the ED and NO-ED groups across time points.
 ................................................................................................................ 130 
Table ‎3-27: The significance of differences for BMI and %EWL between time 
points in the ED and NO-ED groups. ...................................................... 131 
Table ‎3-28: Changes in BMI comparing types of surgery across time points. 133 
Table ‎3-29: Changes in %EWL comparing types of surgery across time points.
 ................................................................................................................ 134 
Table ‎3-30: The significance of differences for BMI and %EWL between time 
points in different types of surgery. ......................................................... 134 
Table ‎3-31: Comparison between types of surgery. ....................................... 134 
Table ‎3-32: The difference in IIEF and IPSS scores in the ED and NO-ED 
groups at baseline (T1). .......................................................................... 135 
Table ‎3-33: IIEF scores of patients from the ED group over time. .................. 138 
Table ‎3-34: The significance of differences in IIEF scores between time points 
in the ED group ....................................................................................... 138 
Table ‎3-35: IIEF scores of the NO-ED group over time. ................................. 140 
Table ‎3-36: The significance level of differences between time points in IIEF 
scores in the NO-ED group. .................................................................... 141 
Table ‎3-37: IPSS scores of the ED group over time. ...................................... 144 
Table ‎3-38: The significance of differences in IPSS scores between time points 
in the ED group. ...................................................................................... 144 
Table ‎3-39: IPSS scores for the NO-ED group over the time. ........................ 147 
Table ‎3-40: Wilcoxon signed rank test comparing IPSS scores in the NO-ED 
group over multiple time-points. .............................................................. 148 
Table ‎3-41: The difference in fasting blood glucose and HbA1c values in the ED 
and NO-ED groups at baseline (T1). ....................................................... 148 
Table ‎3-42: Fasting blood glucose level and HbA1c in the ED and NO-ED 
groups over time. .................................................................................... 151 
Table ‎3-43: The significance of differences between time points for fasting blood 
glucose level and HbA1c in the ED and NO-ED groups. ......................... 152 
Table  4-1: Comparison in sexual function between the audit and the literature.
 ................................................................................................................ 169 
xv 
Table ‎4-2: Comparison in urological function between the audit and the 
literature. ................................................................................................. 179 
Table ‎5-1: List of definitions of the numbers in Figure ‎5-1 .............................. 239 
Table ‎5-2: Mann Whitney U test of all variables at baseline ........................... 250 
Table ‎5-3: Mann Whitney U test of all variables at time 2 .............................. 251 
Table ‎5-4: Mann Whitney U test of all variables at time 3 .............................. 252 
Table ‎5-5: Mann Whitney U test of all variables at time 4 .............................. 253 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xvi 
LIST OF EQUATIONS 
Equation ‎1-1: Body mass index .......................................................................... 1 
Equation ‎1-2: Percentage excess weight loss .................................................. 19 
 
xvii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xviii 
LIST OF ABBREVATIONS  
AGE  Advanced glycation end-products 
AHA/NHLBI   American Heart Association/National Heart, Lung 
and Blood Institute 
AIDS                                   Acquired immune deficiency syndrome 
ANOVA  Analysis of variance  
AUA   American Urological Association  
BACH                                 Boston area community health study  
BMI  Body mass index 
BMJ                                   British Medical Journal 
BMSFI  Brief Male Sexual Function Inventory 
BOMSS   British Obesity and Metabolic Surgery Society 
BOO                                   Bladder outlet obstruction  
BP  Blood pressure  
BPD   Biliopancreatic diversion  
BPE  Benign prostate enlargement  
BPH  Benign prostatic hyperplasia 
BSSM                                 British Society for Sexual Medicine  
CAD   Coronary artery disease  
CDC   Centre for Disease Control and Preservation 
CDR                                   Clinical data repository  
cGMP   Cyclic guanosine monophosphate  
CNS    Central nervous system 
COREC   Central Office for Research Ethics Committees  
CUHREC   Cranfield University Health Research Ethics  
                                            Committee 
CVD    Cardiovascular disease 
DIO    Diet- induced obesity  
DM     Diabetes mellitus 
DS    Duodenal switch  
ED    Erectile dysfunction 
xix 
ECG    Electrocardiogram  
EF    Erectile function 
EGP                                   Endogenous glucose production 
FBG                                    Fasting blood glucose 
FDA                                    Food and Drug Administration  
ESR                                    Erythrocyte sedimentation rate 
Free T4                               Free thyroxine 
FSH                                    Follicle stimulating hormone 
eNOS    Endothelial nitric oxide synthase  
EPIC                                  European prospective investigation into cancer and   
                                           Nutrition  
EpiLUTS                            Epidemiology of LUTS study  
EWL    Excess weight loss 
GC    Guanylate cyclase 
Glc6Pase   Glucose-6-phosphatase  
GFR                                   Glomerular filtration rate 
GTP    Guanosine-5'-triphosphate  
HbA1c                                Haemoglobin A1c 
HCT                                    Haematocrit test 
HDL    High-density lipoprotein 
HFD    High fat diets 
HOMA-IR                           Homeostasis model assessment of insulin resistance  
HPFS                                 Health Professionals Follow-up Study  
ICS    International Continence Society  
ICIQ-SF International Consultation on Incontinence 
Questionnaire-Short Form  
IDF    International Diabetes Federation 
IIEF    International Index of Erectile Function 
IP3    Inositol triphosphate 
IPSS    International Prostate Symptom Score 
IR    Insulin resistance  
IS    Intercourse satisfaction  
xx 
IT    Information technology 
IWQOL-L   Impact of Weight on Quality of Life - Lite 
JIB    Jejunoileal bypass  
LAGB    Laparoscopic adjustable gastric banding  
LDL                                     Low density lipoprotein 
LGB    Laparoscopic gastric banding  
LH                                      Luteinizing hormone 
LSG    Laparoscopic sleeve gastrectomy  
LUTS    Lower urinary tract symptoms 
MCH                                   Mean corpuscular haemoglobin 
MCHC                                Mean corpuscular haemoglobin concentration 
MCV                                   Mean corpuscular volume  
MDT    Multidisciplinary team  
MetS    Metabolic syndrome 
MPV                                   Mean platelet volume 
MSHQ   Male Sexual Health Questionnaire  
NBSR    National Bariatric Surgery Register 
NHS    National Health Service 
NICE    National Institute for Health and Care Excellence 
NIDDM                               Non-insulin dependent diabetes mellitus 
nNOS    Neuronal nitric oxide synthase 
NO    Nitric oxide  
NOS    Nitric oxide synthase 
OF    Orgasmic function 
OS    Overall satisfaction  
OVB    Overactive bladder  
PDE5    Phosphodiesterase type 5  
PDE5-Is                              PDE5-inhibitors 
PEPCK   Phosphoenolpyruvate carboxykinase  
PGE1    Prostaglandin E1  
PKA    Protein kinase A 
PLB    Phospholipase B 
xxi 
PLC    Phospholipase C 
POLER                               Prolong preoperative weight loss programme 
PSA    Prostate specific antigen  
PYY                                    Peptide tyrosine tyrosine 
RDW                                  Red blood cell distribution width 
ROCK    RhoA–Rho-kinase  
RYGB    Roux Y gastric bypass  
ISC    International Scientific Committee 
SD    Sexual desire 
SG    Sleeve gastrectomy 
SHBG                                 Sex hormone binding globulin  
T2DM    Type 2 diabetes mellitus 
TSH                                    Thyroid stimulating hormone 
UCL                                    University College London  
UCLH    University College London Hospital  
UI    Urinary incontinence 
UK    United Kingdom  
USA    United States of America 
VBG    Vertical band gastroplasty  
WHO    World Health Organization 
 
 
1 
1 INTRODUCTION 
1.1 Obesity 
1.1.1 Definition and classification 
Obesity is a chronic disease defined as a high amount of body fat in relation to 
lean body mass resulting from high calorific intake that surpasses usage of 
energy (Wang et al. 2008a). Obesity has been classified (Table ‎1-1) according 
to the body mass index (BMI; Equation ‎1-1) which is the measurement of the 
mass in the human body, in kilograms, divided by height in meters squared.  
Equation  1-1: Body mass index (Welbourn et al. 2014) 
𝐵𝑀𝐼 =  
𝑊𝑒𝑖𝑔ℎ𝑡 (𝑘𝑔)
𝐻𝑒𝑖𝑔ℎ𝑡2 (𝑚2)
 
 
Table  1-1: Classification of body mass index (BMI) for 
obesity according to NICE guidelines (NICE 2014). 
Types BMI (kg/m
2
) 
Healthy weight 
 
18.5-24.9 
Overweight 
 
25-29.9 
Obesity type I 
 
30-34.9 
Obesity type II 
 
35-39.9 
Obesity type III 
 
and more 
 
The increase in obesity is a worldwide epidemic according to the World Health 
Organization (WHO), which estimates that more than 1.6 billion individuals are 
currently overweight and 400 million are obese (World Health Organisation 
2000). Moreover, obesity has been linked to insulin resistance and type 2 
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diabetes mellitus (T2DM; (Wickremesekera et al. 2005) which can impact on the 
quality of life or can lead to mortality if left untreated (Fujimoto 2000).  
1.1.2 Epidemiology of obesity  
The worldwide epidemic of obesity and obesity related diseases such as T2DM 
continues to increase. Compared to the data from 1980, the overall prevalence 
in the world of individuals being overweight or obese has risen from 28.8% to 
36.9% in men. Globally, every country is failing in its attempts to combat obesity 
(Ng et al. 2014) and, as such, many researchers have asserted that obesity is 
the characteristic disease of the 21st century (O'Brien 2010).  
The United Kingdom is the 3rd most obese country in Western Europe after 
Iceland and Malta. In 2013, around 67% of men aged 20 years and over were 
overweight or obese with the incidence of obesity increasing since 1980 by 13% 
in that age group (Public Health England 2015).  
The Public Health England (2010) revealed that in England in 2008, around 
24% of men and 25% of women aged 16 or over were classified as obese, and 
66% of men and 57% of women were overweight (NICE 2014). In the United 
States of America (USA) between 1960 and 1980, the percentage of individuals 
who were obese increased from 13.4% to 14.4%, and by 2000 the percentage 
doubled to 30.4% (Wang et al. 2008a, World Health Organisation 2000). In 
2008, the percentage had increased to 33.8% and studies estimate that the 
percentage between 2010 and 2020 will be 37.4% for men and 44.2% for 
women (Wang et al. 2008a).  
In the USA, the Centre for Disease Control and Prevention (CDC) found that the 
prevalence of obesity began to accelerate in the early 1980s. A 2008 report by 
Diabetes Australia (2008) found that over 77 million American adults are 
currently suffering from obesity, with a similar percentage of cases also being 
found in Australia, with roughly 3 million or 22% of adults suffering from the 
disease (O'Brien 2010). 
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1.1.3 Pathophysiology of obesity 
The average middle-aged man and woman’s body weight is made up of around 
21% to 27% of fat. In the context of obesity, individuals consume more calories 
than they expend, and their appetite is not always satisfied or reduced by the 
rise in energy stores (Gurevich-Panigrahi et al. 2009). Furthermore, the adipose 
tissue and how much of it is produced are strictly regulated via hormonal and 
neural signals which are sent to the brain (Gurevich-Panigrahi et al. 2009). 
Therefore, energy balance is regulated by a complex system involving sensors 
of energy stores, found in the adipose tissue, as well as a mechanism to 
successfully send the information to vital control sites or the hypothalamus for 
successive integration, which determines energy outflow and food intake 
(Gurevich-Panigrahi et al. 2009, Lean 2000). Table ‎1-2 illustrates the symptoms 
and consequences of obesity. 
Table  1-2: Symptoms and Consequences of Obesity (Lean 
2000).  
Physical symptoms  
 Arthritis  
 Back pain  
 Breathlessness  
 Oedema, cellulitis  
 Stress incontinence  
 Sweating  
 Varicose veins  
Anaesthetic and surgical hazards  
 Hernia  
 Chest infections 
 Sleep apnoea  
 Wound dehiscence  
Metabolic problems  
 Hypercoagulation  
 Hypertension  
 Ischaemic heart disease (IHD) 
and stroke  
 Non-insulin dependent diabetes 
mellitus (NIDDM)  
 Hyperlipidaemia  
Endocrine problems 
 Hirsutism  
 Oestrogen-dependent cancers 
(breast, endometrium, prostate)  
 Oligomenorrhoea  
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Social Isolation  
 Agoraphobia  
 Discrimination 
 Family, marital stress  
 Unemployment  
 infertility  
 Menorrhagia  
Psychological effects 
 Tiredness  
 Depression 
 Low self-esteem  
 Self-deception and distortion of 
thought  
  
  
Genetic experiments performed on animal models have facilitated the 
understanding of the regulation of fat metabolism. For example, mice have been 
shown to become obese as a result of at least five identified genes being 
mutated: the “obesity” gene encoding leptin, the “diabetes” gene, “fat” genes, 
“tubby” and “agouti yellow” (Friedman et al. 1998). Homozygosity for mutant 
forms of obesity or diabetes genes produces mice that eat excessively and 
have low energy expenditure, they become obese and suffer from several 
metabolic abnormalities such as hyperglycaemia, hypothermia, 
hyperinsulinaemia, reduced thyroid hormone and decreased reproductive 
function (Gurevich-Panigrahi et al. 2009).  
Leptin is a peptide hormone which is released predominantly from the adipose 
tissue and delivers signals to the brain based on the quantity of fat stores 
(Jackson 1999). Some obese patients are known to have mutations in both their 
leptin and leptin receptors (Jackson 1999). Given that normal leptin and obesity 
genes are observed in many obese individuals, the potential reasons for obesity 
have been suggested to include the alleles of several genes associated with 
regulating energy and metabolism, as well as environmental factors (Jackson 
1999). 
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In obese individuals more calories are consumed than expended, which can be 
due to a reduction in physical activity, metabolic rate and thermogenesis which 
eventually decrease energy expenditure, leading to increased energy storage 
and obesity (Figure  1-1; (Gurevich-Panigrahi et al. 2009). 
 
Figure  1-1: Energy balance and the aetiology of obesity (Gurevich-
Panigrahi et al. 2009). 
The relationship between energy expenditure and storage, and food intake determines energy 
balance. Obesity is perceived as a disorder that takes into account a myriad of factors caused 
by various genetic and environmental factors (Gurevich-Panigrahi et al. 2009). 
1.1.4 Obesity and co-morbidities 
Obesity, as has been previously described, increases the likelihood of 
developing so-called obesity related comorbidities. The most prevalent of these 
is T2DM, with around 382 million individuals estimated to be affected 
(Guariguata et al. 2014). Furthermore, there are two key epidemiological 
studies that strongly link increased weight and diabetes: the Male Health 
Professionals Follow-up Study (HPFS) who studied 51,000 male patients (Chan 
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et al. 1994) and the Nurses’ Health Study which studied 112,000 female 
patients (Colditz et al. 1995) both demonstrated a significant increase in T2DM 
with weight gain. Moreover, the Nurses’ Health Study (Colditz et al. 1995) 
shows that the likelihood of individuals developing T2DM who have a BMI of 25 
is five times higher than that of an individual who has a BMI of 22. This increase 
is proportionate to BMI, with a BMI of 30 or more increasing likelihood of 
developing BMI 27-fold and a BMI of 35 or more increasing the likelihood 93-
fold, when compared to a person with a BMI of 22.   
Obesity has been suggested to lead to strokes, ischaemic heart disease, and 
diseases related to metabolic syndrome, such as polycystic ovary syndrome, 
obstructive sleep apnoea, dyslipidaemia and hypertension (Ning et al. 2010). It 
is also important to point out that the disease is suggested to increase the 
likelihood of cancer, especially colon, pancreatic, breast, renal and bladder 
cancers, among others (Calle et al. 2003). Furthermore, obesity has also been 
suggested as a risk factor for depression, and degenerative diseases of the 
knees and hips (Mokdad et al. 2003).  
1.1.5 Treatment  
1.1.5.1 Non-surgical treatment options  
A number of non-surgical options are available for the treatment of obesity, 
such as lifestyle changes, for example reducing calorie intake, being more 
physically active and medical therapy (O'Brien 2010).  
There are a number of different recommendations on weight management that 
have been suggested (Franz et al. 2007), including diet alone, diet and 
exercise, exercise alone, meal replacements1, very-low-energy diets2, weight-
                                            
 
1
 Meal replacements are drinks, bars, soups, etc. intended as a substitute for a solid food meal 
which were used for two or more meals per day and as an adjunct to a reduced-energy diet 
(Franz et al. 2007). 
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loss medications (e.g. orlistat3), and advice alone. 
1.1.5.1.1 Lifestyle changes 
The first line of treatment for obesity consists of two principal changes in 
lifestyle: a low calorie diet, and physical exercise (Papamargaritis et al. 2012). 
Studies have suggested that eating healthier foods and engaging in more 
physical activities is the safest way to lose weight (Bond et al. 2009, Gaesser 
2013).  
However, a conflicting study (Mauro et al. 2008) argues that many individuals 
lack the willpower or motivation to stick to a healthy diet, which in turn leads 
them back to their previous lifestyle that has contributed to their obesity. Indeed, 
75% to 80% of individuals often regain weight after losing it, thus indicating that 
they do not stick to their regular diet plan after significant weight loss (Polivy et 
al. 2002). Therefore, they often turn to weight loss medications or as a last 
resort, to surgical methods such as bariatric surgery. A suggested clinical 
strategy to induce weight loss is shown in Figure  1-2. 
                                                                                                                                
 
2
 Very low energy diet is a diet of 800 kcal or less per day, usually in the form of a liquid diet 
(Franz et al. 2007). 
3
 Orlistat (also known as tetrahydrolipstatin) is a drug designed to treat obesity. It is marketed as 
a prescription drug under the trade name Xenical (NHS Choices 2015a). 
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Figure  1-2: Various approaches to the treatment of obesity.  
Obesity is a particularly challenging medical condition due to its complex aetiology. Non-
pharmacological treatment such as exercise and healthy diet should continue if there is a 
satisfactory response. On the other hand, an unsatisfactory response would prompt alternative 
treatment such as pharmacotherapy. However, such treatment must only be carried out for 
patients whose BMI exceeds 30 and for those who have obesity-related medical conditions. 
After considering pharmacotherapy, in the event of those patients who do not lose a minimum of 
2kg within the first 4 weeks of treatment, a reassessment and readjustment of their medication, 
exercise and dietary plans must be performed. The clinician must then consider stopping or at 
least replacing the patient’s medication with another, in the event of the patient not responding 
well to the current medication. Finally, if there is no response to the newly prescribed 
medication, exercise and dietary plans, then surgical therapy is considered (Gurevich-Panigrahi 
et al. 2009). 
1.1.5.1.2 Weight loss medications 
Medications such as orlistat (Xenical, Alli) are designed to treat obesity by 
inhibiting gastric and pancreatic lipases (the enzymes that break down 
triglycerides in the intestine) thereby reducing fat absorption (Thomson PDR 
2006). Patients who take orlistat lose on average an extra 2.9 kg (95%CL-3.2 to 
-2.5 kg) within a 12 month period (Li et al. 2005a)(Kang et al. 2012), as well as 
reducing the risk of T2DM and exhibiting reductions in their overall cholesterol. 
Side effects related to the mechanism of action of this group of drugs include 
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diarrhoea, faecal incontinence, oily spotting, flatulence, bloating, and dyspepsia 
(Ioannides-Demos et al. 2006, Padwal et al. 2003). Some cases of liver failure 
have also been reported (Thomson PDR 2006). Table ‎1-3 describes the 
pharmacologic options of obesity treatment. 
Table  1-3: The pharmacologic options of obesity treatment 
(Gurevich-Panigrahi et al. 2009).  
Groups 
 
Example Mechanism of action Adverse effects 
Appetite 
suppressors 
Sibutramine 
(Reductil)
® 
Inhibits 
norepinephrine and 
serotonin reuptake in 
central nervous 
system (CNS) 
Hypertension, tachycardia, dry 
mouth, insomnia, headache, 
constipation (Yanovski et al. 
2003). 
 
Inhibitors of fat 
absorption 
Orlistat 
(Xenical, Alli)
® 
Binds gastrointestinal 
lipases 
Gastrointestinal side effects, 
decreased absorption of fat-
soluble vitamins such as vitamin 
A, D, E and K (Thomson PDR 
2006). 
 
Stimulators of 
thermogenesis 
 
(New and 
investigational 
drugs)  
 
Rimonabant 
(Acomplia)
® 
Suppresses appetite, 
increases 
thermogenesis 
Severe psychiatric mood related 
disorders (Akbas et al. 2009). 
 
1.1.5.1.3 Efficacy of non-surgical methods 
Based on a systematic review by Randall and colleagues (2014) which explored 
the effectiveness of non-surgical weight management interventions for obesity 
in the UK, the majority of the research articles identified a significant reduction 
in weight and/or BMI following engagement in a physical activity or diet-based 
intervention for both adult and child populations for a duration of twelve weeks 
and the largest reduction in weight was 9.8 kg recorded through a structured 
calorie controlled diet plan and management (Randall et al. 2014). However, 
this review is not explicit in detailing the optimisation of public health 
interventions since it only focused on UK-based articles ignoring many high 
quality articles that have been published elsewhere (Randall et al. 2014).  
Another systematic review by Gloy and colleagues (2013), points out that non-
surgical weight-loss interventions seem to produce conservative short-term 
10 
results but that these results are short lived, particularly in the morbidly obese 
(Gloy et al. 2013). This is known as “yo-yo syndrome” in which patients 
constantly gain and lose weight, and may end up developing severe long-term 
psychological and health problems (Amigo et al. 2007).  
Numerous randomized controlled trials have shown that a modest weight loss of 
between 2 and 5 kg can be achieved in 12 months simply through lifestyle 
changes (O'Brien 2010). On the other hand, a systematic review by Franz and 
colleagues (2007) showed that weight-loss interventions involving attention to 
diet alone, diet and exercise, meal replacements, and weight-loss medications 
combined with diet, all with the exception of Sibutramine seem to produce 
encouraging results, but only in the short-term (Franz et al. 2007), as shown in 
Figure  1-3. Table  1-4 shows the advantages and disadvantages of lifestyle 
interventions versus pharmacotherapy interventions for weight loss.  
 
 
Figure  1-3: Average weight loss of subjects completing a weight 
management intervention for at least one year (Franz et al. 2007).  
Data presents the average weight loss of all patients on each intervention at the specified time-
point. The eight interventions studied were: exercise alone (yellow), diet and exercise (green), 
diet alone (dark blue), meal replacements (used for two or more meals per day; marine blue), 
very-low-energy diet (under 800 kcal per day; grey), Orlistat (in combination with lifestyle 
interventions; red), Sibutramine (in combination with lifestyle interventions; dark red) and advice 
alone (black). Weight loss was observed during the first six months of all interventions, and 
weight-loss reached plateaus after six months (Franz et al. 2007).    
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Table  1-4: Advantages and disadvantages lifestyle changes and weight loss medication 
(O'Brien 2010, Franz et al. 2007).  
 
Non-surgical method 
 
Advantages Disadvantages Weight Loss Range 
 
Lifestyle changes (e.g. 
improved diet, regular 
exercise and 
psychological therapy) 
 Safest way to lose weight  
 No adverse side-effects from weight 
loss medications 
 Better quality of life (Bond et al. 2009, 
Gaesser 2013) 
 People often fail to stick to their diet plan 
and exercise regime 
 Most people end up losing weight and 
regaining it within 1-5 years after dieting 
 Most people end up turning to bariatric 
surgery as a result of failing to lose an 
adequate amount of weight (Franz et al. 
2007).  
 
 
Varies depending on 
whether people stick 
to their dietary plan 
(Franz et al. 2007). 
 
 
Weight loss medication 
 
 Simplest and quickest way to lose 
weight 
 No strict diet or rigorous exercise 
required 
 Easily accessible on the market.  
 There are various types of medications 
that tailor to patients’ differing needs. 
 Orlistat in particular, has been shown to 
yield huge weight loss within a 12 
month period, as well as reducing the 
risk of T2DM and exhibiting reductions 
in overall cholesterol (Franz et al. 2007, 
Papamargaritis et al. 2012, Kang et al. 
2012).  
 
 Can be expensive 
 Patients are often unaware of drug 
contents and risks, particularly those 
purchased online 
 Can cause a number of adverse side-
effects, such as wooziness, nausea, and 
upset stomach.  
 Gastrointestinal side effects (e.g. 
diarrhoea, faecal incontinence, oily 
spotting, flatulence, bloating, and 
dyspepsia (Ioannides-Demos et al. 2006, 
Padwal et al. 2003).  
 
 
2.9kg weight loss 
within the first 12 
weeks (based on 
orlistat, and may differ 
among alternative 
drugs; (Franz et al. 
2007). 
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1.1.5.2 Surgical treatment options (bariatric surgery)  
The Greek roots of the word bariatric consist of (bar) mean weight, (iatr) 
meaning treatment and (ic) meaning pertaining to. Bariatric is defined as the 
division of medicine that deals with the causes, prevention, and treatment of 
obesity (The American Heritage® Stedman's Medical Dictionary 2014). Bariatric 
surgery therefore is a surgical procedure that is carried out to support 
individuals in losing weight, thus lowering the risk of death and severe obesity if 
combined with an improved lifestyle and better eating habits. 
There are a number of surgical treatment options available, which include: 
endoscopic methods, for example, intra-gastric balloon, gastric banding, 
laparoscopic or open biliopancreatic diversion (BPD), Roux-en-Y gastric bypass 
(RYGB) and sleeve gastrectomy (O'Brien 2010).  
1.1.5.2.1 Indication of bariatric surgery  
According to the National Institute for Health and Care Excellence (NICE) 
guidelines, patients are considered eligible for bariatric surgery if their BMI is 40 
or more, or if they have a related condition such as diabetes and have a BMI of 
35 or more. It is also recommended that all non-surgical actions are attempted 
prior to resorting to surgery (NICE 2014). Figure  1-4 describes the pathway of 
patients who are referred for bariatric surgical service according to the British 
healthcare system. 
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Figure  1-4: The process of weight assessment and management 
according to obesity surgery services of the NHS (Welbourn et al. 2014). 
NICE guidance and BOMSS
4
 standards describes the pathway of patients within the multi-
disciplinary bariatric surgical service and states that patients who are referred for bariatric 
surgery will come from primary or secondary care specialist obesity services (Welbourn et al. 
2014). 
 
1.1.5.2.2 Evolution of bariatric surgery  
In the early 1950s, the only bariatric surgery available was the jejunoileal 
bypass (JIB). Later, in the 1970s, gastric stapling surgeries such as Roux-en-Y 
gastric bypass (RYGB)5 (Figure ‎1-6) and biliopancreatic diversion (BPD)6 
(Figure  1-7) started to emerge (Olbers et al. 2006).  
Despite the initial success of JIB, several adverse events were directly related 
to the surgical procedure such as liver failure, hair loss, arthritis and vitamin 
depletion (Singh et al. 2009). By the 1980s, JIB was phased out following a 
                                            
 
4
 BOMSS - British Obesity and Metabolic Surgery Society. 
5
 RYGB is a variant of attaching the gastric mini-reservoir with the small bowel using a Roux-en-
Y loop. Cesar Roux (1857-1934), a Swiss surgeon, was the first who suggested and promoted 
this variation of the anastomosis, to bypass the digestive segment (Popenţiu et al. 2011). 
6
 BPD was originally described by Scopinaro in 1979 as an alternative to jejunoileal bypass for 
severely obese patients (Scopinaro et al. 1979). 
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reported 91 deaths, as well as the surviving patients experiencing deleterious 
consequences from having the procedure (Singh et al. 2009, Griffen et al. 
1983).  
Recently, all types of bariatric surgery procedures have been able to achieve 
significant weight loss in the morbidly obese, but such procedures still do not 
appeal to some patients who suffer from obesity due to factors such as the risk 
of death and long term complications (O'Brien 2010).  
The adoption of laparoscopic methods to perform advanced abdominal surgery, 
such as a gastric banding procedure, which has been widely used and 
developed over the past 15 years, has significantly improved safety, thereby 
encouraging patients to undergo these surgeries (O'Brien 2010). In Australia, 
for example, in 1993, only 400 bariatric surgeries were performed, while in 
2008, that figure increased to over 14,000. According to Buchwald et al. (2009), 
there were an estimated 344,000 surgeries carried out globally in the same year 
(2008). Buchwald et al. also pointed out that the most common type of surgery 
was the Roux-en-Y gastric bypass, both open and laparoscopic, which 
represented 47% of the total number of bariatric operations.  
The second most common surgery was gastric banding, which stood at 42% of 
the total number, followed by sleeve gastrectomy, which stood at 5%, and then 
BPD, at 2%. Moreover, in Europe, RYGB is on the rise, even though gastric 
banding is still the most common type of surgery (Buchwald et al. 2009). Indeed, 
according to the United Kingdom National Bariatric Surgery Registry (NBSR), 
RYGB was the most common form of bariatric surgery performed in the UK 
between 2011 and 2013 (Table ‎1-5; (Welbourn et al. 2014). 
In the USA, gastric banding is now overtaking RYGB, while gastric banding in 
Australia is the preferred method of surgery, accounting for over 95% of 
bariatric surgeries carried out in the country (O'Brien 2010, Buchwald et al. 
2009).  
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An important aspect that influences the choice of surgical methods and success 
rates in different countries is healthcare funding; for instance, the most common 
surgical procedure today is gastric banding, since it is the safest method of 
bariatric surgery. However, one of the most vital components of gastric banding 
is adjusting the band over time to satisfy one’s appetite, thus it is important to 
have a follow-up program. In Australia the national healthcare scheme 
(Medicare) covers this follow up process and banding has come to be the most 
favoured approach in the country. On the other hand, Europe has limited 
funding to cover follow ups, thus complications arise in banding. Still further, 
Latin America, has no funding at all for aftercare, and thus there is little 
opportunity to receive banding (O'Brien 2010).     
Table  1-5: Type of bariatric surgery performed between 
2011 and 2013 according to the UK-NBSR (Welbourn et al. 
2014).   
Operation type Number of surgeries 
Roux-en-Y gastric bypass 9526 
Gastric band 4075 
Sleeve gastrectomy 3797 
Gastric balloon 386 
Duodenal switch 19 
Duodenal switch and sleeve 12 
Billio-pancreatic diversion 5 
 
1.1.6 Types of bariatric surgery  
Bariatric surgery is divided into two types, restrictive and malabsorptive. 
Restrictive surgery works by decreasing the quantity of food intake, an example 
of which is vertical band gastroplasty (VBG). This involves dividing the stomach 
into a small proximal pouch (<20 ml) and a more distal one (Dixon et al. 2012). 
While, malabsorptive surgery works by limiting the nutrient absorption by 
bypassing the duodenum and small intestine; the examples for this procedure 
are: biliopancreatic diversion with or without duodenal switch, and Roux-en-Y 
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gastric bypass; this procedure also has a restrictive component (Dixon et al. 
2012). 
1.1.6.1 Gastric band  
In a laparoscopic adjustable gastric banding (LAGB), what is inserted around 
the stomach is an adjustable plastic or silicone ring, just underneath the gastro-
oesophageal junction, thus forming a small pouch (Figure  1-5 (Dixon et al. 
2012).  
Gastric banding has been shown to be one of the most efficacious and cost 
effective types of bariatric surgery (O'Brien, 2010).  The continued effect is 
achieved via the adjustability of the band; it is also reversible, allowing access 
to potential alternative therapeutic options in the future. Following this type of 
surgery long-term skilled aftercare is required, as well as surgical maintenance, 
with roughly 10% requiring revisional surgery, which is a surgery performed on 
patients who experienced complications from a previous bariatric surgery or did 
not attain significant weight loss from the initial surgery within the ten years 
succeeding surgery. Such post-surgical care significantly increases the cost of 
gastric banding.  
Given the reduced level of risk associated with gastric banding compared to 
other surgical methods (e.g. risk of T2DM, heart attacks and strokes etc.; 
(O'Brien 2010, Dixon et al. 2012, Dixon et al. 2012). Research by Maggard et al. 
(2005) suggests that only 1 in 2000 or 1 in 3000 deaths rates occur in gastric 
banding, which is 10-15 times less than RYGB, for instance. In addition, O'Brien 
(2010) affirms that only roughly 10% of patients require a revisional procedure. 
Therefore, due to its gentle and effective nature, as well as the procedure not 
involving removing any part of the stomach like other surgical methods, gastric 
banding is the ideal procedure for those who wish to undergo a less risky 
procedure. 
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Figure  1-5: Gastric band (Dixon et al. 2012). 
The gastric band is placed at the top of the stomach with no significant gastric pouch above. It is 
proposed that compression of vagal afferents within this area of gastric cardia mediate the 
satiety effect (O'Brien 2010). 
1.1.6.2 Roux-en-Y gastric bypass 
Since the early 1980s, one of the most effective bariatric surgery procedures 
known across the world has been the Roux-en-Y gastric bypass (RYGB; Dixon 
et al., 2012). During this procedure, the stomach is separated from the upper 
pouch (with a volume of roughly 15–30 mL), and the lower gastric remnant. 
Thereafter, by way of a gastro-jejunal anastomosis, the pouch is anastomosed 
to the jejunum in a RYGB manner (Papamargaritis et al. 2012). In other words, 
the procedure involves reducing the size of the stomach to a small pouch, thus 
encouraging the reduction of food intake during meals. The pouch is directly 
attached to the small intestine, which therefore lowers the amount of calories 
and fat that the patient can absorb from suitable foods they can eat for added 
weight loss (Tham et al. 2014); Figure ‎1-6).  
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Figure ‎1-6: Roux-en-Y gastric bypass (RYGB; (Dixon et al. 2012).  
The RYGB involved complete separation of a small section of upper stomach from the body of 
stomach, creation of a Roux-en-Y length of proximal jejunum which is anastomosed to the 
proximal gastric pouch. Intake is restricted by the small pouch, gastric emptying is restricted by 
the narrow gastrojejunostomy and food is diverted from the duodenum (O'Brien 2010). 
 
RYGB is seen as the most effective way of achieving significant excess weight 
loss (EWL) within a short time period (Hall et al. 1990). The percentage of 
excess weight loss (%EWL) is a common metric for reporting weight loss after 
bariatric surgery.  The %EWL can vary depending on the definitions of ideal 
body weight (IBW) used and the preoperative weight (Montero et al. 2011). 
EWL is the amount of existing extra weight that is lost in the body after an 
intervention (Equation ‎1-2).  
However, such approaches like RYGB come with some limitations, for example, 
the pouch size cannot be adjusted nor is it reversible. Another downside is that 
over time, its effectiveness has been shown to wear off. A year after RYGB, 
EWL is around 60-70%, and subsequently this drops to 50% for those who 
attend the follow up after five years. According to Welbourn et al. (2014) of the 
UK National Bariatric Surgery Registry, between 55%-70% EWL can be 
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achieved through RYGB, whilst sleeve gastrectomy achieves only 55-60% 
EWL. Both of these are more effective than gastric banding which produces 
only 45-55% EWL. Therefore, these figures affirm why RYGB is the most 
effective procedure worldwide (Welbourn et al. 2014).  
Equation  1-2: Percentage excess weight loss (% EWL; 
(Welbourn et al. 2014) 
 
%𝐸𝑊𝐿 =  
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑚𝑎𝑠𝑠(𝑘𝑔) − 𝑐𝑢𝑟𝑟𝑒𝑛𝑡 𝑚𝑎𝑠𝑠 (𝑘𝑔)
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑚𝑎𝑠𝑠 (𝑘𝑔) − [25 (𝑘𝑔 𝑚−2) × ℎ𝑒𝑖𝑔ℎ𝑡2 (𝑚2)]
× 100 
 
RYGB has been suggested to be effective in overcoming obesity related 
diseases such as T2DM, potentially through a post-prandial rise in the incretins 
such as glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). 
The mechanism of how bariatric surgery reverses diabetes will be discussed in 
further detail in section ‎1.1.7. 
Since the likes of biliopancreatic diversion have shown similar outcomes to 
RYGB, such as reversing diabetes and achieving substantial weight loss (Flum 
et al. 2004), patients decide to undergo these types of surgeries to help 
overcome their obesity, despite the inherent risk of such surgeries (Flum et al. 
2004).  
1.1.6.3 Biliopancreatic diversion  
Only a partial gastrectomy is required in biliopancreatic diversion (BPD), which 
leaves a gastric pouch with a volume of 400 ml. Then, to the nearest ileocaecal 
valve, the small bowel is joined to it (250 cm). After that, both the alimentary 
limb and the gastric pouch are joined together, thus creating a Roux–en–Y 
gastroenterostomy (Papamargaritis et al. 2012); Figure  1-7) 
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Figure  1-7: Biliopancreatic diversion (BPD; (Dixon et al. 2012). 
The BPD is procedure comprises partial gastrectomy (about 50-60%) and gastroentero-
anastomosis. The ileum is then divided 250 cm proximal to the ileocaecal valve and the distal 
end is anastomosed to the resected stomach. The proximal end of small bowel, which carries 
the biliary tract, is then sutured to the distal ileum at about 50 cm from the ileocaecal valve 
(Mingrone et al. 2009).  
 
BPD has been proposed as the most metabolically severe choice of surgery, 
and has such has proven unpopular among surgeons and patients, despite the 
positive published outcomes. According to Anderson and co-workers (2013), 
the metabolic consequence of BPD is that patients can eat their everyday 
meals, but remain malnourished (Anderson et al. 2013); (Faintuch et al. 2004), 
besides developing common deficiencies, such as a deficiency of fat soluble 
vitamins, including vitamin B1, vitamin B12, and folate, iron-deficiency anaemia, 
hypocalcaemia, and protein calorie malnutrition (Aills et al. 2008).  
It has been almost four decades since BPD was first made available (Scopinaro 
et al. 1979) and plays only a small role in modern bariatric surgery. Figures by 
Buchwald and Oien (2009) suggest that BPD makes up less than 2% of 
bariatric surgeries, despite significant weight loss results being achieved with 
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this procedure (75-80% EWL), thus it should be a second-line bariatric surgical 
choice (Buchwald et al. 2009).  
1.1.6.4 Sleeve gastrectomy   
A sleeve gastrectomy (SG) consists of transecting the stomach in a vertical 
direction, forming a gastric tube, and what is left is a pouch with a 150-200 mL 
volume. Thereafter, the left over stomach is removed (Figure  1-8; 
(Papamargaritis et al. 2012). The sleeve is the initial element of the duodenal 
switch procedure, which is a common alternative to BPD. Given that it is a 
simple and effective surgical procedure that requires no follow up, it has 
become one of the most popular single procedures in the world (O'Brien 2010).  
 
Figure  1-8: Sleeve gastrectomy (Dixon et al. 2012).  
The stomach is transected vertically, creating a gastric tube and leaving a 150–200 mL pouch. 
The greater curve of the stomach is transected approximately 4–6 cm proximal to the pylorus 
and the remaining stomach is excised (Papamargaritis et al. 2012). 
 
A 2009 systematic review of 36 studies exhibited an average weight loss of 
55% within three years (Brethauer et al. 2009), however one study has reported 
a 40% weight regain within the five years post-operation (Weiner et al. 2007). 
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Furthermore, a study by the NBSR reaffirms these figures by pointing out that 
up to 55-60% EWL can be achieved by having sleeve gastrectomy surgery 
(Welbourn et al. 2010).  
Moreover, it is often expected that the sleeve will not sustain weight loss due to 
the expansive nature of the stomach, and this would call for the completion of 
the duodenal switch (DS). DS yields malabsorptive and restrictive effects 
(O'Brien 2010). The malabsorptive effect is achieved by redirecting a large 
portion of the small intestine, making one common channel and two separate 
pathways, while the restrictive effect is achieved by taking out roughly 70% of 
the stomach along the greater curvature. However it should be noted that 
leakage can occur in less than 1% of cases and often lasts for a number of 
months, thereby producing further cost, morbidity and anxiety (O'Brien 2010).  
1.1.6.5 Efficacy of types of bariatric surgery  
Despite the positive effects of bariatric surgery, it is by no means the quickest 
solution for obesity. Bariatric surgery is a process that begins by carrying out a 
preliminary clinical evaluation and patient review, and after surgery, patient 
follow-up, which lasts roughly 3-4 weeks depending on the type of bariatric 
surgery (Shen et al. 2004). Table ‎1-6 summarises the advantages and 
disadvantages that have been reported between the most common types of 
bariatric surgery.     
Furthermore, perioperative complications and, in worst case scenarios, death, 
are a possibility in all procedures. Thus, revisional surgery is common as 
preserving the right anatomy is essential for effectiveness. In spite of the 
previous issues, bariatric surgery can help to resolve the issue of obesity, since 
it can attain significant weight loss, better quality of life and health, as well as 
prolonged life expectancies (O'Brien 2010).  
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Table  1-6: Advantages and disadvantages several common types of bariatric surgery 
(Welbourn et al. 2014, O'Brien 2010, Buchwald et al. 2004) 
Type of bariatric 
procedure 
Advantages Disadvantages Excess weight 
loss (Welbourn et 
al. 2014). 
Percentage of total number of 
bariatric procedures performed 
in UK (Welbourn et al. 2014). 
Gastric band First step for other procedures 
 
Safer, since the surgical procedure is 
low-risk. 
 
Fewer side effects than other 
operations. 
 
Fully reversible, since the stomach’s 
anatomy is unaltered. 
 
Faster recovery times; it is a 30-45 
minute procedure with very little scaring 
and patients are fully recovered within 
roughly one week (O'Brien 2010). 
Patients can experience band slippage, 
where the band slides up and down the 
stomach from its starting position. 
 
Stomach enlargement 
 
Band migration; this happens when the 
gastric band progressively wears 
through the stomach wall. 
The band can cause discomfort, 
thereby forcing patients to have the 
band removed. 
 
Nutritional deficiencies; iron, calcium, 
and vitamin B12 being among the most 
common. 
 
Acid reflux symptoms as a result of the 
gastric band being placed too tight 
(O'Brien 2010). 
 
Approximately  
45-55%  
 
23.2% 
Roux-en-Y gastric 
bypass 
Effective for patients with a higher BMI 
as more excess weight loss can be 
attained via this procedure. 
 
Helps to reduce the risk of T2DM and 
can induce hormonal changes, thus the 
need for diabetic medication is 
reduced, or in some cases, no 
medication is required at all. 
 
Helps to overcome obesity related 
issues, such as high cholesterol and 
Even though it is possible to reverse 
this procedure in a technical sense, 
such cases are rare, thus leaving very 
little options. 
 
Complications are more serious 
compared to other procedures; the 
worst case being death. 
Patients can suffer from nutritional 
deficiency because of the reduced 
absorption of nutrients and vitamins 
(O'Brien 2010).  
Approximately 
55-70%  
 
53.8% 
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Type of bariatric 
procedure 
Advantages Disadvantages Excess weight 
loss (Welbourn et 
al. 2014). 
Percentage of total number of 
bariatric procedures performed 
in UK (Welbourn et al. 2014). 
blood pressure, among others. 
 
No need for continuous adjustments, 
which are needed in other procedures 
such as gastric banding (O'Brien 2010) 
 
Biliopancreatic 
diversion 
The amount of food eaten is not 
restricted. 
 
Patients are able to maintain weight 
loss.  
 
Roughly 95% of patients will completely 
reverse their diabetes within around 
two years (Buchwald et al. 2004).  
 
Surgical complications are more likely 
compared to other procedures.  
 
Nutritional deficiencies such as 
deficiencies in iron, calcium, vitamin A 
and D and protein. 
 
60% chance of developing gallstones 
due to rapid weight loss.  
 
Dumping syndrome which occurs in the 
course of eating high amounts of fat, 
sugar or alcohol, or large amounts of 
food, which causes nausea, vomiting, 
diarrhoea, sweating, faintness, 
weakness and increased heart rate 
(Buchwald et al. 2004).  
Approximately  
75-80%   
 
N/A 
7
 
 
Sleeve gastrectomy It reduces the volume of the stomach, 
thus making the patient feel full faster; 
the part of the stomach that produces 
ghrelin, which is responsible for the 
sensation of hunger, is completely 
removed, thus eliminating prolonged 
More risk of insufficient weight loss 
Patients may regain weight compared 
to band or bypass surgeries. 
 
The procedure is irreversible, since 
particular parts of the stomach are 
Approximately 
55-60%  
 
21.5% 
                                            
 
7
 No data was reported for the prevalence of this operation as a proportion of the total number of surgeries performed; however, this operation falls 
under the category of other, which accounts for approximately 1.5% of total bariatric surgeries performed between the years 2011 (Welbourn et al. 
2014).  
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Type of bariatric 
procedure 
Advantages Disadvantages Excess weight 
loss (Welbourn et 
al. 2014). 
Percentage of total number of 
bariatric procedures performed 
in UK (Welbourn et al. 2014). 
hunger. 
 
The stomach will function as normal, 
thus patients’ can still eat their 
everyday foods, but in reduced 
portions. 
 
Patients will not suffer from dumping 
syndrome, since the pyloric part of the 
stomach remains intact. 
Reduced operative times in the 
hospital. 
 
No foreign bodies are placed in the 
stomach as in band surgeries (O'Brien 
2010). 
 
removed (Buchwald et al. 2004).  
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1.1.7 Mechanisms of weight loss and metabolic improvement 
following bariatric surgery 
The proposed mechanisms for weight loss following bariatric surgery can be 
divided into three main categories: 1) malabsorption, in which weight loss is due 
to a decreased absorption of nutrients and particularly fat in the intestines, 2) 
restriction, in which weight loss is due to decreased nutrient absorption in the 
stomach as well as decreased food intake due to reduced stomach size and 3) 
hormonal, in which a change in hormones released from the gut and fat tissue 
resulting in change in absorption of fat, satiety, food intake and food preference 
is the cause of weight loss. 
Gastric bypass procedures, for example, BPD were originally thought to 
increase calorie malabsorption since the signs of decreased fat absorption such 
as increased faecal fat, diarrhoea and an increase in the occurrence of 
hypoalbuminaemia (a lower than normal level of albumin in the blood)  were 
observed following BPD (Cornicelli et al. 2010).   
RYGB was primarily intended to combine two mechanisms: malabsorption and 
restriction (Papamargaritis et al. 2012). This procedure has been suggested to 
cause malabsorption due to pancreatic and biliary secretions that mix with the 
food in short segments of the small intestine (Proczko-Markuszewska et al. 
2011).  Some researchers have described normal levels of albumin and faecal 
fat, while other researchers have observed only small increases in faecal fat 
levels following RYGB procedure (Papamargaritis et al. 2013). Hence, the 
malabsorption after RYGB has been proposed to depend on the length of the 
intestine and food choices (Papamargaritis et al. 2012).  
Some bariatric procedures are intended to reduce stomach size such as RYGB, 
SG and LAGB (Papamargaritis et al. 2012). Early gastric distension occurrence 
due to the smaller size of the stomach leads to a decrease in the size of the 
meals taken and to early satiety (Papamargaritis et al. 2012, Tadross et al. 
2009, Le Roux et al. 2006, Stylopoulos et al. 2009).  
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Moreover, most of the bariatric researchers in LAGB propose that gastric 
restriction is not the main physiological mechanism for weight loss 
(Papamargaritis et al. 2012).  Another theory that can help to explain body 
weight loss, blood glucose balance and body energy is the gut hormones and 
their effect. The main gut hormones involved in these processes are: glucagon 
like peptide-1 (GLP-1), peptide YY (PYY) and ghrelin (Papamargaritis et al. 
2012, Pournaras et al. 2010).  
1.1.7.1 Glucagon like Peptide-1  
Glucagon like Peptide-1 (GLP-1) is produced by L-cells which are mainly found 
in the ileum, and secreted by the gastrointestinal tract within minutes of food 
intake, causing glucose dependent secretion of insulin (Papamargaritis et al. 
2012, Basso et al. 2011). Bariatric surgery has been shown to enhance 
postprandial GLP-1 secretion which is associated with an increase in insulin 
release from pancreatic beta cells while suppressing glucagon release from 
pancreatic alpha cells (Karra et al. 2010). GLP-1 also promotes satiety both 
through a direct inhibitory effect on gastric emptying and a stimulatory effect on 
the satiety centre in the hypothalamus. It is thought that the increased speed by 
which undigested nutrients are delivered to the small intestine after bariatric 
surgery increases the release of GLP-1 in response to a meal. This increase is 
thought to be a partial mechanism that contributes to weight loss (Karra et al. 
2010). 
1.1.7.2 Peptide YY 
Peptide YY (PYY) is a 36-amino acid peptide produced by the L-cells of the 
distal small intestine and colon which is released into the circulation after food 
ingestion together with GLP-1 (Karra et al. 2010). PYY also inhibits gastric and 
pancreatic secretion. PYY has similar functions to GLP-1, as it slows gastric 
emptying, stimulates satiety centrally, and regulates appetite and body weight 
(Karra et al. 2010, Fenske et al. 2012). Similarly to GLP-1, the delivery of 
undigested nutrients to the intestine after bariatric surgery occurs more rapidly, 
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increasing secretion of PYY which may contribute to weight loss (Karra et al. 
2010).   
1.1.7.3 Ghrelin  
Ghrelin is a 28 amino acid peptide produced by the X/A-like cells of the fundus 
and the body of the stomach (Papamargaritis et al. 2012, Karra et al. 2010, 
Fenske et al. 2012).  Ghrelin has an important role in the stimulation of insulin 
regulatory hormones such as glucagon and C-peptide (Porcellati et al. 2003), 
inhibiting the insulin-sensitising hormone adiponectin and suppressing insulin 
secretion (Papamargaritis et al. 2012, Karra et al. 2010). Increasing the level of 
ghrelin causes an increase in hunger and its suppression occurs just minutes 
after food intake. However, the level of ghrelin increases with diet-induced 
weight loss, which may be an obstacle behind long-term weight loss. Bariatric 
surgeries decrease ghrelin levels which could be advantageous in controlling 
weight loss (Karra et al. 2010).  
1.1.7.4 Adipose tissue   
Leptin and ghrelin are two hormones that have been recognized to have a 
major influence on energy balance. Leptin is a mediator of long-term regulation 
of energy balance, suppressing food intake and thereby inducing weight loss.  
Ghrelin on the other hand is a fast-acting hormone, seemingly playing a role in 
increasing hunger (Klok et al. 2007), which is known to be higher in obese 
patients, but it decreases after bariatric surgery, independent of weight loss 
(Drucker et al. 2006). Leptin, on the contrary to ghrelin, is a cell-signalling 
hormone that helps to regulate body weight, food intake and appetite, as well as 
modulating the size of the body’s adipose tissues (Wortley et al. 2004). 
Adiponectin is a protein that is involved in the regulation of glucose levels and 
fatty acid breakdown. Obese patients present lower levels of this hormone 
which plays a role in insulin resistance. It increases after bariatric surgery, 
independent of weight loss (Drucker et al. 2006, Gan et al. 2007). 
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1.1.7.5 Change in food preference  
Some human studies published support the idea that patients’ experience 
changes in eating behaviour from high to low fat foods after bariatric surgery 
(Papamargaritis et al. 2012, Olbers et al. 2006, Dixon et al. 2012, Favretti et al. 
2002). Moreover, a rodent study also showed the same effect after a bariatric 
procedure (Suzuki et al. 2011). The authors suggest that the eating behaviour is 
affected by two factors; internal signals, for example, hormonal or neural, and 
external signals, such as food amount and social conditions (Rolls 2012).  
Furthermore, Le Roux reported in 2012 that one of the mechanisms for weight 
loss after bariatric surgery might be an effect on food preference. These could 
be the effect of post-ingestion and taste perceptions (Papamargaritis et al. 
2012). However, one of the possible causes of weight reduction and changes in 
food preferences might be dumping syndrome due to quick gastric emptying 
and the increased secretion of gut hormones. Dumping syndrome is a series of 
symptoms, consisting of abdominal discomfort, weakness, and diarrhoea or 
quick bowel evacuation, which occurs straight after meals in those patients who 
have had gastric surgery (Papamargaritis et al. 2013). There are two phases of 
dumping syndrome that progress after a bariatric surgery: early dumping 
initiates 15-30 minutes after eating, with symptoms like nausea, vomiting, 
diarrhoea and fatigue (Tack et al. 2009). Late dumping occurs one to three 
hours after, with symptoms such as sweating, dizziness and weakness (Tack et 
al. 2009).  
According to Papamargaritis and co-workers (2012), patients who undergo 
RYGB present a decreased preference for sweet food (Papamargaritis et al. 
2012). Olbers and co-workers (2006) report that taste preference is changed 
after RYGB in both animals and humans (Olbers et al. 2006). One year after 
RYGB, patients reported consuming fewer sweet foods and making more 
healthy choices like fruits and vegetables (Tam et al. 2011). 
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1.1.7.6 Change in appetite  
Some patients have reported changes in appetite, increased satiety and 
decreased hunger a few days after bariatric surgery (Le Roux et al. 2006, Dixon 
et al. 2005). In 2006, Le Roux and his group proposed that the probable 
mechanisms for changes in hunger and satiety, such as decreased food intake 
and the ability to maintain weight loss for longer after bariatric procedures, are 
due to the changes in the postprandial levels of GLP-1 and PYY that induce 
satiety, before any major weight loss (Basso et al. 2011). 
1.1.8 Effects of bariatric surgery on diabetes  
There have been direct and strong links shown between obesity and T2DM 
through both preclinical and clinical studies (Torquati et al. 2005). The majority 
of patients who are diagnosed with T2DM are overweight, with 50% obese and 
9% morbidly obese (Dixon et al. 2005). Consequently, weight loss is possibly 
the most powerful treatment for T2DM: both surgical (Proczko-Markuszewska et 
al. 2011, Pournaras et al. 2010), or non-surgical weight loss (Chakaroun et al. 
2012), have resulted in a significant percentage of patients with T2DM 
achieving glycaemic control and entering remission (Gan et al. 2007, Lee et al. 
2012).  
Bariatric surgery has been shown to cause remission in T2DM (Buchwald et al. 
2004). Indeed, the first report of the improvement of diabetes after gastrectomy 
was more than 50 years ago (Table ‎1-7) (Vidal et al. 2008, Rizzello et al. 2010).  
In 1995, there were changes described in glycaemic control after gastric bypass 
surgery in morbidly obese patients with diabetes (Pories et al. 1995). The 
effects of bariatric surgery on T2DM have been described in two systematic 
reviews (Buchwald et al. 2004, Maggard et al. 2005). Buchwald and Maggard 
reported a range of 64–100% improvement in T2DM and there was a direct 
relationship between weight loss and remission (Buchwald et al. 2004, Maggard 
et al. 2005). Weight loss and diabetes resolution were shown in patients 
undergoing biliopancreatic diversion/duodenal switch, gastric bypass, and 
31 
banding procedures (Buchwald et al. 2004).  Insulin levels dropped significantly 
postoperatively; as did haemoglobin A1c (HbA1c) and fasting glucose values 
(Buchwald et al. 2009).   
However, the most striking observation was that the improvement in glycaemic 
control occurred within days of surgery, before any significant weight loss had 
been achieved, and this therefore suggested that the mechanism is 
independent of weight loss (Buchwald et al. 2009, Pories et al. 1995).  
The effect of bariatric surgery on T2DM is believed to be, at least in part, 
through a decrease in hepatic and peripheral insulin resistance (Pournaras et 
al. 2010, Gan et al. 2007). Several studies have demonstrated a drop in insulin 
resistance as quickly as six days after bariatric surgery (Wickremesekera et al. 
2005). Remarkably, this acute change in insulin resistance has been reported to 
occur many weeks before weight loss is observed (Wickremesekera et al. 2005, 
Pournaras et al. 2010). Although the exact mechanism explaining how bariatric 
surgery can alter insulin resistance so quickly has not been elucidated, several 
hypotheses have been proposed. These include alteration in gastrointestinal 
peptides (i.e. GLP-1), in inflammatory response or in change in appetite and 
food preference (Pournaras et al. 2010).  
Although a good diet and an adequate amount of exercise are vital towards 
treating T2DM, bariatric surgery has recently been suggested as an alternative 
therapeutic approach for T2DM (Dixon et al. 2012, Stylopoulos et al. 2009, 
Schauer et al. 2003). As a result, bariatric surgery has now been labelled as a 
“metabolic surgical procedure” or “metabolic surgery” (Rubino et al. 2010b). 
Table ‎1-7 describes a number of studies that have observed an improvement in 
blood glucose levels as well as insulin resistance within a short period following 
bariatric surgery. There are currently several competing hypotheses that offer 
explanations of how glycaemic improvement might occur before weight loss, 
following bariatric surgery: the hindgut hypothesis, the foregut hypothesis, the 
inflammation hypothesis and the gluconeogenesis hypothesis, all of which are 
discussed below. 
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1.1.8.1  Hindgut hypothesis (changes in insulin secretions) 
The main site for the absorption of nutrients following digestion and for 
maintenance of the balance of fluids in the gastrointestinal system is the small 
intestine, which consists of three parts: the duodenum, the first segment after 
the stomach (25 cm length), the jejunum, the middle segment after the 
duodenum (100 -110 cm length) and the ileum, the lower segment of the small 
intestine after the jejunum (150 -160 cm length; (Papamargaritis et al. 2012). 
The food is redirected after the surgery, and partly digested food is delivered to 
the distal gut.  The shorter gastrointestinal tract results in an increase in insulin 
secretions and gut hormones such as GLP-1 and PYY (Pournaras et al. 2010).  
This leads to improved glycaemic control (the effect of food on an individual’s 
blood glucose level) in the short-term (within days) and to weight loss in the 
long-term (within months) (Mingrone et al. 2009).  
1.1.8.2 Foregut hypothesis (changes in hepatic insulin 
resistance) 
Bypass surgeries affect the proximal part of the small intestine, which 
decreases the secretion of insulin and encourages insulin resistance through as 
yet unknown gastrointestinal factors (Pories et al. 2001). The remission in 
T2DM is due to the increase in secretion or effect of insulin and reduction of 
anti-incretins (Rubino et al. 2010b). After bypass surgery, the rapid delivery of 
nutrients to the lower intestine (the duodenum) increases stimulation of L-cells, 
which results in increased secretion of hormones such as GLP-1 that improve 
insulin release and action, thus resulting in a decrease in blood glucose (Rubino 
et al. 2010b). However, this may have a contradictory effect, as the duodenum 
tries to correct the anti-incretin reduction, which results in the reduction of 
insulin secretion and production, resulting in a higher risk of T2DM (Garrido-
Sanchez et al. 2012). In rodents, the improvements in T2DM have been shown 
to be due to reduced hepatic glucose production (Papamargaritis et al. 2012).  
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Table  1-7: Summary of evidence for the effect of bariatric surgery on diabetes.  
Reference Surgery type Improvement in insulin resistance Time of 
improvement in 
insulin resistance 
(Basso et al. 
2011) 
 
Sleeve 
gastrectomy  
Restoration of the first phase of insulin secretion and improved insulin sensitivity in diabetic 
obese patients immediately after SG, prior to any food passage through the gastrointestinal 
tract and prior to any weight loss. Appears to be associated with GLP-1, ghrelin, and PYY 
hormonal alterations of likely gastric origin and is not down to meal nor weight related 
changes. 
 
3 days, but 
not significant 
(Rizzello et al. 
2010)  
Sleeve 
gastrectomy 
Reduction in serum glucose and insulin concentration, as well as the homeostasis model 
assessment of insulin resistance (HOMA IR)8 value. 
 
5 days 
(Wickremesek
era et al. 
2005)  
Roux-en-Y 
gastric bypass 
The modification in insulin resistance observed after RYGB, which helps to overcome T2DM 
occurs within 6 days of the procedure, prior to any substantial weight loss being observed. 
 
6 days 
(Isbell et al. 
2010)  
Roux-en-Y 
gastric bypass 
Signs of insulin sensitivity improving are observed 6 days after the RYGB procedure without 
any significant weight loss. 
Within 1 week after the RYGB, prior to any observable weight loss, insulin sensitivity 
(HOMA-IR) had improved by 25%. 
 
6 days 
                                            
 
8
 HOMA IR is defined as the product of fasting plasma insulin and glucose divided by 22.5 and is a tool used to estimate insulin sensitivity from a single 
sample (Matthews et al. 1985).  
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Reference Surgery type Improvement in insulin resistance Time of 
improvement in 
insulin resistance 
2-10 weeks after the RYGB, recurring stability in fasting levels of GLP-1 is detected.   
   
(Pournaras et 
al. 2010)  
Gastric bypass 
and gastric 
banding 
T2DM is improved by undergoing a gastric bypass procedure, and in the best case 
scenario, the patient is put in a state of remission, regardless of weight loss. 
It remains unexplained how within the first hours after the procedure, insulin resistance 
improves, although insulin production usually rises within the same week, which could be 
justified by the improved postprandial GLP-1 responses. 
 
 
7 days 
(Garrido-
Sanchez et al. 
2012)  
Gastric bypass 
and 
biliopancreatic 
diversion 
Unlike those procedures that include the duodenum (i.e., SG), surgical procedures that 
exclude the duodenum (i.e., BPD) show abrupt modifications in the extent of insulin 
resistance in those patients who are morbidly obese.  
 
15 days 
(Mingrone et 
al. 2012)  
Gastric bypass 
and 
biliopancreatic 
diversion 
Weight loss dose not significantly predict diabetes remission within 2 years or 
improvements in glycaemia after 1-3 months. 
 
 
1 month 
(Vidal et al. 
2007)  
Laparoscopic 
SG, 
laparoscopic 
Roux-en-Y 
gastric bypass 
 
Laparoscopic SG and RYGB caused a similar rate of T2DM resolution 4 months after the 
procedure. 
 
4 months 
(Reis et al. 
2010)  
Gastric bypass 
 
This procedure resulted in improved weight loss and better erectile function, as well as 
increased total testosterone (TT), follicle-stimulating hormones (FSH), free testosterone 
(FT) and prolactin (PRL) levels.  
 
 
4 months 
(Torquati et al. Roux-en-Y 
gastric bypass 
Most patients stopped taking all antidiabetic medications including insulin, six months after 
surgery. After the RYGB, there is a premature occurrence of improved glucose metabolism, 
and this is not totally associated with weight loss.  
 
6 months 
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Reference Surgery type Improvement in insulin resistance Time of 
improvement in 
insulin resistance 
2005)  
(Vidal et al. 
2008)  
Sleeve 
gastrectomy 
1 year after the procedure, both SG and RYGB are equally as effective in encouraging the 
remission of T2DM. 
12 months 
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1.1.8.3 Anti-incretin hypothesis 
As discussed in section ‎1.1.7, incretins are gastrointestinal peptides whose 
secretions are activated by the passage of food through the small intestine 
(Sjöholm 2009). GLP-1 lowers glucose by decreasing gastric emptying, 
restoring insulin sensitivity, and decreasing glucagon secretion, which may 
result in a reduction in the production of hepatic glucose (Basso et al. 2011). 
The initial stimulation of L-cells after bariatric surgery may cause increased 
production of GLP-1 and improved insulin secretion (Rizzello et al. 2010).  
In addition to incretins, other hormones might affect the glucose balance after 
bariatric surgery, including ghrelin, PYY, leptin and adiponectin (Papamargaritis 
et al. 2012). This may be explained by an increase in anti-incretin, which could 
disturb the incretin/anti-incretin balance. Furthermore, diabetic patients who 
have had a gastric bypass may show inhibition of the excess release of anti-
incretins, but this hypothesis has not been confirmed (Rubino et al. 2010b).  
1.1.8.4 Inflammation hypothesis 
Another hypothesis that has been presented is the so-called inflammation 
hypothesis. The first organ that interacts with infectious agents or food-borne 
toxins is the gastrointestinal tract (Rubino et al. 2010b). The micro-biota of the 
gut can affect energy metabolism, obesity and T2DM (Rubino et al. 2010a). 
Inflammation in the adipose tissue has been shown to be one of the major 
factors in the regulation of hepatic insulin sensitivity (Troy et al. 2008). In 2011, 
Tam and his group linked inflammation in the GI tract with a high fat diet (HFD) 
and obesity. This link is further supported by research confirming that germ-free 
mice have less body fat and are resistant to diet-induced obesity (DIO) and that 
DIO is related to changes in gut micro-biota and increased gut inflammation 
(Tam et al. 2011). 
1.1.8.5 Gluconeogenesis hypothesis 
Intestinal gluconeogenesis is the de novo production and release of glucose by 
the small intestine. The main enzymes of gluconeogenesis are glucose-6-
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phosphatase (Glc6Pase) and phosphoenolpyruvate carboxykinase (PEPCK) 
(Figure  1-9; (Troy et al. 2008).  Moreover, the small intestine can be a 
significant supplier of glucose production when the liver is deficient. Intestinal 
gluconeogenesis encourages glucose infusion into the portal vein.  
 
Figure  1-9: Intestinal Gluconeogenesis Pathway (The medical biochemistry 
page 2015).  
Glucose and glutamine reach intestinal enterocytes from the arterial blood supply. The 
glutamine’ carbon atoms are a major substrate for intestinal gluconeogenesis, being catalysed 
by glutaminase and alanine transaminase (ALT) resulting 2-oxoglutarete  (α-ketoglutarate) that 
is transformed to oxaloacetate (OAA) and then to phosphoenolpyruvate (PEP). PEP is then 
diverted into the gluconeogenic pathway. Glucose can be oxidized to pyruvate through 
glycolysis and then the carbon atoms of pyruvate can be reduced to lactate or transaminated to 
alanine, both of which can function as major gluconeogenic substrate in the liver following 
delivery through portal circulation (The medical biochemistry page 2015). 
 
Protein-rich diets are shown to reduce hunger and induce the expression of 
G6Pase, PEPCK-c, and glutaminase in the intestine after food intake in both 
humans and animal models (Mithieux 2012). The gut releases glucose into the 
portal blood supply following the intake of a protein-rich diet and the level of 
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glucose release from the gut is sufficient to account for the level of reduction in 
food intake. This glucose which results from intestinal gluconeogenesis, does 
not increase overall endogenous glucose production (EGP), this is due to the 
liver compensating by reducing its own level of gluconeogenesis while 
increasing glycogen storage.  Animal studies demonstrate that portal sensing of 
intestinal gluconeogenesis is a key mechanism in the satiety effect induced by 
dietary protein (Mingrone et al. 2012, Mithieux 2012). When mice are fed a 
protein-rich, carbohydrate-free diet they do not show a decrease in their level of 
food intake and show a loss of satiety induction when portal vein afferent nerve 
(nerves send signals from body locations to the brain) connections are 
chemically or surgically destroyed (Mithieux 2012).  
Hence, a gastric bypass could possibly increase intestinal gluconeogenesis 
(Troy et al. 2008) and may also cause an enhancement of hepatic insulin 
sensitivity, in theory due to decreased hepatic gluconeogenesis, without having 
an effect on peripheral insulin sensitivity (Mingrone et al. 2009).  
1.2 Urogenital dysfunction  
The term urogenital refers to both urinary and genital organs. The male 
urogenital system consists of several parts, which include the testes, 
epididymis, vas deferens, ejaculatory ducts, urethra, penis, prostate and 
accessory glands (Figure ‎1-10) (Virtual Medical Centre 2015).   
The male sexual organ is the penis and its internal structure consists of the 
tunica albuginea, the corpora cavernosa, the urethra, two main arteries; and 
several veins and nerves (Courtenay 2002).  
The corpora cavernosa are two chambers that fill most of the penis. The 
chambers are filled with a spongy erectile tissue that, during an erection, fills 
with blood, expands and becomes rigid.   
A membrane called the tunica albuginea surrounds the corpora cavernosa 
which helps maintain the erection by keeping blood in the penis. The urethra is 
the tube which runs down the underside of the penis, under the corpora 
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cavernosa and connects the urinary bladder to the meatus, which is located at 
the glans (penis head) (Courtenay 2002). The prostate is a small gland located 
in the pelvis and surrounds the urethra and plays an important role in the 
production of semen and in ejaculation (Figure ‎1-10) (Virtual Medical Centre 
2015, Courtenay 2002). 
 
Figure ‎1-10: Male urogenital system anatomy (Virtual Medical Centre 2015). 
The male urogenital system consists of several parts, which include the testes, epididymis, vas 
deferens, ejaculatory ducts, urethra, penis, prostate and accessory glands (Virtual Medical 
Centre 2015). 
 
1.2.1 Definition of erectile dysfunction (ED)  
Erectile dysfunction (ED) is defined according to the National Institute of Health 
Consensus Development Panel on Impotence as the consistent inability to 
obtain or maintain an erection for satisfactory sexual intercourse (National 
Institutes of Health 1993). ED affects the quality of life and life satisfaction, not 
only of the patient but also his partner, causing loss of self-confidence and 
depression (Bushmakin et al. 2014). Erection is a complex neurovascular event 
consisting of the relaxation of the trabecular smooth muscles, arterial dilatation 
and activation of the corporeal veno-occlusive mechanism (Wespes et al. 
2002). 
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1.2.2 Epidemiology of erectile dysfunction 
ED is a common medical disorder, which was coined by a National Institute of 
Health consensus panel in 1993, and mainly affects middle-aged men aged 
over 40 (Braun et al. 2000). Current studies show a 1-10% prevalence of ED in 
men under 40, and this prevalence increases with age; there is 2-9% 
prevalence in men in the 40-49 age group, and it increases to 20-40% in the 60-
69 age group (Scopinaro et al. 1979, Bose et al. 2009, Dallal et al. 2008). In 
addition, there is a 50-100% prevalence in men aged over 70 (Braun et al. 
2000). By 2025, the expected number of ED cases worldwide is expected to 
reach 322 million (Aytaç et al. 1999). A more recent study by Schwartz and 
Kloner (2011) claims that over 150 million men are currently suffering from ED, 
particularly middle-aged men over the age of 40 (Schwartz et al. 2011). In 
addition, Kalejaiye and Persad (2014) expect that the prevalence of ED will 
continue to rise as the population ages (Kalejaiye et al. 2014), and thus will 
more than likely meet Aytac’s projected figures by 2025 (Aytaç et al. 1999).  
It is clear that ED is a major health problem today, especially for the ageing 
population. A number of studies have found that ED is linked to diabetes, 
depression, hypertension, hyperlipidaemia, metabolic syndrome, and lower 
urinary tract symptoms (LUTS) (Shamloul et al. 2013).  Furthermore, several 
studies have linked ED with cardiovascular disease (CVD) (Chung et al. 2011, 
Inman et al. 2009, Clark et al. 2007) as well as stroke, and all-cause mortality 
(Dong et al. 2011). Several studies (Dong et al. 2011, Cheng et al. 2007, Rosen 
et al. 2005) have also found that particular environmental and lifestyle factors, 
such as a lack of physical activity, obesity and smoking, all contribute towards 
ED. It has also been suggested that modifying one’s lifestyle habits through 
dietary reform and engaging in more exercise, decreases the risk of ED 
(Esposito et al. 2004).  
ED can also be a consequence of urogenital surgery. In 2003, 225,000 men 
were diagnosed with prostate cancer in the US alone, and out of these, 45% 
underwent radical prostatectomy surgery to remove the prostate gland. A major 
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disadvantage of this surgery is that most men will suffer from either permanent 
or temporary erectile dysfunction due to physical injury to the cavernous nerves 
during the surgery (Nandipati et al. 2006). 
In addition to radical prostatectomy, postsurgical ED can be caused by radical 
cystectomy; urinary diversion (in the case of bladder cancer), and colorectal 
cancer surgery. Not only may there be a loss of erection, but damage to 
cavernous tissue can also cause a reduction in penile size in both length and 
circumference. Such changes are likely to become apparent in the first few 
months after the surgery (Kirby et al. 2014). Furthermore, there is a 16-86% 
variance in the recovery of potency following radical prostatectomy. Even 
though radical changes in surgical technique seem to be hopeful, there are still 
high rates of ED currently being reported (Shamloul et al. 2013).  
1.2.3 Physiology of penile erection 
Within the central nervous system, sexual stimuli (tactile, visual, olfactory, and 
imaginative) are processed and integrated. Certain autonomic and somatic 
pathways are then activated inside the central and peripheral nervous systems, 
thus leading to a penile erection; this is the result of both the penis’s cavernosal 
and vascular smooth muscle becoming relaxed (Nunes et al. 2012). In contrast, 
a flaccid or detumescent penis consists of a heightened smooth muscle tone, 
and thus the tone of the penile smooth muscle is the key factor of erectile 
function. Furthermore, a rise in arterial inflow is achieved through the vascular 
smooth muscle becoming relaxed in the blood vessels supplying the penis, and 
through concurrent relaxation of the cavernosal smooth muscle. When 
combined with the decreased outflow via the contraction of striated 
ischiocavernosus muscles and the compression of subtunical venules, the 
intracavernosal blood pressure exceeds the systemic blood pressure, thus 
leading to a rigid erection (Nunes et al. 2012, Lue et al. 2004).  
Therefore, the key event in penile erection is the relaxation of vascular and 
cavernosal smooth muscle. The key signalling molecule involved in  penile 
smooth muscle relaxation is nitric oxide (NO), which is released from the 
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nitregic nerves and endothelial cells (Figure  1-11) (Lue et al. 2004). NO levels in 
the blood vessels and corpus cavernosum increase as sexual stimulus activates 
certain parts of the central nervous system and autonomic nerves. NO diffuses 
rapidly to neighbouring smooth muscle cells and activates intracellular soluble 
guanylate cyclase enzymes which synthesise cyclic guanosine monophosphate 
(cGMP) from guanosine-5-triphosphate (GTP). Elevated intracellular cGMP 
concentrations lead to a reduction of intracellular calcium concentrations 
resulting in vascular and cavernosal smooth muscle relaxation. Intracellular 
cGMP concentrations in the smooth muscle cells are tightly regulated by an 
enzyme called phosphodiesterase type 5 (PDE5) which hydrolyses cGMP to 
inactive 5’GMP. PDE5 inhibitors achieve enhanced penile erection by 
enhancing smooth muscle relaxation by slowing down the breakdown of cGMP 
levels (Sáenz de Tejada et al. 2004). 
 
Figure  1-11: Molecular mechanism of penile smooth muscle relaxation 
(Sáenz de Tejada et al. 2004).  
Legend: GC – guanylate cyclase; IP3 – inositol triphosphate; PKA – protein kinase A; cGMP – 
cyclic guanosine monophosphate; PLB – phospholipase B; PLC – phospholipase C; NO – nitric 
Oxide (Sáenz de Tejada et al. 2004). 
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1.2.4 Pathophysiology of erectile dysfunction 
Normal sexual activity is a bio-psychosocial process that involves the 
psychological, vascular, endocrine, and neurological systems (Shamloul et al. 
2013). The physiological process of penile erection is a multifaceted process 
including the peripheral nervous system, CNS and hormonal and vascular 
systems (Ulrich et al. 2001). Any irregularities in these systems, either from 
disease or medication, will have an influence on erectile function (Fedele 2005). 
The pathophysiology of ED can be divided into three mechanisms:  
1) Psychogenic erectile dysfunction is defined as the persistent inability to 
achieve or maintain a satisfactory erection for sexual performance due to 
psychological or interpersonal factors (Rosen 2001). Earlier, psychogenic 
dysfunction was presumed to be the most common type, with 90% of 
impotent men thought to suffer from this condition (Dean et al. 2005).  
Sexual behaviour and penile erection are controlled by the hypothalamus, 
the limbic system, and the cerebral cortex. Therefore, stimulatory or 
inhibitory messages can be relayed to the spinal erection centres to facilitate 
or inhibit an erection (Dean et al. 2005). 
2) Endothelial factor: because corporeal smooth muscle controls the vascular 
event leading to an erection, change of smooth muscle content and 
ultrastructure can affect erectile response (Dean et al. 2005). Diseases like 
diabetes and hypercholesterolemia have been shown to alter the 
endothelium-mediated relaxation of the cavernous muscle and impair 
erection (Dean et al. 2005). 
3) Neurogenic factor: It has been estimated that 10% to 19% of ED is of 
neurogenic origin (Dean et al. 2005). Even though the presence of 
neurologic dysfunctions does not eliminate other causes, confirming that ED 
is neurogenic in origin can be challenging. Since an erection is a 
neurovascular process, disorders affecting the brain, spinal cord, cavernous 
and pudendal nerves can induce ED (Dean et al. 2005).  
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However, during radical prostatectomy, which is a procedure required when the 
patient needs all or part of the prostate gland removed, injury can occur to the 
cavernosal nerve which may lead to erectile dysfunction but also to urinary 
incontinence. The recovery of erectile function is highly unlikely, although not 
entirely impossible (Nandipati et al. 2006, Chung et al. 2013). Nerve sparing 
prostatectomy is a technique that has been developed in an attempt to reduce 
erectile dysfunction following radical prostatectomy (Nandipati et al. 2006). 
There are two bundles of nerves which run parallel to the prostate, and these 
nerves assist in controlling erections. The surgeon carefully removes prostate 
tissue away from the nerve bundles without damaging them during a nerve 
sparing prostatectomy, as removing the prostate without causing harm to the 
nerves means it is far more likely for the patient to be able to have erections 
post-surgery; however, nerve sparing surgery increases the risk of some cancer 
cells not being removed (Garcia et al. 2014). Nerve sparing surgery is only 
suitable for patients with prostate cancers in the very early stages, and the 
cancer must be located entirely inside the prostate. Despite the majority of the 
nerves being preserved in the surgical procedure, some temporary ED usually 
occurs, however with the nerve-sparing technique; particularly bilateral nerve-
sparing, permanent ED is less likely compared to non-nerve sparing surgery, 
with recovery usually taking place within the first year or two after the procedure 
(Garcia et al. 2014). 
In sexual medicine, the concept of “Penile Rehabilitation” is relatively new, 
which involves medical and therapeutic treatment with the aim of restoring 
penile health and function before, during or after surgery, illness, trauma, or 
even lack of use. Penile rehabilitation is important for aiding men in regaining 
satisfactory sexual function. PDE5 inhibitors such as sildenafil, tadalafil or 
vardenafil are often used to treat ED post-surgery, (Kirby et al. 2014).  
In addition, the preoperative use of PDE5 inhibitors may help in protecting blood 
vessels and autonomic nerves (Gontero et al. 2004a, Gontero et al. 2004b). 
Moreover, some studies have shown that such medical treatments can in fact 
increase the amount of smooth muscle in the penis (Corbin 2004, Li 2015).  
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1.2.5 Diagnosis of erectile dysfunction  
There are several questionnaires that are widely used to diagnose urogenital 
dysfunction such as: The Male Sexual Health Questionnaire (MSHQ) which 
assesses the sexual function and satisfaction in older men with urogenital 
symptoms of LUTS and sexual dysfunction (Rosen et al. 2004). Brief Male 
Sexual Function Inventory (BMSFI) is a measure of sexual function in males 
(O'Leary et al. 1995). The International Consultation on Incontinence 
Questionnaire-Short Form (ICIQ-SF) is a four-item, disease-specific 
questionnaire that assesses the symptoms and quality of life for patients with 
urinary incontinence (Gotoh et al. 2009). The International Index of Erectile 
Function (IIEF; (Yule et al. 2011) and International Prostate Symptom Score 
(IPSS; (Plante et al. 1996) are tools used to evaluate the sexual and urological 
functions in males.  
The International Index of Erectile Function (IIEF) was designed and developed 
specifically for the assessment of male sexual function (Rosen 1999). The IIEF 
is simple, psychometrically sound and has been extensively validated. It is self-
administered and it has been demonstrated to have good sensitivity and 
specificity for detecting treatment-related changes in patients with erectile 
dysfunction (Rosen et al. 2004).  
The International Index of Erectile Function (IIEF) is a questionnaire that 
consists of 15 questions with multiple choice answers. IIEF was established in 
1996–1997 and has been used in several clinical trials including in populations 
of diabetic men (Yule et al. 2011).  
The IIEF questionnaire (Appendix A) consists of different domains: erectile 
function (6 questions); orgasmic function (2 questions); sexual desire (2 
questions); intercourse satisfaction (3 questions) and overall satisfaction (2 
questions; (Rosen 1999).  Each question is scored on a scale of 0-5 (see 
Appendix A; (Rosen et al. 1997).  
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Responses are recorded on a Likert-type scale9 with response choices over a 5 
or 6 point scale for questions 1-10 and 11-15 respectively. The lower anchor for 
the 6 point Likert-type scale is 0 while the highest rating is 5. The 5 point Likert-
type scale ranges from 1 to 5 with 1 representing the lower anchor. 
The questions are not weighted and total scores range from 5 to 75. The 
domain scores are computed by summing the scores for each individual 
question in each domain. The domain scores have the following ranges: erectile 
function (1-30), orgasmic function (0-10), sexual desire (2-10), intercourse 
satisfaction (0-15) and overall satisfaction (2-10).  
On the erectile function sub-scale, lower scores indicate worse erectile 
dysfunction, while on the remaining sub-scales higher scores indicate less 
dysfunction. All questions have to be completed. 
The IIEF assessment has two key limitations in assessing sexual dysfunction in 
males: very limited assessment of partner relationships and only a superficial 
assessment of psychosexual background. Therefore, this questionnaire must be 
seen as a means of support for comprehensive sexual examination and history 
(Rosen et al. 1997) including questions about erectile problems that have had 
an impact on the patient’s sex life during the previous four weeks prior to his 
appointment. In Rosen’s study patients were also asked to describe their 
erectile function according to questions 1, 2, 3, 4, 5 and 15 (Rosen et al. 1997). 
The maximum score of erectile function (EF) domain is 30, and any score lower 
than 25 suggest impaired EF. An optimal cut-off score of 25 or less has been 
used for the diagnosis of ED (Cappelleri et al. 1999) and, in accordance with 
Cappelleri’s study, the evaluation of erectile function as a domain of IIEF has 
been divided into five categories according to severity: No ED (EF score from 
                                            
 
9
 Likert-type scale is one of various different rating scales that have been developed to measure 
attitudes directly (i.e. the person knows their attitude is being studied). Examples of the multiple 
choices in the Likert scale are as follows: strongly agree/ agree/ undecided/ disagree/ strongly 
disagree (Wilson et al. 2000).  
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26 to 30); mild ED (EF score from 22 to 25); mild to moderate ED (EF score 
from 17 to 21); moderate ED (EF score from 11 to 16), and severe ED (EF 
score 6 to 10; (Cappelleri et al. 1999).  
1.2.6 Treatment of erectile dysfunction 
The principal step in treatment of ED is taking a detailed history of medical, 
sexual and psychosocial conditions (Esposito et al. 2004). Medical therapy with 
phosphodiesterase type 5 (PDE5) inhibitors is the first line of treatment 
(Costabile et al. 2003), and these medications are highly acceptable for patients 
and easy to administer, because of their efficacy and low side effects 
(Hatzimouratidis et al. 2009, Kubin et al. 2003). Unfortunately, the response rate 
to PDE5 inhibitors is lower in diabetic men than in non-diabetic (Goldstraw et al. 
2007). In about 30-40% of diabetic patients, PDE5 inhibitor treatment is not 
successful due to autonomic neuropathy and peripheral vasculopathy 
(Goldstraw et al. 2007, Sarwer et al. 2012). 
Further treatments consist of psychosexual therapy such as sex education and 
interpersonal therapy for relationship problems (Rosen 1999); shifts in lifestyle 
to being more healthy and active by increasing physical activity; weight 
reduction, quitting smoking (Horasanli et al. 2008), and testosterone 
supplementation.  
Second line therapies include intracavernosal injections, intraurethral injections 
and vacuum constrictive devices (Shamloul et al. 2013). However, vacuum 
erection devices and transurethral injection of Prostaglandin E1 (PGE1) are not 
commonly used either because of urethral infections following the use of PGE1 
and because of the difficulty of using vacuum devices (Esposito et al. 2004, 
Hatzimouratidis et al. 2009).  
When ED management is unsuccessful, a penile prosthesis (a device that is 
implanted in place of cavernosal bodies and produces an erection that allows 
the patient to have a normal sexual intercourse) is recommended as a third line 
of therapy (Shamloul et al. 2013). However, as soon as the patient has 
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undergone the penile prosthesis procedure, it becomes impossible to achieve 
smooth muscle relaxation, since the corporal tissue has been removed. The 
penile prosthesis has two key forms: semi-rigid and inflatable prosthesis. Semi-
rigid prostheses are often simple to implant and are more durable compared to 
inflatable prostheses, although they are unable to create a complete erection. 
Additionally, it is often difficult to fully cover the prosthesis after surgery. The 
inflatable prosthesis often has two or three parts, such as two penile cylinders 
and, in the case of inflatable prostheses, a scrotal pump (Shamloul et al. 2013). 
A treatment algorithm for ED is shown in Figure ‎1-12.
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Figure  1-12: Treatment algorithm for erectile dysfunction (Miller 2000). 
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1.3 Lower urinary tract symptoms  
1.3.1 Anatomy of urinary function 
The lower urinary tract consists of the urinary bladder and the urethra 
(Figure  1-13). The urethra has both smooth and striated muscle.  
The bladder is a triangle-shaped, hollow organ which is situated in the lower 
abdomen. Ligaments hold it in its place as well as it is attached to other organs 
and the pelvic bones (Andersson et al. 2004).  
The bladder is lined by a mucous membrane and covered on its outer aspect 
partly by peritoneal serosa and partly by fascia. Its muscular wall is formed of 
smooth muscle cells, which comprise the detrusor muscle (Andersson et al. 
2004). The cells of the outer and inner layers have a tendency to be oriented 
longitudinally and those of the middle layer circularly. The bundles of muscle 
cells of variable size are enclosed by connective tissue rich in collagen 
(Andersson et al. 2004).  
The smooth muscle cells of the main bundles may occur in sets of small 
functional units, or fascicles, and the orientation and interaction between 
smooth muscle cells in the bladder are important for the behaviour of the 
bladder and the activity of the cells (Drake et al. 2001).  
The prostate is a gland located between the bladder and the penis (Figure  1-10) 
(Seftel et al. 2008). The urethra goes through the center of the prostate, from 
the bladder to the penis, letting urine and semen flow out of the body. The 
function of the prostate is to secrete an alkaline fluid that nourishes and protects 
sperm during ejaculation. There are some medical conditions that can have an 
effect on this gland such as prostatitis (inflammation of the prostate), prostate 
cancer and enlarged prostate (benign prostatic hypertrophy (BPH). The 
principal consequence of these conditions is an increased difficulty in urination 
(Parsons 2010).  
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The enlargement of the prostate is a very common condition associated with 
ageing and the mechanism behind it is not known (Rosen et al. 2014). An 
enlarged prostate can put pressure on the urethra, which can affect urination in 
various ways, including a difficulty to start or to stop urinating, a weak flow of 
urine, straining, an inability to fully empty the bladder, prolonged dribbling after 
urinating and an increased frequency of urination (Parsons 2010); 
Figure  1-13).    
 
Figure  1-13: Diagram of the bladder. Adapted from (Andersson et al. 2004).  
The bladder can be divided into two main components: the bladder body, which is located 
above the urethral orifices, and the base, consisting of the trigone, urethrovesical junction, deep 
detrusor, and the anterior bladder wall. The urethra contains both smooth and striated muscles 
and the bladder is a hollow smooth muscle organ lined by a mucous membrane and covered on 
its outer aspect partly by peritoneal serosa and partly by fascia (Andersson et al. 2004).  
 
1.3.2 Symptoms and signs of lower urinary tract symptoms  
Lower urinary tract symptoms (LUTS), according to NICE, include voiding 
symptoms (straining, weak/intermittent urinary stream, incomplete emptying, 
hesitancy, and terminal dribbling); post-micturition symptoms (post-micturition 
52 
dribbling), and storage symptoms (urgency, frequency, urgency incontinence 
and nocturia; (NICE 2015). LUTS can be caused by abnormalities in the 
prostate and its functionality, as well as anomalies in the bladder/sphincter and 
urethra. In addition, post-micturition symptoms are one of the most common 
among LUTS, and can be very uncomfortable for the patient (Verhamme et al. 
2003).  
For men, benign prostate enlargement (BPE) is the most common cause that 
often blocks the bladder outlet (Bibel 2012). This occurs when the number of 
cells in the prostate increase due to a condition known as benign prostatic 
hyperplasia (BPH). Other conditions that cause LUTS include urinary tract 
infections, prostate cancer and neurological diseases, among others. Even 
though LUTS do not necessarily lead to severe illness they can, however, 
impact the quality of life for men, and might indicate underlying pathologies of 
the urogenital tract (Kirby et al. 2013) .  
Additionally, most studies showed that obesity increases the risk of BPH 
(Giovannucci et al. 1994, Kristal et al. 2007), but not all (Burke et al. 2006, 
Fritschi et al. 2007). Increasing physical activity has been linked to a decreased 
risk of BPH surgery, while obesity is strongly associated with a lack of physical 
activity (Parsons 2010, Parsons et al. 2013).  
The physiological mechanisms of obesity’s influnce on BPH still needs to be 
described and the independent influence the sex steroid hormones on BPH is 
also unclear (Parsons et al. 2013). The adipose tissue might stimulated the 
aromatization of circulating testosterone into oestrogen leading to changes in 
the balance between testosterone and oestrogen in the prostate tissue which 
may contribute in BPH pathogenesis (Parsons et al. 2013).   
 
However, Glasser et al. (2007) and Sexton et al. (2009) argue that storage 
LUTS are more bothersome and prevalent among men than voiding and post-
micturition LUTS, and tend to be associated with primary bladder dysfunction, 
which might be secondary to BPE, or may become apparent due to other 
factors which may affect the bladder’s physiology (Roosen et al. 2009). 
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Therefore, it is vital for clinicians to consider all potential reasons for LUTS 
before treatment, such as issues with fluid intake and medical conditions, such 
as heart failure and diabetes, as well as urological conditions such as an 
overactive bladder. Nevertheless, BPE is the most common cause of LUTS in 
men, which is due to BPH (Parsons 2010). Moreover, (NICE 2015)  explains 
that BPH becomes more prevalent as men age and roughly 25-50% of males 
who suffer from BPH also suffer from LUTS.     
For the ageing male population, LUTS is a huge burden (Kirby et al. 2013). For 
example, a cohort study of 80,774 males showed that men over the age of 40 
are 15-60% more likely to experience bothersome LUTS than men under 40 
which is a sizable group that may require treatment (NICE 2015).  Even though 
the figures vary in each study due to the different definitions given and study 
methodology, LUTS is highly prevalent and these figures are set to continue 
rising due to increases in life expectancy and thus, of the elderly population 
(NICE 2015, Kirby et al. 2013).  
1.3.3 Epidemiology of urinary tract symptoms  
As men age, the severity of LUTS becomes more prevalent, and this 
progressive rise in the number of ageing men has also resulted in a further 
prevalence in social economic burden, besides the severity of LUTS (Engström 
et al. 2005). The direct cost of this burden is in prescription medications, 
medical visits, diagnostics and sadness. A high score for sadness was reported 
by 29% of men with LUTS, compared with 10% of men with no LUTS. Smokers 
with LUTS had a greater risk of obtaining a high score for sadness than 
smokers with no LUTS (Engström et al. 2005).  
Jackson (1999) previously discovered that the relationship between increased 
prevalence of LUTS and age is limited to symptoms such as urgency, weak 
stream and nocturia, and that other symptoms are prevalent across different 
age groups. Despite the fairly low prevalence of nocturia, frequency, urge 
incontinence and nocturnal incontinence, these symptoms can be highly 
bothersome for those people who experience them (Abrams et al. 2003). 
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Moreover, a Taiwanese epidemiological study found that roughly 15% of the 
male population had reported that their quality of life had reduced due to their 
LUTS (Kuo 2007).  
1.3.4 Epidemiological studies in urinary tract symptoms  
The International Continence Society (ICS) measured the inconvenience of 
men’s LUTS via a questionnaire study, which studied 1,271 male patients 
across 12 countries who were presenting at urology clinics (Llorente 2010). The 
study found a high prevalence (90-94%) in voiding symptoms like increased 
hesitancy, intermittency, and stream compared to storage symptoms, like 
frequency, nocturia and urgency (66-71%), although the latter appear to be the 
most bothersome. On the other hand, the European Prospective Investigation 
into Cancer and Nutrition (EPIC) survey was carried out in five different 
countries (Canada, Germany, Italy, Sweden, and the United Kingdom), and was 
a computer assisted telephone survey that was both population-based and 
cross-sectional (Irwin et al. 2006). It was discovered that both genders exhibit a 
similar prevalence of LUTS, with 66.6% of women and 62.5% of men reporting 
at least one symptom. Meanwhile, storage symptoms were more prevalent in 
women (59.2%) compared to men (51.3%), while voiding symptoms were more 
prevalent in men (27.5%) compared to women (19.5%), and both sexes 
exhibited a similar prevalence in post-micturition symptoms (14.2% in women 
and 16.9% in men).   
Similarly, the Boston Area Community Health (BACH) survey also reported a 
prevalence of LUTS among both sexes (Kupelian et al. 2006), which supports 
the provision of vital information on both the use of medication and quality of 
life. Moreover, the study concluded that as people age, the prevalence of LUTS 
increases, which is concordant with the ICS conclusions. Meanwhile, the 
Epidemiology of LUTS (EpiLUTS) study was performed in the US, UK and 
Sweden via the internet, and was a population-based, cross-sectional survey 
(Coyne et al. 2009). There were two symptom frequency thresholds that helped 
to define the prevalence of LUTS: “at least sometimes”, with 72.3% prevalence 
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in men and 76.3% prevalence in women, and “at least often”, with 47.9% 
prevalence in men and 52.5% prevalence in women.     
What these four epidemiological studies indicate is that the prevalence of LUTS 
is not determined by gender or race, despite voiding symptoms appearing to be 
more prevalent in men, and storage symptoms appearing to be more prevalent 
in women (Llorente 2010). In addition, LUTS has been linked to various chronic 
diseases, and such observations may help to shed some light on the 
pathophysiology of LUTS (Llorente 2010).       
1.3.5 Pathophysiology of urinary tract symptoms    
Given the multifactorial nature of LUTS, its pathophysiology not well 
characterised. Usually, men’s LUTS are due to bladder outlet obstruction 
(BOO), caused by an enlarged prostate, primarily benign prostatic hyperplasia 
(BPH) (Kuo 2000). However, current studies have yet to discover any significant 
relationship between LUTS and bladder outlet obstruction (Kuo 2007).  
The pathophysiology of LUTS can be attributed to bladder dysfunction. Some 
men have both LUTS and storage dysfunction, which comprises of complex 
emptying and bladder storage symptoms. In the past, the treatment of LUTS 
focused more on bladder outlet obstruction (BOO) and emptying symptoms. 
Recent studies have indicated that the urinary bladder’s sensory innervation is 
important in storage, besides emptying LUTS (Kuo 2007).  
Bladder dysfunction that affects emptying or storage of urine is also referred to 
as voiding dysfunction which describes the aberrations in emptying or filling the 
bladder (Sarwer et al. 2012). The primary cause of bladder dysfunction is 
diabetes, and more than half of men and women with diabetes suffer from 
bladder dysfunction. Although the disorder is not usually fatal, it can be linked to 
severe weakening symptoms, diabetic cystopathy (increased post-void residual 
urine volume, poor contractility, and reduced bladder sensation) being the most 
common (Goldstraw et al. 2007). The prevalence of diabetic bladder 
dysfunction is unconnected to the gender or age of the patient and rises with 
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the occurrence and duration of diabetes (Goldman et al. 1999, Kaplan et al. 
1995).  Bladder dysfunction due to diabetes (or diabetic bladder dysfunction) 
may be the result of hyperglycaemia, urothelial dysfunction and also changes in 
the function of neurons (Yoshimura et al. 2005). This neurologic defect has 
been associated with axonal damage and demyelination at several sites in the 
nervous system, caused by high levels of glucose (Fedele 2005). Moreover, 
urothelial cells release a variety of mediators such as nitric oxide (NO), 
prostanoids and ATP (Birder et al. 2002) and an increase in the release of ATP, 
for instance, may lead to different abnormalities with diabetic bladder 
dysfunction (Birder et al. 2002).  
These neurological abnormalities related to bladder dysfunction are associated 
with nitrergic fibres which are responsible for bladder contraction during 
urination as well as sympathetic efferent fibres which control the internal 
sphincter and afferent sensory fibres which modulate transmission of the 
sensation of bladder fullness (Fedele 2005). 
1.3.6 Diagnosis and treatment of urinary tract symptoms      
Diagnosis of LUTS involves patients completing a questionnaire known as the 
International Prostate Symptom Score (IPSS; Table ‎1-8), which helps to 
measure the symptoms of the condition, together with a physical examination. 
The IPSS was approved by the World Health Organization International 
Committee and used since the early 1990s (Plante et al. 1996). It is the most 
widely used self-administered questionnaire for pre-diagnosing patients with 
BPH (Plante et al. 1996).  
The IPSS is based on seven questions about urinary symptoms and one 
question regarding quality of life. Each question relating to urinary symptoms 
permits the patient to choose one out of six answers representing the increasing 
severity of a particular symptom. The responses are based on a Likert scale 
from 0 to 5 where 0 represents “Not at all” and 5 represents “Almost always”. 
The total score can range from 0 to 35 (asymptomatic to very symptomatic), 
(Table ‎1-8).  
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Table  1-8: IPSS Questionnaire Scores (Plante et al. 1996). 
Questions Symptom 
1 Incomplete emptying 
2 Frequency 
3 Intermittency 
4 Urgency 
5 Weak Stream 
6 Straining 
7 Nocturia 
 
The American Urological Association (AUA) Symptom Index presently classifies 
the symptoms from the first seven questions as follows:  mild (symptom score ≤ 
7), moderate (symptom score range 8-19) and severe (symptom score range 
20-35; see Appendix A). 
The last question focuses on the quality of life of the patient and the 
International Scientific Committee (ISC), with the support of the WHO 
recommends the answers to this question to range from “delighted” to “terrible” 
or 0 to 6 (Plante et al. 1996, Barry et al. 1992).  
As soon as the severity of LUTS has been discovered and diagnosed via the 
IPSS, it is vital that an acceptable management programme is established by 
the physician and patient. Men who have mild to average LUTS that does not 
cause any complications or is not bothersome, must be managed 
conservatively within primary care, alongside a range of additional factors 
including lifestyle advice, for instance, adjusting or reducing fluid intake, no 
caffeine intake, alcohol, or artificial sweeteners; exercises, for instance, pelvic 
floor muscle and bladder training exercises; containment products, for instance, 
pads/collection devices, and frequent monitoring (Oelke et al. 2012).  
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It is vital that pharmacotherapy is provided to men who have bothersome LUTS, 
in cases where conservative management options are unsuitable or 
unsuccessful (Abrams et al. 2003, Oelke et al. 2012). Furthermore, considering 
comorbidities, as well as ongoing treatments prior to selecting drug treatments 
for LUTS, is also important. Men who have moderate to severe LUTS have a 
number of pharmacological treatment options available to them, which include 5 
α-reductase inhibitors, antimuscarinics, monotherapy with α-blockers, 
vasopressin analogues, or a combination of the above treatments in particular 
clinical circumstances (Oelke et al. 2012). 
1.3.6.1 Monotherapy  
The first-line of treatment for men who suffer from bothersome LUTS and 
request treatment should be α-blockers (Oelke et al. 2012). These drugs also 
have a quick reaction time, and thus should only be used on an irregular basis 
for those patients that require no long-term treatment. Oelke and co-workers 
(2012) have explained that all α-blockers in suitable doses will be similarly 
effective, regardless of the prostate specific antigen (PSA) level or prostate 
size, despite these drugs not having any impact on prostate size (McConnell et 
al. 2003).   
Particular drugs, such as doxazosin and terazosin, call for initial dose titration, 
while others, such as alfuzosin, silodosin and tamsulosin, do not. Men who have 
an enlarged prostate and moderate to severe LUTS, and are likely to be at a 
greater risk of their disease progressing, may be given 5 α-reductase inhibitors 
such as dutasteride and finasteride if the prostate volume is more than 40 ml or 
if the PSA level is greater than 1.4 ng/mL (Roehrborn et al. 1999).  
Fesoterodine, tolterodine and solifenacin are antimuscarinics, which are used to 
manage men’s storage symptoms (Oelke et al. 2012). Even though most 
patients who took part in the clinical trials of these agents were women, these 
studies show that men who have storage symptoms saw similar side effects 
and benefits after using antimuscarinics. Therefore, these drugs are an effective 
first-line treatment for men who suffer from bothersome storage LUTS, and a 
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second-line treatment for men who have used alternative medications that have 
failed. However, for men who have BOO, prescribing antimuscarinics should be 
avoided given the risk of urinary retention (Badlani et al. 2008), which therefore 
necessitates awareness of safety and efficacy profiles of the drugs used (Jones 
et al. 2010).  
Oral agents, such as vasopressin analogues and loop diuretics, which reduce 
urine production during night time hours, may be provided to men who suffer 
from nocturnal polyuria (so long as other medical conditions are ruled out, such 
as diabetes, polydipsia, or intake of diuretics during night time hours). Prior to 
sleeping, the vasopressin analogue desmopressin is taken once per day, and 
there is a need for careful dose titration (starting on lower dosages of the 
medication and gradually increasing levels in each session) (Oelke et al. 2012). 
1.3.6.2 Combination therapy  
Monotherapy may not be adequate to control all LUTS for particular patients, in 
these cases combination therapy using two or more monotherapies is used. 
Combination treatment is seen as more efficacious than monotherapy, although 
it is important that additional costs and adverse effects are weighed against 
better efficacy (Oelke et al. 2012). A reduced urinary flow, alongside high risk 
BPH progression, and an enlarged prostate are often common symptoms of 
bothersome moderate to severe LUTS in men (Roehrborn et al. 1999). 
Therefore, combining an α-blocker and a 5 α-reductase inhibitor may form the 
ideal solution to reducing these common symptoms. The 5 α-reductase inhibitor 
delays or prevents the disease from progressing, while the α-blocker swiftly 
relieves the bothersome LUTS. It is also important to consider combining both 
an α-blocker with an antimuscarinic for those men who suffer from moderate to 
severe LUTS, alongside existing storage symptoms, if monotherapy is 
unsuccessful (Oelke et al. 2012). 
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1.3.6.3 Associated medications   
The use of other medications, such as cold and influenza medications that 
contain phenylpropanolamine and diphenhydramine, can adversely impact the 
safety and efficacy of antimuscarinics. As previously suggested, it is important 
for physicians to question patients regarding over the counter medication and 
current prescriptions, as well as reminding patients to seek advice prior to 
starting new medication. Furthermore, it is important to keep on top of 
recommended exercise and lifestyle reforms, as well as adjusting or reducing 
fluid intake as well as intake of caffeine, alcohol, and artificial sweeteners 
(Oelke et al. 2012).    
1.3.7 Link between erectile dysfunction and urinary tract symptoms      
In spite of the vast literature supporting the relationship between ED and LUTS, 
it appears that in both primary and secondary care, there is limited awareness 
of this relationship, and this reflects the lack of available treatments (Kirby et al. 
2013) and suitable diagnostic tools (Seftel et al. 2008). For instance, Kirby and 
co-workers (2013) asserted that in an audit of 100 UK patients who suffered 
from LUTS, there were less than 10% of doctors who enquired about ED, and 
over 80% of those patients were not offered any therapy at all, although 91% of 
ED sufferers who were given no treatment wanted medical assistance. 
A survey of the services that inform doctors about treating patients in the UK, 
indicates that despite the potential connection being mentioned, there was still 
no reference of co-diagnosis being provided to patients. For example 
WebMentor, which is a clinical IT system, contains no mention of sexual 
function or ED in LUTS information for GPs, as well as no reference to LUTS in 
ED information (Kirby et al. 2013). Likewise, in the current NICE - LUTS 
guidelines, despite the reference to ED, again, there are no productive 
recommendations on how to enquire about and manage a patient’s ED related 
problems, such as providing  better access to care for their physical and 
emotional conditions (NICE 2015). There are a number of factors that may 
prevent physicians asking their patients about sexual function, such as limited 
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time, lack of knowledge and embarrassment around sexual health; although the 
most significant reason for such failure regarding ED in LUTS is the unfamiliarity 
with the relationship between the two conditions (Kirby et al. 2013).  
1.3.7.1 Studies suggesting a link between ED and LUTS  
1.3.7.1.1 Epidemiological evidence  
In spite of the differences in design, there are a number of large studies 
that have used effective multivariate analyses and provide strong 
evidence linking ED and LUTS (Kirby et al. 2013). Table ‎1-9 
summarises the epidemiological evidence from the studies that have 
been carried out highlighting the relationship between ED and LUTS.
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Table  1-9: Examples of epidemiological evidence for the association between ED and LUTS 
Reference Country/Continent Sample 
Number 
Applicable results for the relationship between ED and LUTS 
(Blanker et al. 
2001) 
 
Holland 3,924 Patients with ED found they had urinary issues; risk of ED is higher in moderate to severe 
LUTS sufferers compared to cardiac and smoking symptoms. 
(Demir et al. 
2009) 
Turkey 190 Patients with severe LUTS had a significantly lower erectile function and greater 
prevalence of ED compared to those who had moderate LUTS. 
 
(Li et al. 2005b) 
 
Asia 1,155 There were increases in both sexual disorders and severity of LUTS with age. ED was 
highly prevalent in older age groups who had severe LUTS (54-84%). Overall, 91% of men 
had moderate to severe LUTS. 
 
(Mehraban et al. 
2008) 
Iran 357 68.2% of patients who suffer from LUTS displayed sexual dysfunction, and all cases were 
age related. 
 
(Ozayar et al. 
2008) 
Turkey 453 36% of men were found to have ED with moderate LUTS and 94% of men with severe 
LUTS had ED. 
(Shiri et al. 2007) 
 
Finland 1,683 Men who had moderate to severe ED showed a higher relative risk of LUTS compared to 
those who did not suffer from ED. 
(Tsao et al. 
2008) 
 
Taiwan 398 The prevalence of moderate to severe ED and LUTS had a strong relationship, especially 
in the 60-69 age group 
(Vallancien et al. 
2003) 
Europe 1,274 There was a strong connection between ED and age, BMI and LUTS, among other 
factors, and those patients who suffered from severe LUTS were more likely to have ED. 
 
(Wang et al. 
2008b) 
 
China 245 A relationship was discovered between ED and severity of LUTS, with almost 96% of 
patients with severe LUTS reporting ED. 
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1.3.7.1.2 Preclinical evidence  
There have been a number of reviews based on the mechanisms that underlie 
the relationship between LUTS and ED (Shiri et al. 2007, Gacci et al. 2011). 
These reviews provide preclinical data and a clear theoretical background to the 
mechanisms that are already being used in clinical practice, including, changes 
in the NO-cGMP pathway, autonomic hyperactivity, pelvic atherosclerosis, and 
RhoA–Rho-kinase (ROCK) signalling (Andersson et al. 2011). Further 
supporting factors, like sex steroid ratio imbalance and chronic inflammation 
could also be important (Penna et al. 2009, Corona et al. 2010). Knowledge of 
pathways that link these mechanisms should aid in better understanding the 
pathophysiology of both conditions (Gacci et al. 2011). Recently it has been 
proposed that neurovascular dysfunction could be the underlying common 
cause for both BPH/LUTS and ED (Cellek et al. 2014). 
1.3.7.2 Risk factors associated with ED and LUTS  
As described previously, several risk factors are associated with erectile 
dysfunction, including, age, obesity, sedentary physical lifestyle and poor 
psychological health, smoking (cigarettes and marijuana), poor glycaemic 
control, certain medications such as antihypertensives, and occurrence of other 
diabetic complications such as neuropathy (Shamloul et al. 2013). Furthermore, 
other risk factors include cardiovascular disease (CVD), depression, insomnia, 
and T2DM, among other psychiatric/psychological disorders (Shamloul et al. 
2013). 
A recent study by Hyde et al. (2012) that studied 3,000 elderly men (75 to 95 
years old), found that factors such as coronary artery disease (CAD), 
depression, diabetes, insomnia and prostate disorders had a strong association 
with ED related issues in these elderly men. The study also found that ED 
diagnosis could be predictive of coronary artery disease (CAD), with a reduced 
CAD risk time, that is to say, the time period in which CAD is likely to occur, of 
two to five years. Therefore, spotting ED, especially in men under the age of 60 
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and those who suffer from diabetes, can result in early diagnosis of CAD (Miner 
et al. 2012).  
On the other hand, there are a number of risk factors that are related to men’s 
LUTS, which include CVD, obesity, BPE, diabetes, inflammation and age, 
among others, all of which have been pointed out in a number of recent studies 
(Lee et al. 2012, Shamloul et al. 2013, Parsons 2010). A recent study has 
shown that using statins might suspend LUTS by five to seven years, from 
developing the condition through the reduction of moderate to severe LUTS, 
BPE and inflammation (St Sauver et al. 2011). Furthermore, ED and LUTS have 
also been found to be related to metabolic syndrome (Hammarsten et al. 2011), 
with waist circumference being heavily linked to various prostate related 
problems. Lee et al. (2012) also found that an increased waist circumference is 
further related to a higher prevalence of T2DM, obesity and CAD, besides ED 
related issues and ejaculatory dysfunction.     
Kirby et al. (2013) further suggested that patients have to meet certain risk 
criteria or risk factors to be affected by ED related issues. A combination of the 
current definitions by the American Heart Association/National Heart, Lung and 
Blood Institute (AHA/NHLBI) and the International Diabetes Federation (IDF) 
have established the following conditions (Zimmet et al. 2011): Blood pressure 
(BP) of 130/85 mmHg or more, elevated waist circumference (males: greater 
than 94cm), fasting glucose of 5.6 mmol/l or more (> 100 mg/dl), high-density 
lipoprotein (HDL) under 1.03 mmol/l (< 40 mg/dl; men) and triglycerides of 1.7 
mmol/l or more (> 50 mg/dl) (Kirby et al. 2013). 
1.4 Obesity and urogenital dysfunction   
Obesity appears to have an adverse effect on urogenital function, especially on 
men with comorbidities such as diabetes and hypertension, which increase 
sexual dysfunction (Kuruba et al. 2007). There have also been several studies 
on the relationship between male sexual dysfunction and morbid obesity; 
however those studies have used modest and inconsistent methods to assess 
the impact of weight loss on other conditions (Dallal et al. 2008).  
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Obesity has also been associated with erectile dysfunction, and the 
mechanisms behind this are probably multifactorial (O'Brien 2010, Sarwer et al. 
2012). However, some of the studies propose that obesity induced ED may be 
reversed when obesity is treated (Dallal et al. 2008).  
1.4.1 Clinical correlation between obesity and urogenital dysfunction  
1.4.1.1 Studies on obesity and sexual function  
Dallal and colleagues (2008) examined 97 men with an average age of 48 and 
average BMI of 51 who went through gastric bypass surgery. The brief male 
sexual function inventory (BMSFI) was given out to examine the sexual function 
of the patients twice before surgery (between 30 and 90 days prior to surgery) 
and after surgery (6 months after) (Dallal et al. 2008). The BMSFI is a measure 
of sexual function in males. It involves 11 questions that cover five aspects: 
sexual drive (2 questions), erectile function (3 questions), ejaculatory function (2 
questions), sexual problem assessment (3 questions), and sexual satisfaction 
(1 question) (O'Brien 2010).  
The objective of this study was to measure sexual function in morbidly obese 
men before and after significant weight loss achieved by gastric bypass (Dallal 
et al. 2008). The finding was that obesity is an extremely difficult disease to 
treat and bariatric surgery despite its inherent risks has been shown to improve 
quality of life and comorbidities (Dallal et al. 2008). Dallal and colleagues also 
suggested that changes in glucose metabolism or the presence of 
cardiovascular disease may not be the main cause of obesity associate erectile 
dysfunction (Dallal et al. 2008).  
Ranasinghe and colleagues (2011) examined, in a retrospective study the 
effects of weight loss following laparoscopic gastric band surgery (LGB) on 
urinary and sexual function in patients with a mean BMI of 47.3 (Ranasinghe et 
al. 2011). Between 2001 and 2009, three questionnaires were mailed to 653 
females (160 responded) and 145 males (36 responded), after exclusion criteria 
were applied (due to some of the patients either having had surgery or being on 
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medication for urinary or sexual function), 142 females and 34 males were 
included in this study (Ranasinghe et al. 2011). The questionnaires that were 
used were the International Consultation on Incontinence Questionnaire Short 
Form (ICIQ-SF), the IPSS and the IIEF. According to the Ranasinghe study, 
there was no improvement in the IIEF score for sexual function in men after the 
weight loss surgery (Ranasinghe et al. 2011).  
Reis and colleagues (2010) measured erectile function and hormonal changes 
after significant weight loss either surgically or non-surgically in morbidly obese 
males (Reis et al. 2010). This study was a prospective randomised controlled 
trial where they studied 20 morbidly obese men for 24 months and divided them 
into two groups: Group A (intervention) included 10 patients who went through 
life style adjustments (exercise and diet) for four months and then a gastric 
bypass. Group B (control) included another 10 patients who were examined on 
a weekly basis who did not receive any lifestyle or surgical intervention. 
All patients performed the IIEF-5 questionnaire and blood chemistry values 
were taken for serum oestradiol, prolactin (PRL), luteinizing hormone (LH), 
follicle-stimulating hormones (FSH), and free and total testosterone (FT and TT; 
(Reis et al. 2010).  
Reis and colleagues suggested that weight loss after gastric bypass (group A) 
improves erectile function and hormonal activity in morbidly obese men to a 
greater extent than with a non-surgical method (group B) to reduce weight. 
Erectile dysfunction is considered to be a reversible complication of obesity 
(Reis et al. 2010). A strong association was found between body weight and 
erectile function, with morbidly obese men showing the same degree of sexual 
dysfunction as non-obese men 20 years older (Kolotkin et al. 2003). Men 
represent about 20% of patients who go through bariatric surgery (Dallal et al. 
2008).  
In addition, some of the causes of peripheral vascular disease are insulin 
resistance and obesity, due to atherosclerosis and endothelial dysfunction 
(Borges et al. 2009). Both are recognised as risk factors for erectile dysfunction 
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(Demir et al. 2006). After weight loss there is an improvement in sexual function 
because of improvement in insulin resistance (Esposito et al. 2004). Since 
bariatric surgery improves insulin resistance through weight reduction, erectile 
dysfunction was expected to improve after bariatric surgery (Wickremesekera et 
al. 2005). However, the improvement in erectile function after bariatric surgery 
is not clear cut (Ranasinghe et al. 2011).  
In contrast, other studies (Dallal et al. 2008) and (di Frega et al. 2005) show six 
patients who went through gastric bypass and developed erectile dysfunction. It 
was suggested that the reason was zinc deficiency due to malabsorption of 
nutrients after gastric bypass surgery. Males showed no significant 
improvement in urinary incontinence (UI) with surgically induced weight loss 
(Ranasinghe et al. 2011). Furthermore, while erectile function did not improve 
after LGB, it trended towards worsening with time (Ranasinghe et al. 2011).  
Esposito and colleagues measured, through randomised controlled trials, the 
effect of lifestyle changes on erectile dysfunction in 110 obese men (BMI >30 
kg/m2) who had erectile dysfunction and did not have comorbidities such as 
diabetes or hypertension. On a very low calorie diet, they showed improvement 
in erectile function, assessed by IIEF. This improvement was independent of 
weight reduction (Esposito et al. 2004).  
1.4.1.2 Studies on obesity and urological function  
The occurrence and development of urological diseases depends on several 
factors, including obesity (Mydlo 2004), which has been shown to be a risk 
factor for stress and mixed urinary incontinence (Kuruba et al. 2007) and 
diabetes (Ranasinghe et al. 2011). Moreover, Lee and colleagues have 
reported that increased waist circumference is associated with worsened 
voiding function and pelvic dysfunction (Lee et al. 2012). 
Kuruba et al (2007) prospectively collected data from 201 patients between 
2004 and 2006 that underwent bariatric surgery. Urinary incontinence was 
improved in 82% of patients after surgery (Kuruba et al. 2007). Similarly, Burgio 
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et al (2007) showed that urinary function improved between three and four 
months after LGB (Burgio et al. 2007). However, both studies were on female 
patients.  
In contrast, Ranasinghe and colleagues (2011) examined, in a retrospective 
study, the effects of weight loss following laparoscopic gastric banding surgery 
(LGB) on urinary incontinence in both male and female patients. However, no 
improvement in urinary function, despite weight loss after LGB, was observed in 
males (Ranasinghe et al. 2011).  
1.4.2 Proposed mechanisms linking obesity to urogenital 
dysfunction   
As noted in various studies, obesity has been strongly linked with the 
development of ED (Traish et al. 2009).  
Demir et al. (2009) have shown that 96.5% of obese males who suffer from 
metabolic syndrome (MetS) had ED. Furthermore, comparable studies found 
that 43% of men suffering from ED also had MetS, and the severity of ED 
worsened with MetS (Bansal et al. 2005). It is interesting to note that insulin 
resistance (IR) also had a significant impact on the severity of ED. Therefore, 
ED signifies a significant risk factor and could potentially be a clear indicator of 
IR and MetS, both of which can result in the risk of CVD. Moreover, men who 
had moderate to severe ED also had the most severe cases of MetS (22-70%). 
Whether obesity is related to ED independently, or through cardiovascular risk 
factors, obese men are more than likely to suffer from ED, which impacts on 
their sexual life. (Andersen et al. 2008) explored the association between ED 
and obesity in men who were aged between 20 and 45, and found that obesity 
is directly related to ED in younger males. Furthermore, another study found 
that men with a BMI greater than 28.7 are 30% more at risk of ED, compared to 
those with a typical BMI of 25 (Kuo 2007, Bacon et al. 2003).  
The association between ED and obesity can be explained by the increased 
levels of various pro-inflammatory cytokines in obese people (Traish et al. 
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2009). However, these authors admit that obesity might be directly associated 
with the aetiology of ED, and they discovered that obese males, irrespective of 
their BMI, besides leading inactive lifestyles, were at a far greater risk of 
developing ED. Although the health risks associated with obesity are more 
common among people with extreme abdominal obesity, which can cause 
dysfunction by releasing pro-inflammatory cytokines, the potential relationship 
between obesity and ED requires further investigation (Esposito et al. 2004, 
Després 2006).  
However, another study (Esposito et al. 2004) found that men who were given 
advice about the ways in which they can effectively lose weight and achieve 
weight loss of 10% or higher by lowering their calorie intake and increasing their 
physical activity, had improved ED compared to controls. Therefore, this is good 
advice for men who suffer from ED, since obesity is clearly associated with ED, 
and weight loss alone can show signs of improvement (Bacon et al. 2003). 
However, (Teloken et al. 2006) points out those previous studies have failed to 
clearly demonstrate that “obesity is a risk factor for ED” and thus they call for 
more research to be carried out to clarify this association.  
Androgen deficiency, which is a medical condition where the body has reduced 
levels of male hormones, has been found to be associated with insulin 
resistance (IR) and T2DM, and thus contributes towards ED (Ginsberg et al. 
2000, Cersosimo et al. 2006). Also, Corona et al. (2009) point out that obesity is 
directly related to lower androgen levels in men who suffer from ED, and that 
obesity related comorbidities, particularly hypertension, are considered 
significant causes of arteriogenic obesity-related ED. On the other hand, it also 
seems that central obesity in particular has a strong relationship with the 
reduction in circulating androgen levels.  Even though androgens are vital to 
typical erectile function, a healthy lifestyle, reducing calorie intake, and 
increasing exercise, are all factors that contribute towards improved erectile 
function in men who suffer from ED (Traish et al. 2009).  
Despite the above studies focussing on the strong relationship between obesity 
and ED, additional research is required to affirm whether individual symptoms of 
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MetS, such as hypertension, have a strong relationship with ED. In a study by 
(Zohdy et al. 2007), 158 obese men were tested and correlated MetS and 
androgen deficiency with ED. The results show that men with higher BMIs had 
increased hypogonadism and ED. In contrast, men who were given 
testosterone therapy for their androgen deficiency showed significant 
improvement in their erectile function (Yassin et al. 2006, Kurbatov et al. 2008).  
The relationship between obesity and ED has also been shown to include 
another mechanism whereby obesity might contribute to infertility in both men 
and women (Hammoud et al. 2006). In a study by (Feldman et al. 2000), 79% of 
men who reported symptoms of ED were in fact not only obese, but suffered 
from cardiovascular problems, and infertility. Furthermore, research has pointed 
out that the association between obesity and ED can be partly justified through 
increased levels of various pro-inflammatory cytokines in obese people 
(Esposito et al. 2004, Després 2006, Esposito et al. 2005). These signs of 
inflammation have a strong connection with endothelial dysfunction, which is 
directly related to ED through the nitric oxide pathway. Therefore, it is unclear 
whether this relationship is because of an independent effect or because of 
CVD risk factors that are common to both ED and obesity (Hammoud et al. 
2006). Furthermore, other risk factors leading to cardiovascular disease, such 
as diabetes, smoking, dyslipidaemia and hypertension, all have a strong 
epidemiological connection with ED. (Seftel 2006) found that hypoandrogenism 
is the main contributor towards sexual dysfunction in males suffering from 
obesity. Moreover, irrespective of whether obesity is related to ED 
independently or through CVD risk factors or hypoandrogenism, men who suffer 
from obesity are highly likely to develop ED, especially if they are above the age 
of 40, which will impact on their fertility and sexual life (Hammoud et al. 2006).  
(Esposito et al. 2005) and (Esposito et al. 2006) studied 55 obese and 55 non-
obese males and the impacts of weight loss programs on ED over a two year 
period. They found that 31% of males did see improvement in ED as a result of 
weight loss, irrespective of age. Therefore, despite the scepticism of such 
programs failing to deliver weight loss for its user, they do seem effective for 
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obese males suffering from ED (Traish et al. 2009). Additionally, many studies 
have pointed out that obesity might be an important independent risk factor for 
ED (Esposito et al. 2004, Traish et al. 2009, Hammoud et al. 2006), and thus 
weight loss programs, among other remedial mechanisms are required to help 
reduce this prevalent risk. 
On reflection, with the ever increasing prevalence of inactive lifestyles and 
dietary reforms, obesity is now the most significant cause of adverse health 
outcomes, which include CVD, infertility, MetS and ED, among other conditions 
(Hammoud et al. 2006). Therefore, healthy lifestyle choices are essential in 
order to overcome or at least reduce the risk of developing these conditions, 
thus leading to a better quality of life. (Esposito et al. 2006) have shown that a 
“Mediterranean Diet”, which is a diet in which foods such as vegetables, fruits, 
nuts, beans, cereal grains, olive oil and fish are eaten on a daily basis, can 
significantly improve men’s health. The results from the study further indicate 
that ED improved in men suffering from MetS on this diet, thereby increasing 
erectile function, particularly in older men (Traish et al. 2009, Esposito et al. 
2006).  
Even though ED may be seen as an indicator for MetS, as previously 
mentioned, the association between these two conditions is difficult to 
determine, since the mechanisms of MetS symptoms like hypertension, are also 
clearly important in the aetiology of ED. (Riedner et al. 2006) also discovered 
that various assessment parameters associated with central obesity can also be 
used to estimate the likelihood of developing ED.   
1.4.3 Effect of bariatric surgery on urogenital function 
1.4.3.1 Animal models 
Various studies using diabetic rat models, and especially T2DM models, show 
that vasodilatory signalling is damaged through a reduction in neuronal NOS 
(nNOS) content/activity, impaired endothelial NOS (eNOS) activity, cavernosal 
hypercontractility, oxidative stress, androgen deficiency and neuronal 
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dysfunction, amongst other factors. Together, these alterations are considered 
potential mechanisms that underlie the development of ED (Jesmin et al. 2003, 
Hidalgo-Tamola et al. 2009).  
In a study by Choi and co-workers (2014), a T2DM rat model was assessed in 
which they investigated the impact of duodenojejunal bypass surgery on 
glucose homeostasis. In the control group that was kept on a standard diet with 
15% fat, a reduced glucose homeostasis was observed, resulting in both 
microvascular and structural damage (Zhiqing et al. 2014). Furthermore, there 
were reduced levels of eNOS and nNOS expression, while there was an 
increase in Rho kinase expression in rats suffering from diabetes that were 
given the sham operation, as opposed to those rats who were given bariatric 
surgery, thereby resulting in vascular dysfunction and cavernosal smooth 
muscle atrophy. As a result of these structural modifications, ED was improved 
in the bariatric surgery group, (Choi et al. 2014). Glucose homeostasis recovery 
was also detected, which resulted in metabolic and biochemical restoration, a 
reduction in the level of Rho kinase expression, and an increased level of eNOS 
and nNOS expression. This microvascular structural restoration resulted in 
macrostructural recovery, thereby leading to functional recovery.  
Apoptosis and DNA and intracellular damage, which result in fibrosis in the 
corpus cavernosum has been shown to be caused by reactive oxygen radicals. 
Choi et al. (2014) found that rats who underwent the bariatric procedure 
exhibited reduced 8-OHdG levels, which is a clear sign of DNA oxidative stress, 
demonstrating that such procedures may reduce oxidative stress related to 
T2DM in the penile corpus cavernosum (Choi et al. 2014). Further changes 
were also observed in the penile corpus cavernosal structure in both the control 
and bariatric surgery groups. T2DM resulted in a reduction in smooth muscle 
and definitive cavernosal fibrosis in the control group, while rats had a higher 
amount of smooth muscle fibres in the cavernosal tissue in the bariatric surgery 
group (Oberbach et al. 2014). Therefore, such procedures can possibly reduce 
cavernosal fibrosis in diabetes. Moreover, these results show that bariatric 
surgery also enhances glucose homeostasis accompanied by biochemical 
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factors, thus resulting in both functional and structural improvements in the 
corpus cavernosum and leading to better erectile function (Palleschi et al. 2015, 
Luke et al. 2015).  
1.4.3.2 Clinical studies  
Several studies evaluating sexual function after bariatric surgery have been 
published to date, as described in section ‎1.4.1.1 (Reis et al. 2010, Dallal et al. 
2008, Esposito et al. 2004, Ranasinghe et al. 2011). 
Dallal and colleagues reported an improvement in sexual function at two years 
after gastric bypass surgery, using the Brief Male Sexual Function Inventory 
(BMSFI; (Dallal et al. 2008). Moreover, Hammoud and colleagues (2009) 
showed an improvement in sexual function after gastric bypass surgery, by 
using the Impact of Weight on Quality of Life (IWQOL-L) questionnaire 
(Hammoud et al. 2009). Reis and colleagues (2010) also showed an 
improvement in sexual function in men who underwent gastric bypass surgery, 
using the short version of the IIEF questionnaire (IIEF-5; (Reis et al. 2010). 
Finally, Mora and colleagues (2013) showed an improvement in sexual function 
in 39 men that underwent gastric sleeve surgery, using the full version of the 
IIEF questionnaire (IIEF) before and at one year after surgery (Mora et al. 
2013).  
In contrast, Ranasinghe and colleagues (2011) failed to demonstrate a 
significant change in the score of each of the 5 IIEF sexual domains in patients 
who underwent the adjustable gastric banding procedure and were evaluated at 
three years post-surgery (Ranasinghe et al. 2011).  
The disagreement between the Dallal, Reis and Mora studies and the 
Ranasinghe study might be due to the variations in the tools used in the studies, 
such as the biomedical tests, the questionnaires, period of the study, and the 
number of participants that took part in the study (Reis et al. 2010, Dallal et al. 
2008, Mora et al. 2013). Also, there is possible influence from the study design 
and the medical centre type: primary, secondary or tertiary and the number of 
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medical centres participating (single or multi-centre). Overall, the evidence for 
improvement of erectile function in males after bariatric surgery is debatable. 
The results do not show a statistically significant improvement in sexual 
function. On the contrary, there was a worsening of erectile function (EF), 
orgasmic function (OF), sexual desire (SD), intercourse satisfaction (IS), overall 
satisfaction (OS) and IIEF total score after bariatric surgery (Reis et al. 2010, 
Dallal et al. 2008, Ranasinghe et al. 2011, Mora et al. 2013). However, Dallal 
and colleagues (2008) demonstrated significant improvement in all aspects of 
the Brief Male Sexual Function Inventory (BMSFI; p< 0.0005 in all aspects; 
(Dallal et al. 2008, Mora et al. 2013).  
Ranasinghe and colleagues (2011) found no improvement in IIEF total score 
(p= 0.70) despite a significant weight loss (p<0.0001) after gastric band 
(Ranasinghe et al. 2011). Thus, the initial findings from this study do not support 
that bariatric surgery is associated with the improvement of sexual function in 
morbidly obese men in the short term. Nevertheless, the total numbers of 
patients with true sexual dysfunction in the study were low and so were the 
numbers of patients with severe sexual dysfunction in each domain. The lack of 
a control group in the study prevents the assessment of the prevalence of 
impaired sexual function in patients who did not undergo bariatric surgery over 
time. 
Numerous studies evaluating urological function after bariatric surgery have 
been published recently (Palleschi et al. 2015, Luke et al. 2015, Schouten et al. 
2013).  Luke and co-workers (2015) evaluated the effects of bariatric surgery on 
lower urinary tract symptoms (LUTS); patients undergoing bariatric surgery with 
LUTS were assessed using the IPSS and weight, serum glucose, insulin and 
prostate-specific antigen (PSA) levels were also noted. The study suggested 
there was an improvement in LUTS after weight loss but there was no 
correlation between the improvement in LUTS and the time course or degree of 
weight loss. Also the study suggests that the improvement in symptoms is 
linked to the improvement in insulin resistance (Luke et al. 2015).  
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Palleschi et al (2015) suggest that overactive bladder (OAB) syndrome may 
improve in morbidly obese patients who were treated by laparoscopic sleeve 
gastrectomy (LSG) (Palleschi et al. 2015). 
Schouten et al (2013) evaluated the prevalence of perioperative urinary 
incontinence and bladder retention after laparoscopic gastric bypass surgery in 
sixty morbidly obese female patients. The study concludes there were no 
differences between the patients with and without postoperative incontinence in 
relation to age, body mass index and presence of diabetes mellitus (Schouten 
et al. 2013).  
1.5 Study rationale, aims and objectives  
1.5.1 Rationale  
Within the past decade, obesity has become a significant health issue in the 
UK. In spite of this, the number of people with obesity continues to rise. In 2008, 
roughly 34% of the UK population was obese, which is up from less than 20% a 
decade ago (NHS Information Centre 2014), thus making the UK the fifth most 
obese country in the developed world. Indeed, McQuigg et al. (2005) concluded 
that weight management interventions should be a public health priority to 
alleviate the burden of disease in the general population (McQuigg et al. 2005). 
Furthermore, the effect of obesity on the National Health Service (NHS) is a 
concern of the Department of Health, and it is estimated that the disease 
currently costs the NHS over £4bn each year (NICE 2014). Obesity-related 
morbidity and mortality has a significant impact on individuals’ quality of life with 
associated risks such as cancer and cardiovascular disease and places a large 
burden on the NHS (Randall et al. 2014). Furthermore, obesity has known links 
to hypertension, diabetes, cardiovascular disease and urogenital dysfunction, all 
of which have a substantial impact on health services (Ranasinghe et al. 2011). 
Lower urinary tract symptoms, diabetes mellitus, obesity, inactive lifestyle and 
hypertension are all risk factors for erectile dysfunction (ED) which is a strong 
predictor for cardiovascular and coronary artery diseases due the multifactorial 
aetiology of the disease that interacts with many organs to complete the 
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erection process (Shamloul et al. 2013). As a result of this multifactorial 
aetiology it may be hard to define the factors involved in developing ED. 
Although the baseline characteristics of patients with ED are well characterised, 
the effect of obesity, in particular, on the incidence of ED has not been clarified 
(Mydlo 2004).  
Therefore, the aim of the first audit was to assess the effect of BMI on 
urogenital function using the IPSS in men over 18 and to collate and analyse 
other baseline characteristics such as age, smoking status and medical history. 
This is the first assessment of the baseline characteristics of patients with ED at 
University College London Hospital (UCLH). 
 
Moreover, bariatric surgery is one of the treatment options that is able to 
provide significant weight loss, prolonged life expectancy, and improve a 
number of co-morbidities of obesity, like hypertension, T2DM and urogenital 
dysfunction. Furthermore, there are limited studies into the relationship between 
obesity and male urogenital function, since there have only been a few studies 
that have been published studying patients who suffer from morbid obesity, or a 
BMI of 40 or above. For those reasons, this study has been driven by the desire 
to understand the ways in which bariatric surgery may have an impact on 
sexual and urological dysfunction in men.  
Specifically, the short-term effect of bariatric surgery on erectile and urological 
function is under studied. As mentioned in this chapter, the effect of bariatric 
surgery on blood glucose can precede the effect on body weight. Accordingly, 
the effect of bariatric surgery on erectile and urological function prior to weight 
loss has not been studied. This is particularly interesting as this gives an 
opportunity to assess whether the improvement in erectile and urological 
function is due to glycaemic improvement or due to weight loss and its 
associated effects. 
The aim of this project is therefore to study the short term (four weeks post-
operation) and longer term (three and six months post-operation) effects of 
bariatric surgery on the urological and erectile function of men with morbid 
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obesity as seen in Figure ‎1-14. It is hypothesised that there could be two 
possible outcomes:  
First outcome; if the recovery of erectile function occurs early (i.e. before 
weight loss; as depicted with a red broken line in (Figure ‎1-14)) in parallel with 
normalised blood glucose, this proposes that the improvement of blood glucose 
has more impact than body weight on pathophysiology of urogenital 
dysfunction.  
Second outcome; if the recovery of EF occurs later (i.e. in parallel to weight 
loss; as depicted with a broken black line in (Figure ‎1-14)), this suggests that 
body weight is as important as, if not more than, the normalisation of blood 
glucose. 
The effect of bariatric surgery on erectile function (Reis et al. 2010) has been 
studied in obese men with T2DM but none of those studies have investigated 
the effect in the short term (i.e. before weight loss occurs).   
Currently, the effect of bariatric surgery on bladder function is unknown.  
Therefore, this study will be the first to investigate the short term effects on the 
urogenital function which will permit interrogation of the link between insulin 
resistance and urogenital dysfunction in men with morbid obesity during the 
early post-operative stages, so as to fill the gap in the literature.  
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Figure  1-14: Study rationale scheme.  
Blue solid line (FBG); the expected changes in blood glucose level (Pournaras et al. 2010). 
Green solid line (BMI); the expected changes in body weight (Nijamkin et al. 2012). Red solid 
line (DOS); indicates day of the bariatric surgery. Red broken line indicates the first outcome 
(reversible ED); expected reversal of ED in parallel with normalisation of blood glucose. Black 
broken line indicates the second outcome (irreversible ED); expected reversal of ED in parallel 
with weight loss. 
1m pre op: one-month pre-operation; DOS: day of surgery; 1m post-op: one month post-
operation; 3m post op: three months post-operation; 6m post op: six months post-operation. 
 
1.5.2 Aims and objectives 
The overall aim of the proposed research is to evaluate the baseline 
characteristics of patients with erectile dysfunction and to determine the impact 
of bariatric surgery on erectile and urological function in morbidly obese men by 
conducting two separate clinical audits and analysing the audit data at different 
time points.  
1.5.2.1 Objectives  
1. To conduct an initial audit to investigate the baseline characteristics of 
men over 18 years of age and attending the urological clinic at UCLH 
using IIEF and IPSS questionnaires. 
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2. Perform an audit to explore the effect of BMI on urogenital function in 
men over 18 years of age and attending the urological clinic at UCLH 
using IIEF and IPSS questionnaires. 
3. To collate and analyse other baseline characteristics such as age, 
smoking status, and medical history.  
4. To conduct a second audit to investigate the effect of bariatric surgery 
on the urogenital function and BMI of morbidly obese men over 30 
years of age and BMI of 35 and over. 
5. To analyse the urogenital function and biomarker data acquired in the 
second audit to assess the effect of bariatric surgery on urogenital 
function and recommend further work based on these analyses. 
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2 METHODS  
The following chapter sets out the details of the research methodology 
undertaken to support this thesis. It describes the approach and the primary 
purpose of the two clinical audits performed. Details are given of each of the 
processes required for the use of two questionnaires: the international index of 
erectile function, or IIEF (Rosen et al. 1997) and the international prostate 
symptom score, or IPSS (Plante et al. 1996). Ethical considerations are 
provided in sections ‎2.1.4 and ‎2.2.4. The necessary statistical analyses used to 
address the study questions are explained in sections ‎2.1.5 and ‎2.2.5. All 
documentation relating to this process, including patient information sheets and 
approval letters can be found in Appendix B. 
2.1 Audit of baseline characteristics of urogenital function    
According to the National Institute for Health and Care Excellence (NICE) and 
the Healthcare Commission, clinical audits can be described as a quality 
improvement process which aims to improve patient care and outcomes by 
carrying out a systematic review of care according to specific criteria and the 
subsequent adjustment to the previous process that is carried out (Copeland 
2005).  
Performing a good audit requires both time and sufficient funding, whether the 
audit is prospective or retrospective.  
Time is assigned by most NHS trusts to implement the presentation of audits 
and allow room for discussion. Importantly, the sample chosen for the audit 
should be sufficiently small to allow for rapid data acquisition, but big enough to 
ensure that the data is representative (Copeland 2005).  
2.1.1 Baseline characteristics audit design  
The baseline characteristics audit was designed as a prospective cohort study, 
set up to investigate the effect of BMI on urological function and its role in the 
management of urological diseases, in response to predicted trends in health 
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care and gaps identified in the existing literature. A cohort study classically 
examines multiple health effects from an exposure; subjects are defined 
according to their exposure levels and followed for disease occurrence (Weiss 
et al. 2014). The baseline characteristics audit was organised around two 
research questions: (1) “what are the baseline characteristics of patients with 
erectile dysfunction?” (2) “are there any effects of obesity on urological 
conditions?”  
The audit was set up and conducted over a nine month period between June 
2014 and March 2015, involving patients with any urological condition, in 
attendance at the urology clinic at University College London Hospitals (UCLH).   
The study was conducted using a multidimensional scale for assessment of 
erectile dysfunction the IIEF (Rosen et al. 1997), and the IPSS (Plante et al. 
1996). Additional information was acquired from patients’ records using the 
UCLH database. 
2.1.2 Baseline characteristics audit setting   
This audit was carried out at the urology department, surgical specialities, 
UCLH in accordance with the requirements of the research governance 
frameworks. The audit complied with all reporting requirements, systems and 
duties of action put in place by the trust.  
2.1.3 Patient recruitment  
The patients participating in the baseline characteristics audit were recruited at 
the UCLH Urology clinics for either treatment of ED or other urological 
conditions such as infertility (controls). 
2.1.3.1 Study population  
UCLH delivers first class general and specialist services to both local patients 
and those from throughout the UK and abroad. The hospital has 665 inpatient 
beds and 12 operating theatres. The hospital is located on Euston Road in the 
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Fitzrovia area of the London Borough of Camden. The hospital provides acute 
services to the local populations of Camden, Islington, Barnet, Enfield, Haringey 
and Westminster. Over 950,000 outpatients, over 125,000 accident and 
emergency attendances and over 156,000 patients are admitted each year 
(University College London Hospitals, NHS Foundation Trust, 2015). From the 
patients who have been listed to attend the urological clinic at the UCLH, there 
is a high proportion aged above 45, and the patient sample in this audit reflects 
this point.  
2.1.3.2 Recruitment of participants  
All patients who have been or are newly diagnosed with erectile dysfunction or 
transferred from GP practices with other urological problems were selected 
using the clinical data repository (CDR) at the UCLH. Those patients who met 
the inclusion and exclusion criteria have been included in the audit.  
Inclusion criteria:   
 Patients were required to be listed for attending one of the urological 
clinics at UCLH.  
 Patients were also required to be able to read, speak and understand 
English due to the non-availability of interpreters throughout the audit 
period.  
 Patients were required to be between 18 and 75 years old. 
Exclusion criteria: 
 Patients were excluded if they were considered by the clinician to be 
too unwell to take part in filling in the questionnaires.  
 Patients were excluded if they had another serious illness such as a 
neurodegenerative disease or cancer. 
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 Any patients who were younger than 18 and older than 75 were 
excluded. 
In order to safeguard patient confidentiality, Mr Asif Muneer and Mr David Ralph 
were responsible for the recruitment process to comply with the research 
governance framework at UCLH NHS Trust.  The prospectively collected data 
from those patients who attended the urology clinics for ED from June 2014 to 
March 2015 were analysed. During this period, sixty patients met the inclusion 
and exclusion criteria and were asked to complete the two questionnaires 
voluntarily. 
2.1.3.3 The patient recruitment process and data collection 
The NHS network and clinical data repository (CDR) system database was 
accessed via one of the NHS computers at the urology department, UCLH in 
order to identify patients who met the audit inclusion and exclusion criteria. A list 
of patients who met the inclusion and exclusion criteria was then given to the 
surgeons (Mr. Asif Muneer and Mr. David Ralph) who made the final selection 
according to the audit inclusion and exclusion criteria and accordingly recruited 
the patients, and then gave the NHS patient ID number of the recruited patients 
to the researcher.  
In the Urology Clinic, the researcher accessed the patient information using one 
of the NHS computers and created a unique identifier for the recruited patients 
(BC001, BC002, BC003…)10. The surgeons or fellows who recruited the 
patients gave the patients the two questionnaires (see Appendix A) and 
information sheet (see Appendix B) and undertook the biochemistry and 
haematology requests as per standard of care.  
Due to the requirements for patient confidentiality, the participating urologist and 
not the researcher, invited the patients to participate in the audit and 
                                            
 
10
 BC stands for baseline characteristics.   
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administered the questionnaires. The researcher then received the completed 
anonymous questionnaires directly from the urologists. The patients were asked 
not to put their names or any other personal information on the questionnaires 
to ensure the study was totally anonymised. The only data that were transferred 
to Cranfield University were two completed questionnaires (IIEF and IPSS) as 
well as age, body mass index (BMI), smoking status, medical history and blood 
chemistry values. No subject identifiable data were transferred.  
The researcher created an Excel spreadsheet which links the unique identifier 
(assigned by the researcher) to the NHS patient ID that complies with the 
honorary audit assistant authority. The file that links the NHS patient ID and 
researcher’s unique identifier was kept in the NHS system at all times. No other 
copy was created. This file has never been taken out of the NHS system. 
Another spreadsheet was stored on the researcher’s laptop where each patient 
had a unique identifier, along with the results of the questionnaires and clinical 
data. Neither the NHS patient ID nor any other personally identifiable data were 
kept in this file/folder. This file was kept on the researcher’s laptop which is 
password protected. The folder and file have their own passwords. Moreover 
the file is encrypted using 128 advance encryption standard as recommended 
(UCL Library Services 2015).  
Hard copies (paper) of all questionnaires were locked away at Cranfield 
University. The data collection process followed UCL/UCLH standards under 
the NHS data protection policy (UCL Library Services 2015). 
2.1.3.4 Assessment of baseline blood chemistry and 
haematology  
A complete blood profile test, requested by one of the audit team, was used to 
assess participants’ overall blood chemistry. Venous blood was drawn from the 
study participants following UCLH guidelines by an experienced member of staff 
(Table ‎2-1) (Appendix A).   
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Table  2-1: List of items that were investigated in the blood 
test. 
Biochemistry tests Haematology tests 
 
Fasting blood glucose 
HbA1c  
Prolactin  
Testosterone 
a 
  
Free testosterone 
b
  
Bioavailable testosterone 
b 
  
FSH (Follicle stimulating hormone)  
TSH (Thyroid stimulating hormone)  
FT4 (Free T4)  
Alkaline phosphate 
Alkaline transaminase 
Total bilirubin 
Albumin 
LH (Luteinising hormone)  
Sodium 
Potassium 
Creatinine 
ESR (Erythrocyte sedimentation rate) 
Urea 
Estimated GFR (Glomerular filtration rate) 
Cholesterol  
Triglyceride  
HDL (High density lipoprotein) 
LDL (Low density lipoprotein) 
Cholesterol: HDL ratio 
SHBG (Sex hormone binding globulin)
a 
White cells count 
Red cell count 
Haemoglobin 
HCT (Haematocrit test) 
MCV (Mean corpuscular volume) 
MCH (Mean corpuscular haemoglobin)  
MCHC (Mean corpuscular haemoglobin   
concentration) 
RDW (Red blood cell distribution width) 
Platelet count 
MPV (Mean platelet volume) 
Neutrophils 
Lymphocytes 
Monocytes 
Eosinophil 
Basophils 
a 
Additional tests (not part of the UCLH routine) requested by the surgeon.   
b 
Parameters calculate separately using albumin, SHBG and testosterone serum values (de 
Ronde et al. 2006).   
 
2.1.4 Ethical considerations  
Ethical approval to conduct this audit was obtained from Cranfield University 
Health Research Ethics Committee (CUHREC; Appendix B) in June 2014. The 
relevant documents were then submitted to the urology department at the 
UCLH NHS Foundation Trust in June 2014. The audit was then approved by the 
audit leads for surgical specialties and Gastrointestinal Specialties. The 
researcher was then able to undertake the role of an honorary audit assistant 
within the urology department, surgical specialties, UCLH.  
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The patient information sheet explained the aims of the audit and what was 
being asked of the patient, and stated clearly that participation in the audit was 
voluntary and would not affect the patient’s medical care in any way. Patients 
were only asked to fill in the two questionnaires once they had met with the 
surgeon, and read and understood the information sheet (Appendix B). 
2.1.5 Statistics   
The research design and statistical analysis were carried out by the researcher 
with the statistical support from the statistics department, UCL Institute of Child 
Health And Great Ormond Street Hospital for Children NHS Trust.  
Statistical analysis was performed by using the statistical package SPSS 
version 22 (SPSS Inc., Chicago, IL, USA) for Windows, to perform exploratory 
data analysis and produce descriptive statistics.  
Normality was tested using the skewness and kurtosis test11, the values for 
these parameters should be zero in an ideal normal distribution with values 
between -1 and +1 indicating a normal distribution (Groeneveld et al. 1984).  
The data were also visually inspected through observation of the frequency 
distribution (histogram): when a histogram’s shape approximates a bell-curve it 
suggests that the data follows a normal distribution (Ghasemi et al. 2012) 
(Figure  2-1).   
The data not normally distributed when skewed to any side; positive skew when 
the right tail is longer, negative skew when the left tail is longer (Groeneveld et 
al. 1984).  
                                            
 
11
Skewness is the measurement of symmetry while kurtosis is the measurement of 
“peakedness” of the data (Groeneveld et al. 1984).  
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Figure  2-1: Examples of testing normality by histogram.   
The data in charts (1, 2) were positively skewed (the right tail is longer of both charts), most of 
the distribution is concentrated on the left of the figure and chart (3) the data have a strong 
negative skew (the left tail is longer) most of the distribution is concentrated on the right of the 
figure and chart (4) the data is slightly positively skewed but considered as normally distributed.  
 
The normally distributed data have been expressed as the mean ± standard 
deviation. Parametric tests were also used, such as two samples independent t-
test to compare the means of two groups. Welch’s t-test12 (or unequal variances 
t-test) was used to test the hypothesis that two populations have equal means 
but unequal variances and unequal sample sizes (Ruxton 2006). While, chi-
squared test (X2) was used to calculate the variances of the presence of the 
medical conditions; Fisher’s exact test was used for the same purpose but when 
the sample size of the variances were smaller than seven patients per medical 
condition (Petrie et al. 2013) and the level of significance was p<0.05 (Altman 
                                            
 
12
 Welch’s t-test (or unequal variances t-test) are two-sample tests of difference, in populations 
that have equal means. Welch's t-test is an adaptation of Student's t-test, and is more reliable 
when the two samples have unequal variances and unequal sample sizes (Ruxton 2006).    
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1990).  Pearson correlation coefficient was used to investigate any association 
between the normally distributed variables (Petrie et al. 2013). 
Not normally distributed data have been expressed as the median and the 
interquartile range (IQR)13 also called middle fifty. The non-parametric tests 
were used to explore the differences in blood test values between the ED group 
and NO-ED group, Mann Whitney U test14 was used to perform this calculation 
and the level of the significance  was p<0.05 (Altman 1990). Spearman’s 
correlations15 were utilised to assess the predictors of sexual and urological 
functions. The correlation analysis was performed using the IIEF and IPSS 
scores as dependent variables, and age, BMI, comorbidities and blood tests as 
independent variables.  
 
 
 
 
                                            
 
13
 IQR is the measurement of variability, based on dividing a data set into quartiles. Quartiles 
divide a rank-ordered data set into four equal parts. The values that divide each part are called 
the first, second, and third quartiles; and they are denoted by Q1, Q2, and Q3, respectively 
(Kokoska et al. 2000). 
14 Mann–Whitney U test is a nonparametric test that is used for two samples that come from the 
same population but one population is likely to have larger values than the other whereas t-test 
can only be applied on normal distributions (Petrie et al. 2013). 
 
15
 Spearman's rank correlation coefficient or Spearman's (rho) is a nonparametric measurement 
of the statistical dependence between two variables and is defined as the Pearson correlation 
coefficient between ranked variables (Corder et al. 2014). 
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2.2 Bariatric surgery audit   
The bariatric surgery audit was conducted as a prospective planned audit for 
surgical specialities at University College London hospitals, NHS foundation 
trust, in collaboration with the urology and the bariatric surgery units.  
The UCLH bariatric centre for weight management and metabolic surgery 
centre was opened in July 2007 and is now a major obesity and bariatric centre 
in the United Kingdom. The centre offers comprehensive medical and surgical 
services for the treatment of adolescents and adults with obesity. The 
service has a multidisciplinary approach, including three specialist consultant 
surgeons, two consultant physicians, psychiatrists, psychologists, clinical nurse 
specialists, and dieticians. Anaesthetic support is provided by a team of five 
bariatric anaesthetists (NHS- Services 2015). The centre sees about 700 new 
patients per year and operates on around 360 of these patients (NHS- Services 
2015). Morbidly obese male patients scheduled to undergo bariatric surgery 
were approached before the operation by the bariatric nurse at the specialist 
clinic and were invited to take part in the audit. The audit was carried out by the 
centre for weight loss, metabolic and endocrine surgery, surgical specialities, 
UCLH. The participants were recruited by Mr Majid Hashemi, bariatric surgery 
fellows and the bariatric nurse specialist. The audit complied with all reporting 
requirements, systems and duties of action put in place by the UCLH- NHS 
Trust. 
Patients were required to be listed for attending a bariatric clinic with one of the 
following surgeons at UCLH; Mr Majid Hashemi, Mr Marco Adamo, Mr Andrew 
Jenkinson, Prof Nicolas Finer and Mr Mohamed Elkalaawy.  
2.2.1 Inclusion and exclusion criteria 
Inclusion criteria:   
 Patients were required to be listed for bariatric surgery at UCLH.  
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 Patients were also required to be able to read, speak and understand 
English due to the non-availability of interpreters throughout the audit 
period.  
 Patients were required to be aged 30 years or older. 
Exclusion criteria: 
 Patients were excluded if they were considered by the clinician to be 
too unwell to take part in filling in the questionnaires.  
 Patients were excluded if they had another serious illness such as a 
neurodegenerative disease or cancer. 
 Patients younger than 30 and older than 75 were excluded. 
Participants were given questionnaires and had their weight and height 
measured and were referred for basic blood tests by a member of the research 
team one month before surgery as well as one, three and six months after the 
surgery. 
2.2.2 Patient recruitment process and data collection: 
Patients who met inclusion and exclusion criteria listed above were selected 
using the clinical data repository (CDR) system at UCLH. A list of patients who 
matched the inclusion and exclusion criteria was then given to the surgical 
team. In order to protect patient confidentiality and abide by ethical 
considerations, Mr Majid Hashemi or one of the bariatric surgery team, and not 
the researcher recruited the patients. However, all responsibilities and roles of 
the honorary audit assistant were undertaken by the researcher to comply with 
the research governance framework of the UCLH NHS trust. The data were 
collected from February 2013 to July 2015.  
In order to safeguard patient confidentiality, the surgeon or nurse specialist, and 
not the researcher, invited the patients by giving out the questionnaires 
(Appendix A). The researcher then received the completed anonymous 
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questionnaires directly from the surgeon, surgical fellow or bariatric nurse 
specialist. The patients were asked not to put their names or any other personal 
information on the questionnaires and the audit was therefore totally 
anonymised. The only data that were transferred to Cranfield University were 
two completed questionnaires (IIEF, IPSS), as well as age, BMI, medical history 
and blood chemistry values. No subject identifiable data were transferred.  
When a patient agreed to take part in the audit, the researcher gave the patient 
a unique identifier number (001, 002, 003…). This identifier number was written 
at the top of the questionnaires before they were given to the patient. The 
researcher created a file that linked the unique identifier number to the NHS 
identifier number. No copies were made of this file and the file has never left 
UCLH system in order to comply with the UCL's information security policy 
(UCL Library Services 2015). 
The data from the anonymised questionnaires and blood tests were collected 
on a spreadsheet by the researcher. This file was kept on the laptop which was 
double password protected. The folder and file had their own passwords. 
Moreover, the file is encrypted using 128 advance encryption standard as 
recommended by the NHS (UCL Library Services 2015). Hard copies (paper) of 
all questionnaires were kept in a locked cupboard at Cranfield University. The 
data collection process followed UCL/UCLH standards under the NHS data 
protection policy (UCL Library Services 2015).  
2.2.3 Bariatric surgery audit design 
The audit was designed as a prospective cohort study which was set up to 
investigate the impact of bariatric surgery on patients’ sexual and urological 
function. It was conducted between February 2013 and July 2015 with male 
patients who underwent surgery and follow-up for gastric bypass, sleeve 
gastrectomy or gastric band at UCLH.  
Audit patients were divided in to three groups according to their sexual activity.  
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The first group was the erectile dysfunction group (ED), patients were 
considered to have ED if the IIEF-EF score was below 25. 
The second group was the non-erectile dysfunction group (NO-ED); patients 
were defined as not having ED when their EF score was equal to, or greater 
than 25.  
The third group was the control group, consisting of patients who were listed for 
surgery, but whose surgery was abandoned during the operation due to the 
discovery of a large cirrhotic liver and a poor response to standard liver 
shrinkage. It was therefore deemed unsafe to proceed with the operation. As a 
result of the abandoned surgery, these patients enrolled in the POLER 
programme (prolonged preoperative weight loss programme), and were then 
listed for a second attempt at surgery. The patients were restricted to 1100 
calories per day: 95 g protein, 100 g carbohydrates and 20 g fat from semi 
skimmed milk fortified with milk powder, Fybogel (medication to relieve 
constipation), multivitamins and fluid with at least one salty drink a day.   
The audit aimed to determine the effect of bariatric surgery on male patients’ 
body mass index (BMI), urological symptoms, and sexual function. 
2.2.3.1 Assessments   
2.2.3.1.1 Initial assessments (one stop assessment clinic)  
The first assessment took approximately 4 hours. The patient was assessed by 
the dietician, clinical nurse specialist and surgeon; the patient may also have 
been seen by a physician at this visit. The patients were asked a number of 
questions about medical history, weight loss history and eating habits. They 
were also provided with information to help them choose the operation which 
best suited their expectations, lifestyle, eating habits, medical condition and 
physical anatomy. The average time elapsed between the first assessment 
appointment and the day of the surgery was around 8 months; the minimum 
time taken was 3 months. During this period additional studies may have been 
required, such as sleep studies (i.e. to screen for obstructive sleep apnoea); 
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psychological assessment (i.e. some patients were seen by the psychologist for 
more personalised support) or physician support (i.e. some patients were 
required to undergo a medical review). 
After the first assessment patients’ cases were discussed at the 
multidisciplinary team (MDT) meeting and patients were informed of the team’s 
decision regarding surgery after this meeting by mail (Figure ‎2-2).  
 
Figure  2-2: The plan of bariatric surgery (NHS- Services 2015). 
According to the NICE guidelines, the eligible candidates should be referred from the primary 
care for bariatric surgery. The initial assessment offered a range of alternative interventions in 
an attempt to give the patients a chance to lose weight and improve their comorbidities, which 
usually takes from one to three months until the candidate is approved for surgery by the MDT.  
All patients will have undergone a pre-assessment, then booked a date for surgery. This 
process takes up to 12 months depending on further investigation. After the surgery, the patient 
is referred back into the primary care service for continued follow-up if necessary (NHS- 
Services 2015).  
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2.2.3.1.2 Pre-assessment  
Patients attended a presentation to help them prepare for surgery and this 
assessment was run by the bariatric nurse specialist one month prior to the 
surgery. Patients were asked to have a blood test, an electrocardiogram (ECG) 
and a breathing test performed during the appointment and some patients were 
referred to the anaesthetist. 
2.2.3.1.3 Assessment of sexual function  
Sexual function was assessed using the 15 questions in the International Index 
of Erectile Function (IIEF; Appendix A) (Rosen et al. 1997), in the same way as 
the previous audit (see section ‎1.2.5). 
2.2.3.1.4 Obesity assessment 
The choice of surgical procedure performed during the audit (see section ‎1.1.6) 
was based on specific selection criteria:  patients with BMI >35 kg/m2 and listed 
for bariatric surgery; the patient must be aged or over 30, and they must have 
no other serious illness such as cancer or neurodegenerative diseases currently 
diagnosed.   
Obesity was measured by using the body mass index (BMI; kg/m2). The BMI 
score was used to compare and analyse the health effects of body weight on 
human bodies of all heights (NHS Choices information 2013).  
The audit also used the percentage of excess weight loss (%EWL) to describe 
weight loss after bariatric surgery, and 25 kg/m2 was used as the upper limit for 
a normal BMI (Welbourn et al. 2014). The formula used to calculate %EWL is 
shown on page 19. The baseline for %EWL calculations was taken as the 
weight one month prior to surgery (T1). 
2.2.3.1.5 Assessment of urinary functions  
Urinary function was assessed using the seven questions of the International 
Prostate Symptom Score (IPSS; (Plante et al. 1996).  
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The quality of life due to urinary conditions was assessed using the last 
question in the IPSS questionnaire, to analyse the impact of urinary function on 
daily living, and the answers assigned ranged from ‘delighted’ to ‘terrible’ 
(Appendix A).  
2.2.3.2 Follow- up  
The patients were administered the IIEF and IPSS questionnaires after the 
bariatric procedure at the one, three and six month post-surgery visits. As a part 
of their routine clinical follow-up, the blood tests were repeated either during 
their follow-up visit or one day before to give fasting blood test results.  
Table  2-2: Plan of the follow-up appointments of bariatric 
surgery patients.  
Follow-up appointments 
after surgery 
Appointment with Questionnaires administered  
4 weeks nurse specialist IIEF and IPSS  
8 weeks nurse specialist  
12 weeks dietician IIEF and IPSS 
6 months nurse specialist IIEF and IPSS 
9 months dietician  
12 months nurse specialist or surgeon 
or dietician 
 
Yearly member of the team  
    
2.2.4 Ethical considerations  
Ethical approval to conduct the audit was obtained from Cranfield University 
Health Research Ethics Committee (CUHREC; Appendix B) in February 2013 
(Project reference No 03.13: on 13th February 2013). The relevant documents 
were then submitted to the urology department within UCL hospitals NHS 
Foundation Trust in February 2013. The researcher undertook the role of an 
honorary audit assistant within the centre for weight loss, metabolic and 
endocrine surgery, surgical specialties, surgery and cancer board, UCLH.  
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The patient information sheets explained the aims of the study and what was 
being asked of the patient, and clearly stated that participation in the study 
would not affect the patient’s medical care in any way. Patients were only asked 
to complete two questionnaires once they had met with the surgeon or one of 
the audit members, and read and understood the information sheet (Appendix 
B). 
2.2.5 Statistics   
Statistical analysis methods used in this audit were the same as those used for 
the baseline characteristics audit described in section ‎2.1. 
The time-points used were: baseline or one month pre-operation (T1), one 
month post-operation (T2), three months post-operation (T3), and six months 
post-operation (T4) Changes in the variables across the time-points were 
assessed by Friedman’s test,   which is the non-parametric alternative to the 
parametric one-way repeated measures ANOVA by ranks (Corder et al. 2014). 
It aims to test the differences between two groups (ED, NO-ED) based on the 
mean rank differences of the groups amongst the three time points (T2, T3 and 
T4). The probability distribution of Friedman’s test was calculated by chi-
squared (X2) and p values; p values <0.05 were considered significant (Altman 
1990).  
Wilcoxon signed rank test16 is also a non-parametric test which was used to 
compare repeated measurements between the two groups (ED and NO-ED 
groups) and between two time points to compare their population mean ranks 
(Corder et al. 2014). 
                                            
 
16
 Wilcoxon signed rank test can be used as an alternative to the paired Student’s t-test in 
normally distributed samples (Corder et al. 2014). 
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3 RESULTS  
This chapter presents the analysis of questionnaires and other parameters from 
two audits; the baseline characteristics of urogenital function and bariatric 
surgery impact on urogenital functions.     
3.1 Baseline characteristics of urogenital function audit  
3.1.1 Data distribution  
The distribution of the data was analysed and the skewness test was performed 
with cut-off values of -1 and +1. If the skewness test result was < -1 or > +1, the 
data was considered to be not normally distributed (Table ‎3-1).  
Table  3-1: Test of normality for baseline characteristics of 
urogenital function audit (N=60).  
Descriptive statistics  
Variable  Minimum Maximum Median Mean
 
Skewness 
test 
Normality 
Age 22.0 67.0 47.5 46.2 -0.1 Yes 
Weight (kg) 57.4 110.3 81.9 83.9 0.3 Yes 
Height (cm) 158.4 192.7 173.4 174.4 0.2 Yes 
BMI 20.1 38.4 26.4 27.6 0.9 Yes 
Fasting blood glucose 3.7 26.8 4.9 5.4 7.1 No 
HbA1c 27.0 102.0 36.0 38.2 4.1 No 
Prolactin 99.0 291.0 160.5 181.6 0.3 Yes 
Testosterone 4.7 44.0 17.1 18.0 1.5 No 
Free testosterone 0.1 6.1 0.3 0.5 5.1 No 
Bioavailable testosterone 0.3 29.0 6.9 7.9 2.2 No 
White blood cells 4.6 11.6 6.22 6.8 1.0 No 
Red blood cells 3.5 5.7 5.15 5.0 -0.8 Yes 
Haemoglobin 97.0 171.0 151.5 151.0 -1.3 No 
HCT 0.3 0.5 0.5 0.6 -0.9 Yes 
MCV 81.2 95.2 90.8 90.2 -0.7 Yes 
MCH 26.6 33.2 30.1 30.1 -0.4 Yes 
MCHC 33.0 354.0 332.5 323.6 -5.1 No 
RDW 12.1 15.5 13.4 13.6 0.5 Yes 
Platelet count 99.0 340.0 231.0 231.3 -1.0 No 
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Descriptive statistics  
Variable  Minimum Maximum Median Mean
 
Skewness 
test 
Normality 
MPV 9.9 13.7 11.6 11.6 0.6 Yes 
Neutrophils 2.3 7.0 3.6 4.0 0.9 Yes 
Lymphocytes 1.04 3.6 2.1 2,1 0.4 Yes 
Monocytes 0.1 0.9 0.5 0.5 0.5 Yes 
Eosinophil 0.04 1.0 0.2 0.2 3.4 No 
Basophils 0.01 0.1 0.04 0.04 0.6 Yes 
FSH 1.9 41.0 3.7 6.2 3.6 No 
TSH 0.8 6.5 2.03 2.1 1.8 No 
Free T4 1.2 23.0 14.4 14.9 -1.3 No 
Alkaline phosphate 45.0 309.0 66.0 71.2 6.2 No 
Alkaline transaminase 12.0 124.0 25.0 33.2 2.8 No 
Bilirubin total 3.0 19.0 10.0 10.5 0.4 Yes 
Albumin 37.0 51.0 47.0 46.6 -1.1 No 
LH 1.2 18.7 4.6 5.2 2.2 No 
Sodium 132.0 146.0 141.0 140.8 -0.8 Yes 
Potassium 0.4 5.5 4.40 4.3 - 4.0 No 
Creatinine 62.0 198.0 88.0 89.8 2.8 No 
ESR 2.0 33.0 2.0 3.1 5.9 No 
Urea 2.4 10.7 5.0 5.1 1.6 No 
Estimated GFR .00 89.0 89.0 83.0 -0.1 Yes 
Cholesterol 3.0 9.1 4.4 4.4 3.0 No 
Triglyceride 0.7 3.6 1.0 1.1 3.2 No 
HDL 0.8 2.1 1.4 1.4 0.2 Yes 
LDL 1.1 6.2 2.50 2.6 1.7 No 
Ratio Cholesterol to HDL  1.7 7.0 3.3 3.4 1.3 No 
SHBG 18.0 234.0 46.0 47.2 4.8 No 
T2DM 0.0 1.0 0.0 0.1 2.2 No 
Psoriatic Arthritis 0.0 1.0 0.0 0.03 5.3 No 
Obstructive Sleep Apnoea 0.0 1.0 0.0 0.1 2.2 No 
Hypercholesterolemia 0.0 1.0 0.0 0.02 5.3 No 
Anxiety 0.0 1.0 0.0 0.02 7.7 No 
Depression  0.0 1.0 0.0 0.1 3.5 No 
Non Alcoholic Fatty Liver 0.0 1.0 0.0 0.02 7.7 No 
Gout 0.0 1.0 0.0 0.02 7.7 No 
Hyperlipidaemia 0.0 1.0 0.0 0.02 7.7 No 
Irritable Bowel Syndrome 0.0 1.0 0.0 0.02 7.7 No 
Peyronie’s disease 0.0 1.0 0.0 0.1 3.5 No 
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Descriptive statistics  
Variable  Minimum Maximum Median Mean
 
Skewness 
test 
Normality 
Fertility Problem 0.0 1.0 0.0 0.1 2.7 No 
Proteinuria 0.0 1.0 0.0 0.02 7.7 No 
Right Testicular Atrophy 0.0 1.0 0.0 0.03 5.3 No 
Left Testicular Atrophy 0.0 1.0 0.0 0.02 7.7 No 
Klinefelter syndrome 0.0 1.0 0.0 0.02 7.7 No 
AIDS 0.0 1.0 0.0 0.02 7.7 No 
Hypertension 0.0 1.0 0.0 0.03 5.3 No 
Coughlan syndrome 0.0 1.0 0.0 0.02 7.7 No 
Asthma 0.0 1.0 0.0 0.02 7.7 No 
Hydrocele testis 0.0 1.0 0.0 0.02 7.7 No 
Overweight (25 ≥ BMI<30) 0.0 1.0 1.0 0.5 -0.1 Yes 
Morbidly obese (BMI>30) 0.0 1.0 0.0 0.3 1.1 No 
Erectile function 1.0 30.0 11.0 13.8 0.4 Yes 
Orgasmic function 0.0 10.0 6.5 6.1 -0.3 Yes 
Sexual desire 2.0 10.0 6.0 5.5 0.1 Yes 
Intercourse satisfaction 0.0 15.0 6.0 6.2 0.3 Yes 
Overall satisfaction 1.0 10.0 4.5 5.1 0.4 Yes 
IIEF total score 6.0 74.0 31.5 36.7 0.4 Yes 
Incomplete emptying 0.0 5.0 1.0 1.7 0.8 Yes 
Frequency 0.0 5.0 2.0 1.8 0.6 Yes 
Intermittency 0.0 5.0 0.5 1.3 1.0 No 
Urgency 0.0 5.0 1.0 1.5 0.8 Yes 
Weak stream 0.0 5.0 1.0 1.5 0.9 Yes 
Straining 0.0 5.0 0.0 1.1 1.3 No 
Nocturia 0.0 5.0 1.0 1.7 0.9 Yes 
QoL( Quality of life) 0.0 6.0 3.0 2.6 0.1 Yes 
IPSS total score 0.0 32.0 8.0 10.5 0.7 Yes 
 
 
3.1.2 Patient cohort profile: general demographics 
Overall, the sample contained 60 patients. These patients ranged in age 
between 22 and 67 years old, with a mean (± SD) age of 46.2 ± 13.6 years 
(Figure ‎3-1)  
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Figure  3-1: The patient cohort profile- age distribution. 
Patient weight ranged between 57.4 kg and 110.3 kg and the mean weight was 
83.9 ± 12.3 kg. Patient height in the sample ranged from 158.4 cm to 192.7 cm, 
with a mean of 174.4 ± 6.9 cm. Each patient’s BMI was calculated based on 
weight and height (weight (kg)/height (m) 2); BMI in current sample ranged from 
20.1 to 38.4, with a mean of 27.6 ± 4.0 kg/m2 (Table ‎3-2).  
Table  3-2: Descriptive statistics of the general demographic 
details of patients.  
 Total Sample (n=60) 
 Mean (±SD) 95% CI 
Age (year) 46.2 (13.7)  (42.7, 49.6) 
Height (cm) 174.4 (6.9) (172.7, 176.1) 
Weight (kg) 83.9 (12.3) (80.8, 87) 
BMI (kg/m
2
) 27.6 (4.0) (26.6, 28.6) 
 
The above statistics indicate that most of the patients were overweight 
(25≤BMI<30). Table ‎3-3 outlines patient characteristics separated into two study 
groups (ED and NO-ED; patients who scored <25 in EF-IIEF were placed in the 
ED group). The results in Table ‎3-3 show that both of the study groups were 
overweight (25≤BMI<30). The two groups were compared using independent 
samples t-test (Welch’s t- test); height was the only variable found to differ 
significantly between groups (Table ‎3-3). 
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Table  3-3: General descriptive statistics of the ED and NO-
ED groups.  
                    ED 
a
 Group (n=48)           NO-ED 
b
 (n=12) 
 Mean (±SD) Mean (±SD) p 
Age (year) 47.1 (13.7) 42.4 (13.5) 0.29
c 
Height (cm) 175.8 (6.95) 169.0 (3.3) 0.002
c 
Weight (kg) 84.4 (10.5) 82.0 (18.3) 0.68
c 
BMI  (kg/m
2
)
 
27.4 (3.3) 28.6 (6.2) 0.50
c 
a 
ED group when the score of the erectile function (EF) domain in the IIEF (IIEF-EF) was less than 25. 
b 
NO-ED group (IIEF-EF score 25 or more). 
c 
Welch’s t- test. 
3.1.3 Multiple medical conditions 
From the medical records, it was found that 80.0% of the patients (n=48) in the 
current sample (n=60) suffer from erectile dysfunction (Figure  3-2). The second 
most common medical problem was found to be obesity (BMI over 25 kg/m2), 
which affected 78.3% of the patients (n=47). Furthermore, 13.3% of the patients 
(n=8) had type 2 diabetes (T2DM), and a similar percentage (13.3%) had 
obstructive sleep apnoea (n=8). In total, 10% of the patients suffered from 
fertility problems (n=6). Other, rarer medical disorders (less than 10.0% of the 
sample) were hypercholesterolemia, psoriatic arthritis, anxiety, depression, non-
alcoholic fatty liver disease, gout, irritable bowel syndrome, Peyronie’s disease, 
proteinuria, and asthma. Moreover, 37.5% of patients (18 paitients out of 48) 
had ED and one additional chronic disease, and 52.1% of patients (25 paitients 
out of 48) had ED and two or more additional chronic diseases. The distribution 
of medical conditions observed in the patient group is shown in Figure  3-3. 
There was no difference in the incidence of these medical conditions in ED and 
NO-ED groups except the incidence of being overweight (BMI ≥ 25) was 
significantly higher in the ED group (Table ‎3-4; p=0.007).  
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Figure  3-2: Patient distribution with ED and other medical conditions 
(N=48).  
Distribution of the occurrence of multiple conditions according to the data derived from patients 
with erectile dysfunction (N=48) out of the total number (N=60). 
 
 
 
  
0
5
10
15
20
25
30
ED ED + 1 medical condition ED + ≥ 2 medical conditions  
N
u
m
b
e
r 
o
f 
p
a
ti
e
n
ts
 
Medical conditions  
103 
 
Figure  3-3: An overview of all patients showing the frequencies of multiple chronic conditions (N=60). 
Distribution of multiple chronic conditions occurrence according to the data derived from patients (N=60) it was found that erectile dysfunction (ED; 
n=48) and obesity (BMI > 25 kg/m
2
; n=47) was present in most patients. Obstructive sleep apnoea (n=8), fertility problems (n=6), Peyronie’s disease 
(n=4) were the next most common conditions, with other medical conditions being present in only one patient per condition. 
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Table  3-4: Medical diagnosis differences between the ED 
and NO-ED groups.   
 
Diagnosis 
ED (n=48) 
% 
NO-ED (n=12) 
% 
 
difference 
 
p
a
 
Type II Diabetes 16.7 0.0 16.7 0.34 
Obesity (BMI > 25 kg/m
2
) 83.3 58.3 25 0.11 
Psoriatic arthritis 2.1 8.3 -6.3 0.36 
Obstructive sleep apnoea 16.7 0.0 16.7 0.34 
Hypercholesterolemia 2.1 0.0 2.1 1.0 
Anxiety 2.1 0.0 2.1 1.0 
Depression 8.3 0.0 8.3 0.57 
Non-alcoholic fatty liver 2.1 0.0 2.1 1.0 
Gout 2.1 0.0 2.1 1.0 
Hyperlipidaemia 2.1 0.0 2.1 1.0 
Irritable bowel syndrome 2.1 0.0 2.1 1.0 
Peyronie’s disease 8.3 0.0 8.3 0.57 
Fertility problems 8.3 16.7 -8.3 0.59 
Proteinuria 2.1 0.0 2.1 1.0 
Right testicular atrophy 4.2 0.0 4.2 1.0 
Left testicular atrophy 2.1 0.0 2.1 1.0 
Klinefelter syndrome 2.1 0.0 2.1 1.0 
AIDS 2.1 0.0 2.1 1.0 
Hypertension 4.2 0.0 4.2 1.0 
Coughlan’s syndrome 4.2 0.0 4.2 1.0 
Asthma 2.1 0.0 2.1 0.20 
Hydrocele testis 0.0 8.3 -8.3 1.0 
a 
Fisher’s exact test results. 
 
3.1.4 Blood biochemistry and haematology  
A total of 24 biochemistry and 15 haematology blood tests were completed for 
all patients. Table ‎3-5 to Table ‎3-8 presented below show descriptive statistics 
for these tests. As indicated previously in Table ‎3-1 these variables were largely 
non-normally distributed. The data from the biochemistry and haematology tests 
illustrate that all patients’ blood test results were within normal ranges 
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(Table ‎3-5 and Table ‎3-6). There was no difference between ED and NO-ED 
groups with respect to any of the blood tests except testosterone levels and 
eosinophil counts (Table ‎3-7 and Table ‎3-8). Although both groups’ serum 
testosterone levels were within the normal range, NO-ED group had higher 
average testosterone than ED group (Table ‎3-7; p=0.038). However, there was 
no difference between ED and NO-ED groups in terms of free testosterone and 
bioavailable testosterone levels.  
Similarly, both groups’ eosinophil counts were within the normal range, but the 
NO-ED group had higher average eosinophil counts than the ED group 
(Table ‎3-8; p=0.0033). 
Table  3-5: Descriptive statistics of blood biochemistry tests 
for all patients.  
Blood test 
 
Median (IQR)
a 
Normal range 
b 
Fasting blood glucose( mmol/L) 4.9 (4.70, 5.40) 3.9 - 5.8  
HbA1c level (mmol/mol) 36.0 (34.00, 38.00) 20 - 42  
Prolactin test (miu/L) 160.5 (139.50, 234.00) 86 - 324  
Testosterone level (nmol/L)  17.1 (13.95, 20.03) 7.6 - 31.4  
Free testosterone (nmol/L) 0.3 (0.25, 0.77)  >0.225 
c 
Bioavailable testosterone (nmol/L) 6.9 (6.7, 9.1) 61-213 (ng/dL)
d 
SHBG (nmol/L) 46.0 (35.50, 51.00) 16-55 
FSH (IU/L) 3.6 (2.90, 6.13) 
1.5 - 12.4   
TSH (miu/L) 2.0 (1.40, 2.66) 0.2 - 4.0  
Free T4 (pmol/L) 14.4 (13.40, 16.90) 10 - 20  
Alkaline Phosphate (IU/L) 66.0 (57.00, 75.00) 40- 129        
Alkaline transaminase ( IU/L) 25.0 (23.00, 35.25) 10- 50          
Bilirubin total (umol/L) 10.0 (7.25, 13.00) 0- 20            
Albumin (g/L) 47.0 (45.00, 48.00) 34- 50          
Luteinising Hormone (LH) (IU/L) 4.5 (3.13, 5.80) 
1.7-8.6  
Sodium (mmol/L) 141.0 (139.00, 142.75) 135-145      
Potassium (mmol/L) 4.4 (4.10, 4.60) 3.5- 5.1       
Creatinine (umol/L) 88.0 (78.50, 92.00) 66- 112       
ESR (mm/hr) 2.0 (2.00, 2.00) 0-20            
Urea (mmol/L) 5.0 (4.30, 5.68) 1.7- 8.3      
Estimated GFR (ml/min/1.73 sqm) 89.0 (78.25, 90.00)  90 - 120 
 
Cholesterol (mmo/L) 4.4 (4.03, 4.80) 
2.5 - 5  
Triglyceride (mmo/L) 1.0 (0.90, 1.20) 
0.4 - 2.3  
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Blood test 
 
Median (IQR)
a 
Normal range 
b 
HDL Cholesterol (mmo/L) 1.4 (1.20, 1.60) 
0.9 - 1.5  
LDL Cholesterol (mmo/L) 2.5 (2.13, 2.90) 
0 - 3.5  
Cholesterol: HDL ratio 3.3 (2.50, 3.80) 
 
a 
The interquartile range (IQR).  
b
 Normal range of blood tests according to the UCLH standards.  
c 
According to the BSSM guidelines (2010), there are no accepted lower limits of free testosterone for the 
diagnosis of hypogonadism. However, a free testosterone level below 0.225 nmol/l can provide supportive 
evidence for treatment with testosterone (Wylie et al. 2010).  
d 
Reference value for age 40-49 (Thrower et al. 2013). 
 
Table  3-6: Descriptive statistics of blood haematology tests 
for all patients (N=60). 
a  
Normal range of blood tests according to the UCLH standards.  
 
Table  3-7: Blood biochemistry tests:  Statistical 
comparison between the ED and NO-ED groups.  
Variable/Blood test ED (n=48) NO-ED (n=12)  
 Mean (±SD)
a 
Median (IQR)
b 
Mean (±SD)
a
 
Median (IQR)
b 
p 
Fasting blood glucose( mmol/L) 5.0 (4.7, 5.4) 4.8 (4.4, 5.2) 0.24 
HbA1c level (mmol/mol) 36.0 (34.6, 39.6) 35.5 (32.0, 36.6) 1.00 
Prolactin test (miu/L) 178.2 (±53.7) 195.5 (±49.5) 0.31 
Testosterone level (nmol/L) 16.2 (13.1,  19.1) 18.1 (16.4, 24.8) 0.038
 
Variable Median (IQR) Normal range 
a 
White blood cells (10
9 
/L) 6.22 (5.18 - 7.34) 3-10 
 
Red blood cells (10
9 
/L) 5.15 (4.80 - 5.34) 4.4-5.8    
Haemoglobin (g/dL) 15.15 (14.17 – 16.1) 13- 17     
HCT (L/L) 0.46 (0.43 - 0.48) 0.37- 0.5     
MCV (fL) 90.80 (87.40 - 92.68) 80- 99        
MCH (Pg) 30.10 (29.50 - 30.80) 27- 33.5   
MCHC (g/dL) 33.25 (32.92 – 34.0) 32- 36      
RDW % 13.40 (13.10 - 14.10) 11.5 -15  
Platelet (10
9 
/L) 231.00 (214.00 - 259.75) 150- 400   
MPV (fL) 11.45 (10.83 - 12.10) 7-13    
Neutrophils (10
9 
/L) 3.62 (2.99 - 4.50) 2-7.5     
Lymphocytes (10
9 
/L) 2.10 (1.81 - 2.41) 1.2- 3.65     
Monocytes (10
9 
/L) 0.47 (0.41 - 0.58) 0.2- 1       
Eosinophil (10
9 
/L) 0.16 (0.10 - 0.20) 0.0- 0.4    
Basophil (10
9 
/L) 0.04 (0.02 - 0.05) 0.0- 0.1    
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Variable/Blood test ED (n=48) NO-ED (n=12)  
 Mean (±SD)
a 
Median (IQR)
b 
Mean (±SD)
a
 
Median (IQR)
b 
p 
Free testosterone (nmol/L) 0.3 (0.2, 0.9) 0.3 (0.2, 0.4) 0.69 
Bioavailable testosterone (nmol/L) 6.9 (6.6, 9.5) 6.8 (5.0, 9.6) 0.86 
SHBG (nmol/L) 45.0 (30.0, 51.0) 47.5 (39.8, 55.8) 0.36 
FSH (IU/L) 3.6 (2.8, 6.1) 5.2  (3.1, 6.4) 0.23 
TSH (miu/L) 2.0 (1.4, 2.7) 1.89(1.39, 2.64) 0.78 
Free T4 (pmol/L) 14.8 (13.4, 16.9) 14.4 (14.1, 16.8) 0.86 
Alkaline Phosphate (IU/L) 66.0  (58.0, 75.0) 62.0 (53.0, 77.8) 0.31 
Alkaline transaminase ( IU/L) 25.0  (22.0 , 41.3) 29.0 (25.0, 32.5) 0.29 
Bilirubin total (umol/L) 10.5 (±3.6) 10.4  (±4.6) 0.96 
Albumin (g/L) 47.0 (45.0, 48.0) 46.5 (46.0, 48.0) 0.92 
Luteinising Hormone (LH) (IU/L) 4.4 (3.0, 5.8) 5.1 (4.5 , 7.8) 0.09 
Sodium (mmol/L) 140.7 (±3.4) 141.4 (±1.7) 0.45 
Potassium (mmol/L) 4.4 (4.1, 4.6) 4.5 (3.9, 4.6) 0.96 
Creatinine (umol/L) 88.0(74.0, 92.0) 89.5 (87.3, 98.3) 0.13 
ESR (mm/hr) 2.0 (2.0, 2.0) 2.0 (2.0, 2.0) 0.13 
Urea (mmol/L) 5.1 (4.3, 5.7) 4.6 (3.7, 5.8) 0.36 
Estimated GFR 83.0(±12.3) 83.3 (± 8.0) 0.92 
Cholesterol (mmo/L) 4.40(4.10, 4.80) 4.35(3.70, 4.58) 0.26 
Triglyceride (mmo/L) 1.0 (0.9, 1.2) 1.0 (0.9, 1.0) 0.34 
HDL Cholesterol (mmo/L) 1.4 (±0.3) 1.3 (±0.2) 0.45 
LDL Cholesterol (mmo/L) 2.5 (2.3, 3.0) 2.3 (2.1, 2.7) 0.10 
Cholesterol: HDL ratio 3.4 (2.4, 3.8) 3.2 (2.6, 3.7) 0.61 
a 
Independent two samples  t-test (parametric test for normally distributed samples).  
b 
Mann-Whitney U test (nonparametric test for non-normally distributed samples).  
 
Table  3-8: Haematology tests:  Statistical comparison 
between the ED and NO-ED groups. 
Variable ED (n=48) NO-ED (n=12)  
 Mean (±SD)
a 
Median (IQR)
b
 
Mean (±SD)
a 
Median (IQR)
b
 
p 
White blood cells (10
9 
/L) 6.2 (5.18 - 7.36) 6.2 (5.07 - 7.31) 0.73 
Red blood cells (10
9 
/L) 5.0 (± 0.5) 5.0 (± 0.4) 0.80 
Haemoglobin (g/dL) 155.5 (141.45 - 162.75) 149.0 (142.25 - 153.0) 0.37 
HCT (L/L) 0.5 (±0.06) 0.5 (± 0.03) 0.57 
MCV (fL) 90.4 (± 3.2) 89.5 (±2.4) 0.34 
MCH (Pg) 30.1 (1.3) 29.7 (1.0) 0.30 
MCHC (g/dL) 332.5 (329.25 - 339.75) 332.0 (326.50 - 341.0) 0.50 
RDW % 13.7 (±0.8) 13.4 (± 0.6) 0.22 
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Variable ED (n=48) NO-ED (n=12)  
Platelet (10
9 
/L) 230.5 (214.00 - 260.00) 240.0 (216.50 - 253.0) 0.77 
MPV (fL) 11.5 (±0.9) 11.7 (±0.9) 0.51 
Neutrophils (10
9 
/L) 4.1 (±1.4) 3.6 (±0.9) 0.32 
Lymphocytes (10
9 
/L) 2.1 (±0.6) 2.1 (±0.2) 0.90 
Monocytes (10
9 
/L) 0.5 (±0.2) 0.5 (±0.2) 0.43 
Eosinophil (10
9 
/L) 0.15 (0.08 - 0.18) 0.20 (0.15 - 0.85) 0.004
 
Basophil (10
9 
/L) 0.04 (±0.02) 0.04 (±0.02) 0.84 
a 
Independent two samples  t-test. 
b 
Mann-Whitney U test. 
3.1.5 International Index of Erectile Function (IIEF) results  
All patients were asked to complete and answer 15 questions about their sex 
life over four weeks prior to the test. The data from the IIEF questionnaire were 
normally distributed. The results of this questionnaire are presented in 
Table ‎3-9. In all domains there was a significant difference between NO-ED and 
ED groups (P<0.05). 
Table  3-9: Descriptive statistics of IIEF results for the ED 
and NO-ED groups. 
 
Variables 
ED (n=48) NO-ED (n=12)  
p Mean (±SD)
a 
Mean (±SD)
a 
Erectile function 11.0 (± 7.7) 25.0 (± 8.9)  <0.001
** 
Orgasm function  5.5 (± 3.3) 8.5  (± 1.5) 0.003
* 
Sexual desire  4.9 (± 2.3) 7.5 (± 2.2) 0.001
* 
Intercourse satisfaction  5.1 (± 3.8) 10.5 (± 4.3) <0.001
** 
Overall satisfaction  4.5 (± 2.6) 7.7 (± 2.9) <0.001
** 
a 
Independent two samples  t-test. 
* 
 p < 0.005 
** 
p ≤ 0.001 
 
3.1.6 International Prostate Symptom Scale (IPSS) results 
The IPSS total score was generated from 7 sub-domain scores as seen in 
section ‎1.3.6. IPSS total scores ranged between 0 and 35. Results for the total 
score and the seven sub-domains of the IPSS are presented in Table ‎3-10. 
Data from the IPSS questionnaire were normally distributed except for 
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intermittency and straining which were not normally distributed. No statistically 
significant differences between NO-ED and ED groups were observed in any of 
the IPSS domains (Table ‎3-10).  
Table  3-10: Descriptive statistics of IPSS results for the ED 
and NO-ED groups, with statistical comparison between 
groups using the Mann-Whitney U test.  
 
Variables 
ED (n=48) NO-ED (n=12)  
p Mean (±SD)
a 
Median (IQR)
b
 
Mean (±SD)
a
 
Median (IQR)
b
 
Incomplete emptying 1.7  (±1.7)
a 
1.7 (±2.0)
a 
1.0 
Frequency 1.9 (±1.6)
a 
1.6 (±1.1)
a 
0.58 
Intermittency 0.0 (0.00, 2.00)
b 
2.0 (0.00, 3.00)
b 
0.16 
Urgency 1.4 (±1.5)
a 
1.4 (±1.4)
a 
0.89 
Weak stream 1.6 (±1.6)
a 
1.3 (±1.7)
a 
0.63 
Straining 0.0 (0.00, 1.00)
b 
1.0 (0.00, 2.75)
b 
0.37 
Nocturia 1.8 (±1.4)
a 
1.2 (±1.1)
a 
0.15 
Q o L 2.7 (±1.8)
a 
2.4 (±2.0)
a 
0.70 
IPSS total 10.5 (±8.7)
a 
10.5 (±8.2)
a 
0.99 
a 
Mean and standard deviation, independent two samples  t-test was used  (parametric test for normally 
distributed samples).  
b 
Median and IQR, Mann-Whitney U test was used (nonparametric test for non-normally distributed 
samples).  
 
 
3.1.7 Correlations between different variables   
All possible correlations between any of the variables were tested. All of the 
results are shown in Figure  5-1, Appendix C. The significant correlations are 
listed in Table  3-11 below and the detailed analysis of these correlations is also 
presented. 
Table  3-11: List of significant correlations between 
variables in baseline characteristics of urogenital function 
audit  
Number of the variables 
in (Appendix C) 
Significant correlation between variables,  p<0.05 
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Number of the variables 
in (Appendix C) 
Significant correlation between variables,  p<0.05 
1 -69 Age - IIEF-OF 
1 - 68 Age – IIEF- EF 
1 - 70 Age – IIEF-SD 
4 -70 BMI- IIEF-SD 
4 -72 BMI- IIEF- OS 
8 -68 Testosterone - IIEF-EF 
8 -70 Testosterone - IIEF-SD 
8 – 69 Testosterone - IIEF-OF 
8 – 72 Testosterone - IIEF- OS 
13 – 73 MCV - IPSS-Incomplete emptying 
13 – 75 MCV - IPSS- Intermittency 
13 – 78 MCV- IPSS- Straining 
14 -75 MCH - IPSS- Intermittency 
14 – 78 MCH - IPSS- Straining 
15 – 70  MCHC - IIEF-SD 
15 – 73  MCHC - IPSS-Incomplete emptying 
16 – 77 RDW - IPSS- Weak stream 
19 – 70 Neutrophils - IIEF-SD 
19 - 74 Neutrophils - IPSS- Frequency 
20 – 74  Lymphocytes - IPSS- Frequency 
22 – 68  Eosinophil - IIEF-EF 
22 – 71  Eosinophil - IIEF- IS 
26 – 80 Free T4 - IPSS- QoL 
31 - 70 LH - IIEF-SD 
33 – 75 Potassium - IPSS- Intermittency 
33 – 76 Potassium - IPSS- Urgency 
35 -68 ESR - IIEF-EF 
35 – 69 ESR - IIEF-OF 
35 -71  ESR - IIEF- IS 
35 – 77  ESR - IPSS- Weak stream 
65 -74 Smoker  - IPSS- Frequency 
68-29 IIEF-EF- Total Bilirubin  
76-37 IPSS- Urgency- Estimated GFR 
76-79 IPSS- Urgency - IPSS- Nocturia 
77 – 37 IPSS- Weak stream - Estimated GFR 
79 - 68 IPSS- Nocturia - IIEF-EF 
79 - 72   IPSS- Nocturia - IIEF- OS 
82 - 26 Free testosterone - Free T4 
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Number of the variables 
in (Appendix C) 
Significant correlation between variables,  p<0.05 
82 – 45  Free testosterone - Psoriatic arthritis 
82 – 61 Free testosterone - Hypertension 
82 – 66 Free testosterone - Overweight (25 ≥ BMI<30) 
83 – 49 Bioavailable testosterone - Depression 
83 - 61 Bioavailable testosterone - Hypertension 
 
3.1.7.1 Correlation between erectile function and obesity  
As the data were normally distributed, Pearson correlation coefficients were 
used to investigate whether patients who are considered overweight or obese 
(BMI >25kg/m2) have different scores in IIEF and IPSS compared to those who 
are not overweight or obese. A significant correlation was found between sexual 
desire and BMI (p=0.01). Furthermore a significant correlation was also 
observed between overall satisfaction and BMI (p=0.01) as seen on Table ‎3-12. 
Table  3-12: Correlation between IIEF domains and BMI 
(N=60). 
IIEF domain Pearson correlation p 
Erectile function 0.12 0.4 
Orgasmic function  0.06 0.7
 
Sexual desire 0.33 0.01 
Intercourse satisfaction 0.16 0.2 
Overall satisfaction 0.32 0.01
  
 
 
When the two groups (ED and NO-ED) were analysed, the correlation between 
sexual desire domain and BMI remained significant for both groups while the 
correlation between overall satisfaction and BMI was lost when analysing either 
group individually (Table ‎3-13).  
Table  3-13: Correlation between BMI and IIEF domains in 
the ED and NO-ED groups. 
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IIEF domains and BMI 
Pearson correlation  
p
a 
ED (n=48) NO-ED (n=12) 
Erectile function  -0.04 0.25  0.4
 
Orgasm function  -0.01 0.12 0.7
 
Sexual desire  0.30 0.40 <0.001
 
Intercourse satisfaction  0.01 0.32 0.2
 
Overall satisfaction  0.16 0.16 0.9
 
a
 Independent two samples  t-test was used (parametric test for normally distributed samples). 
3.1.7.2 Correlation between IPSS domains and obesity  
The IPSS results indicated no significant correlation between any of the IPSS 
domains and BMI when all patients were taken into consideration (Table ‎3-14).  
Table  3-14: Correlation between IPSS domains of and BMI 
(N=60).  
 
IPSS domain 
Spearman’s correlation 
a 
Pearson correlation
 b 
 
p 
Incomplete emptying 0.10
b 
0.5 
Frequency -0.10
b 
0.5 
Intermittency -0.06 
a 
0.7 
Urgency -0.12 
b 
0.3 
Weak stream -0.12 
b 
0.9 
Straining -0.05 
a 
0.7 
Nocturia -0.12 
b 
0.4 
QoL -0.14 
b 
0.3 
IPSS total score -0.10 
b 
0.6 
a 
Spearman’s rho correlation was used as non-parametric test.   
b 
Pearson correlation was used as parametric test.  
 
When the patient cohort was split into ED and NO-ED groups, the lack of 
correlation remained unchanged (Table ‎3-15).   
Table  3-15: Correlation between BMI and IPSS domains in 
the ED and NO-ED groups.  
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IPSS domains and BMI 
Spearman’s correlation 
a 
Pearson correlation
 b
 
 
p
 
ED (n=48) NO-ED (n=12) 
Incomplete emptying 
a 
0.02
a 
0.23
a 
0.9
c 
Frequency 
a 
-0.14
a 
-0.05
a 
0.5
c 
Intermittency
 b 
-0.13
b 
-0.10
b 
0.4
d 
Urgency 
a 
-0.17
a 
-0.08
a 
0.9
c 
Weak stream 
a 
0.07
a 
-0.27
a 
0.7
c 
Straining 
b 
-0.04
b 
-0.14
b 
0.2
d 
Nocturia 
a 
-0.11
a 
-0.20
a 
0.2
c 
Q o L 
a 
-0.08
a 
-0.30
a 
0.9
c 
IPSS total 
a 
-0.05
a 
-0.04
a 
0.8
c 
a 
Spearman’s rho correlation was used as non-parametric test.   
b 
Pearson correlation was used as parametric test.  
c 
Mann-Whitney U test was used (nonparametric test for not normally distributed samples). 
d 
Independent two samples t-test was used (parametric test for normally distributed samples). 
 
3.1.7.3 Correlation between IIEF and IPSS domains 
Correlations between any of the IIEF and IPSS domains in all patients (N=60) 
were investigated using Pearson correlation coefficient except for intermittency 
and straining where Spearman's rank correlation coefficient was used. No 
significant correlation was found in any of the pairs of variables except nocturia 
and three IIEF domains (erectile function, sexual desire and overall satisfaction) 
(Table ‎3-16). The strongest correlation was between nocturia and sexual desire 
(Table ‎3-16). Moreover, the correlations between any of the IIEF and IPSS 
domains in ED (N=48) and NO-ED (N=12) were investigated using independent 
two samples t-test for all domains except with two domains; intermittency and 
straining where Mann-Whitney U test was used. Significant different correlations 
were found between IIEF-sexual desire and IPSS-incomplete emptying, urgency 
and weak stream, p=0.002, p=0.004 and p=0.035 respectively (Table ‎3-17).  
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Table  3-16: Correlations between IIEF and IPSS domains (N=60). 
 
IPSS domains 
Erectile function 
 
Orgasmic function Sexual desire Intercourse satisfaction Overall satisfaction 
r/rho p r/rho p r/rho p r/rho p r/rho P 
Incomplete emptying 
a 
0.07 0.6 0.07 0.6 0.09 0.5 -0.02 0.9 0.09 0.5 
Frequency 
a 
-0.02 0.9 0.01 0.9 -0.08 0.5 -0.04 0.7 0.02 0.9 
Intermittency 
b 
0.01 0.9 0.03 0.9 -0.03 0.8 -0.02 0.9 0.09 0.5 
Urgency 
a 
0.01 1.0 -0.08 0.5 -0.22 0.09 0.04 0.8 -0.11 0.4 
Weak stream 
a 
-0.20 0.2 -0.11 0.4 -0.17 0.2 -0.20 0.1 -0.10 0.4 
Straining 
b 
-0.08 0.5 -0.06 0.7 -0.13 0.3 -0.06 0.6 -0.01 0.9 
Nocturia 
a 
-0.26 0.046
 
-0.25 0.05 -0.34 0.008
 
-0.24 0.07 -0.26 0.045
 
QoL 
a 
-0.18 0.18 -0.20 0.2 -0.2 0.1 -0.12 0.12 -0.08 0.5 
IPSS total score 
a 
-0.08 0.6 -0.07 0.6 -0.15 0.3 -0.1 0.44 -0.06 0. 
a 
Pearson correlation coefficient (parametric correlation test). 
b 
Spearman's rho correlation coefficient (nonparametric correlation test). 
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Table  3-17: Correlations between IIEF and IPSS domains in the ED (N=48) and NO-ED (N=12) 
groups. 
 
IPSS domains 
Pearson correlation 
a 
Spearman’s correlation 
b
 
Erectile function 
 
Orgasmic function Sexual desire Intercourse satisfaction Overall satisfaction 
ED NO-ED p ED NO-ED p ED NO-ED p ED NO-ED p ED NO-ED p 
Incomplete 
emptying 
a 
 
0.11 
 
0.03 
 
0.28
c 
 
0.09 
 
0.03 
 
0.23
c 
 
0.04 
 
0.35 
 
0.002
c 
 
-0.03 
 
0.004 
 
0.66
c 
 
0.06 
 
0.25 
 
0.13
c 
Frequency 
a 
0.10 -0.41 0.40
c 
0.09 -0.47 0.33
c 
-0.05 -0.13 0.14
c 
0.07 -0.41 0.52
c 
0.12 -0.34 0.61
c 
Intermittency 
b 
0.13 -0.10 0.33
d 
0.03 -0.34 0.16
d 
0.01 -0.24 0.66
d 
-0.01 -0.19 0.37
d 
0.12 -0.30 0.56
d 
Urgency 
a 
0.38 -0.47 0.13
c 
-0.05 -0.50 0.41
c 
-0.20 -0.46 0.004
c 
0.15 -0.35 0.42
c 
-0.06 -0.35 0.15
c 
Weak stream 
a 
0.12 -0.51 0.58
c 
-0.10 -0.35 0.59c -0.08 -0.43 0.035
c 
-0.15 -0.41 0.80
c 
0.02 -0.45 0.79
c 
Straining 
b 
-0.05 -0.20 0.65
d 
-0.11 -0.35 0.37
d 
-0.12 -0.17 0.39
d 
-0.04 -0.22 0.74
d 
0.06 -0.39 0.94
d 
Nocturia 
a 
-0.001 -0.49 0.41
c 
-0.19 -0.37 0.91
c 
-0.25 -0.58
 
0.90
c 
-0.08 -0.59 0.41
c 
-0.16 -0.41
 
0.25
c 
QoL 
a 
-0.13 -0.31 0.71
c 
-0.15 -0.34 0.21
c 
-0.25 0.01 0.11
c 
-0.11 -0.49 0.93
c 
0.05 -0.43 0.88
c 
IPSS total score 
a 
0.01 -0.52 0.47
c 
-0.04 -0.44 0.89
c 
-0.12 -0.35 0.91
c 
-0.03 0.15 0.38
c 
0.01 -0.36 0.24
c 
a 
Pearson correlation coefficient ( parametric correlation test). 
b 
Spearman's rho correlation coefficient (nonparametric correlation test). 
c 
Independent two samples  t-test was used (parametric test for normality distributed samples). 
d 
Mann-Whitney U test was used (nonparametric test for not normality distributed samples). 
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3.1.7.4 Correlation between age and IIEF/IPSS domains  
The correlation between age and IIEF and IPSS domains was measured 
through Pearson and Spearman’s correlation coefficient.  
3.1.7.4.1 Correlation between age and IIEF domains   
No significant correlation was found between age and most IIEF domains 
except orgasmic function domain when all patients were included in the analysis 
(Table ‎3-18). Within the ED group, significant correlations were found between 
age and erectile function, orgasmic function and sexual desire (Table ‎3-19). 
Table  3-18: Correlation between age and IIEF domains 
(N=60). 
IIEF domain Pearson correlation p 
Erectile function -0.25 0.05
 
Orgasmic function -0.31 0.017
 
Sexual desire -0.25 0.05
 
Intercourse satisfaction -0.22 0.09 
Overall satisfaction 0.03 0.8 
 
Table  3-19: Correlation between age and IIEF domains 
within the ED group (N=48). 
IIEF domain Pearson correlation p 
Erectile function -0.31 0.03
 
Orgasmic function -0.33 0.02
 
Sexual desire -0.29 0.047
 
Intercourse satisfaction -0.21 0.16 
Overall satisfaction 0.04 0.98 
 
3.1.7.4.2 Correlation between age and IPSS scores 
The data indicated no significant correlation between any of the IPSS domains 
and age (Table ‎3-20).  There was no significant correlation between age and 
any of the IPSS domains within the ED or NO-ED groups (Table ‎3-21).  
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Table  3-20: Correlation between age and IPSS domains 
(N=60)  
IPSS domain Pearson correlation 
a
 
Spearman’s correlation 
b 
p 
Incomplete emptying 
a 
-0.10 0.4 
Frequency 
a 
-0.02 0.9 
Intermittency 
b 
-0.12 0.4 
Urgency 
a 
0.004 0.9 
Weak stream 
a 
0.10 0.5 
Straining 
b 
-0.09 0.5 
Nocturia 
a 
0.18 0.2 
QoL
 a 
0.12 0.3 
IPSS total score 
a 
-0.02 0.87 
a 
Pearson correlation coefficient.  
b 
Spearman's rho correlation coefficient. 
 
Table  3-21: Correlation between age and IPSS domains in 
the ED and NO-ED groups. 
 
IPSS domains aginst age 
Spearman’s correlation 
a 
Pearson correlation
 b
 
 
p
 
ED (n=48) NO-ED (n=12) 
Incomplete emptying 
a 
-0.19
a 
0.33
a 
0.8
c 
Frequency 
a 
-0.12
a 
0.60
a 
0.7
c 
Intermittency
 b 
0.72
b 
-0.002
b 
0.4
d 
Urgency 
a 
0.02
a 
0.01
a 
0.9
c 
Weak stream 
a 
0.06
a 
-0.31
a 
0.5
c 
Straining 
b 
0.65
b 
-0.13
b 
0.2
d 
Nocturia 
a 
0.15
a 
0.32
a 
0.7
c 
Q o L 
a 
0.10
a 
0.22
a 
0.7
c 
IPSS total 
a 
-0.04
a 
0.30
a 
0.9
c 
a 
Spearman’s rho correlation was used as non-parametric test.   
b 
Pearson correlation was used as parametric test.  
c 
Mann-Whitney U test was used.  
d 
Independent two samples t-test was used. 
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3.1.7.5 Correlations among clinical biomarkers, ED, LUTS 
and obesity    
3.1.7.5.1 Biochemistry test correlations  
Spearman’s rho correlation coefficient was used to measure the relationship 
between most biochemistry blood tests and IIEF and IPSS domains, while 
Pearson correlation coefficient was used for others such as prolactin, bilirubin 
total, sodium, estimated GFR and HDL. In this section only significant (p<0.05) 
correlations will be reported.  
Overall a significant positive correlation was found between testosterone and 
erectile function (rho(58)=0.36, p<0.001), orgasmic function (rho(58)=0.42, 
p<0.001), sexual desire (rho(58)=0.26, p<0.04) and intercourse satisfaction 
(rho(58)=0.33, p<0.01).  
Further significant correlations were found between free testosterone and free 
thyroxine (free T4) (rho(58)=0.34, p=0.008), other medical conditions; 
hypertension (rho(58)=-0.27, p=0.036), psoriatic arthritis (rho(58)=0.86, 
p=0.043),  and being overweight (BMI>25) (rho(58)=0.28, p=0.03).  Also, 
significant negative correlations were observed between bioavailable 
testosterone and depression (rho(58)=-0.28, p=0.03)  and between bioavailable 
testosterone and hypertension (rho(58)=-0.26, p=0.047). 
Significant positive correlations were found between free thyroxine (free T4) and 
IPSS –quality of life (QoL) (rho (58)=0.31, p<0.02) and between luteinizing 
hormone (LH) and IIEF- sexual desire, (rho(58)=0.29, p<0.02)  
Significant positive correlations were also found between potassium level and 
two domains of IPSS, intermittency and urgency (rho(58)=-0.31, p<0.010 and 
rho(58)=-0.37, p<0.0010, respectively).  
The ESR level showed a negative significant correlation with erectile function, 
(rho(58)=-0.26, p=0.04), orgasmic function (rho(58)=-0.29, p<0.03) and 
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intercourse satisfaction (rho(58)=-0.28, p<0.03) and a positive significant 
correlation with IPSS- weak stream (rho(58)=0.27, p<0.03).   
A positive Pearson correlation was observed between total bilirubin level and 
IIEF-orgasmic function (r(58)=0.27, p<0.03).  
Moreover, negative Pearson correlations were found between estimated GFR 
and IPSS-urgency and IPSS- weak stream (r(58)=-29, p<0.02) and (r(58)=-0.35, 
p<0.01, respectively). For the complete results please see Appendix C. 
3.1.7.5.2 Haematology test correlations  
A Spearman’s rho correlation test was performed to measure the relationship 
between haematology tests and the IIEF and IPSS scores of the patients. 
MCV was found to be negatively correlated with three IPSS domains - 
incomplete emptying, intermittency and straining (rho(58)=-0.33, p=0.01; 
rho(58)=-0.32, p=0.01; rho(58)=-0.38, p<0.001, respectively). 
MCH was negatively correlated with two IPSS domains - incomplete emptying 
and straining (rho(58)=-0.27, p=0.04 and rho(58)=-0.29, p=0.02, respectively). 
MCHC was found to be positively correlated to sexual desire and IPSS- 
incomplete emptying (rho(58)=0.30, p=0.02 and rho(58)=0.29, p=0.03 
respectively) while RDW was also positively correlated with IPSS-weak stream 
(rho(58)=0.38, p=<0.001). 
Moreover, neutrophil count was negatively correlated with sexual desire 
(rho(58)= -0.29, p=0.02) and positively correlated to IPSS-frequency 
(rho(58)=0.27, p=0.04).   
It was also found that eosinophil count was positively correlated with erectile 
function (rho(58)=0.26, p=0.04) and with intercourse satisfaction (rho(58)=0.27, 
p=0.03) while lymphocyte count was positively correlated with sexual desire 
(rho(58)=0.26, p=0.03). All these correlation results can be found in Appendix 
C. 
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3.1.7.5.3 Comparison of IIEF scores between smokers and non-smokers (N=60)  
There was no difference between smokers and non-smokers for any of the IIEF 
domains as shown in Table  3-22, Table  3-23 and Table  3-24. 
Table  3-22: Comparison of IIEF scores between smokers 
and non-smokers (N=60). 
 
Variables 
Non-smokers 
(n=42) 
Smokers(n=18)  
Mean 
Difference 
 
p
a 
Mean (±SD)
 
Mean (±SD)
 
Erectile function  13.1 (±10.5) 14.1 (±9.5)  0.98 0.49
 
Orgasm function  5.9 (±3.6) 6.2  (±3.1) 0.30 0.36
 
Sexual desire  5.2 (±2.4) 5.5 (±2.6) 0.32 0.60
 
Intercourse satisfaction  5.7 (±4.9) 6.4 (±4.3) 0.71 0.59
 
Overall satisfaction  4.5 (±2.6) 7.7 (±2.9) 0.19 0.24
 
a
 Independent two samples  t-test (parametric test for normally distributed samples).  
 
Table  3-23: Comparison of IIEF scores between smokers 
and non-smokers within the ED group (N=48). 
 
Variables 
Non-smoker (n=33) Smoker (n=15) 
Pearson correlation
 
p Pearson correlation
 
p 
Erectile Function  0.26 0.4 -0.002  0.9 
Orgasm Function  -0.27 0.4 0.03 0.8 
Sexual Desire  0.31 0.3 -0.06 0.7 
Intercourse Satisfaction  0.31 0.3 -0.07 0.6 
Overall Satisfaction  0.13 0.6 0.02 0.9 
 
Table  3-24: Comparison of IIEF scores between smokers 
and non-smokers within the NO-ED group (N=12). 
 
Variables 
Non-smokers (n=9)  Smokers (n=3) 
Spearman’s 
correlation
 
p Spearman’s 
correlation
 
p 
Erectile Function  0.8 0.1 -0.03 0.8 
Orgasm Function  -0.46 0.2 0.05 0.7 
Sexual Desire  0.33 0.2 -0.04 0.8 
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Variables 
Non-smokers (n=9)  Smokers (n=3) 
Intercourse Satisfaction  0.29 0.6 -0.10 0.5 
Overall Satisfaction  -0.07 0.8 0.03 0.8 
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3.2 Bariatric surgery audit  
The distribution of data was analysed and skewness test with cut-off values of -
1 and +1 was applied. If the skewness test result was < -1 or > +1, the data was 
considered to be not normally distributed (Table ‎3-25).   
Table  3-25: Skewness test of the bariatric surgery audit 
(N=35). 
Descriptive Statistics 
  Minimum Maximum Median Mean 
Skewness 
Normality 
test 
Age 30 68 48 47.2 0.1 Yes 
Height (m) 1.6 2 1.8 1.8 0.2 Yes 
BMI T1 37.1 74.4 47.1 48.3 1.5 No 
BMI Dos 36.3 71.2 45.5 47.1 1.4 No 
BMI-T2 34.4 70.3 44.2 46.3 1.3 No 
BMI-T3 30.7 63.2 39 41.5 1.2 No 
BMI-T4 29.2 60.3 36.1 39.3 1.2 No 
%EWL Dos -2 17.6 5.3 5.9 0.9 Yes 
%EWL T2 0.4 34.3 6.3 10 1 Yes 
%EWL T3 -2.2 67.1 33.6 31.3 -0.1 Yes 
%EWL T4 -1.1 75.3 40.5 41.2 -0.4 Yes 
HbA1c-T1 32 95 43 47.7 1.9 No 
HbA1c-T2 30 87 40 43 2.3 No 
HbA1c- T3 29 80 39 42.8 1.9 No 
HbA1c-T4 29 79 39 41.3 2 No 
Blood glucose-T1 4.4 19 5.4 6.3 3.1 No 
Blood glucose-T2 4.1 19 5 5.7 4.2 No 
Blood glucose-T3 4.1 16 5 5.5 4.2 No 
Blood glucose-T4 4 48 4.9 6.6 5.4 No 
Erectile function-T1 2 30 24 19.5 -0.5 Yes 
Erectile function-T2 1 30 20 19.3 -0.5 Yes 
Erectile function-T3 3 30 27 23.5 -1.2 No 
Erectile function-T4 3 30 28 24.6 -1.7 No 
Orgasmic function-T1 1 10 9 7.8 -1.2 No 
Orgasmic function-T2 0 10 8 7.4 -1.2 No 
Orgasmic function-T3 1 10 10 8.6 -2.2 No 
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Descriptive Statistics 
  Minimum Maximum Median Mean 
Skewness 
Normality 
test 
Orgasmic function-T4 2 10 10 9 -2.6 No 
Sexual desire-T1 2 10 7 6.8 -0.3 Yes 
Sexual desire-T2 2 10 7 6.7 -0.3 Yes 
Sexual desire-T3 2 10 8 7.9 -1 Yes 
Sexual desire-T4 1 10 10 8.6 -2 No 
Intercourse satisfaction-T1 0 15 9 8.1 -0.4 Yes 
Intercourse satisfaction-T2 0 15 8 8.3 -0.4 Yes 
Intercourse satisfaction-T3 0 15 12 10 -1 Yes 
Intercourse satisfaction-T4 0 15 13 10.8 -1.2 No 
Overall satisfaction-T1 1 10 7 6.3 -0.4 Yes 
Overall satisfaction-T2 1 10 7 6.5 -0.4 Yes 
Overall satisfaction-T3 1 10 9 8 -1.3 No 
Overall satisfaction-T4 3 10 9 8.4 -1.5 No 
Incomplete emptying-T1 0 5 1 1.5 0.8 Yes 
Incomplete emptying-T2 0 5 1 1.3 1.1 No 
Incomplete emptying-T3 0 4 1 0.9 1.1 No 
Incomplete emptying-T4 0 3 0 0.6 1.2 No 
Frequency-T1 0 5 1 1.8 0.6 Yes 
Frequency-T2 0 5 1 1.3 1.1 No 
Frequency-T3 0 5 1 1.3 1.3 No 
Frequency-T4 0 5 0 0.8 1.8 No 
Intermittency-T1 0 5 1 1.4 0.8 Yes 
Intermittency-T2 0 5 1 1.1 1.2 No 
Intermittency-T3 0 5 0 0.7 2.3 No 
Intermittency-T4 0 3 0 0.5 1.7 No 
Urgency-T1 0 5 1 1.4 1 Yes 
Urgency-T2 0 5 1 1 1.7 No 
Urgency-T3 0 4 0 0.7 1.7 No 
Urgency-T4 0 4 0 0.5 2.5 No 
Weak stream-T1 0 5 1 1.2 1.4 No 
Weak stream-T2 0 4 1 0.9 1.7 No 
Weak stream-T3 0 5 0 0.6 2.4 No 
Weak stream-T4 0 4 0 0.3 3.3 No 
Straining-T1 0 2 0 0.5 1.1 No 
Straining-T2 0 2 0 0.5 1 Yes 
Straining-T3 0 1 0 0.3 1.2 No 
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Descriptive Statistics 
  Minimum Maximum Median Mean 
Skewness 
Normality 
test 
Straining-T4 0 4 0 0.3 4.1 No 
Nocturia-T1 0 5 1 1.4 1.2 No 
Nocturia-T2 0 4 1 1.1 0.8 Yes 
Nocturia-T3 0 3 1 0.7 1 Yes 
Nocturia-T4 0 4 0 0.5 2.4 No 
Q o L-T1 0 6 2 2.3 0.2 Yes 
Q o L-T2 0 5 2 2.4 0.3 Yes 
Q o L-T3 0 4 2 1.8 0.5 Yes 
Q o L-T4 0 4 1 1.3 1.2 No 
IPSS total score -T1 0 28 7 9.2 0.8 Yes 
IPSS total score -T2 0 26 7 7.3 1.3 No 
IPSS total score -T3 0 23 3 5.2 1.6 No 
IPSS total score -T4 0 19 2 3.5 1.9 No 
Surgery  type 1 3 2 1.8 0.5 Yes 
T1: one month pre-operation; T2: one month post-operation; T3: three month post-operation; 
T4: six month post-operation. 
 
3.2.1 Analysis of variance  
Repeated measures ANOVA is a statistical method used to analyse the 
differences among multiple measurements taken from the same sample of 
individuals. Valid use of this method relies on the data adhering to certain 
parametric assumptions, including sample size and normality of model 
residuals. If these data assumptions are not met, then Friedman’s test is a 
suitable nonparametric alternative.  
In the current audit, the surgery type represents the intervention being 
assessed, specifically, this audit was used to assess changes in ED-related 
outcome measures at multiple time-points both prior to and following surgery. 
Specifically, measurements were taken at the baseline or one month pre-
operation (T1), and then again at one month (T2), three months (T3), and six 
months (T4) post-operation.  Outcomes were measured over time to examine 
any changes that may have occurred in the patients’ sexual and urological 
health following the intervention.  
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Changes over time in sexual and urological health (using IIEF, IPSS, BMI, 
fasting blood glucose and HbA1c) were assessed independently for both ED 
and NO-ED patients. The results of these analyses are presented in the current 
section. 
3.2.2 The patient cohort profile (bariatric surgery audit)   
Out of 49 eligible patients only 35 completed the study; these patients were 
divided in to three groups according to their sexual function: ED, NO-ED and 
control (sham) as described below. 
The first group consisted of patients with ED (ED group), which, contained 
twenty patients. Within this group, eighteen individuals were considered to be 
true ED patients (IIEF-EF score below 25); the remaining two were not 
considered to be true ED patients as, although EF scores for these two patients 
were below 25, they were not considered true ED because their loss of sexual 
activity stemmed from the lack of a partner, as illustrated in Figure ‎3-4 and 
Figure ‎3-5.  
 
Figure  3-4: Not true ED patient (example1). 
 
Figure  3-5: Not true ED patient (example2).  
Patient 012/1 
Patient 019/1 
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The second group consisted of patients without ED (NO-ED group); patients 
were defined as having NO-ED when their erectile function (EF) score was 
equal to, or greater than 25. Twelve patients fell into this group.  
The third group was the control group (sham), which contained three patients, 
two of whom presented with true ED (sham ED) and one without ED (sham NO-
ED) (Figure ‎3-6). The sham group consisted of patients who were listed for 
surgery, but whose surgery was abandoned during the operation due to the 
discovery of a large cirrhotic liver and a poor response to standard liver 
shrinkage. It was therefore deemed unsafe to proceed with the operation. As a 
result of the abandoned surgery, these patients enrolled in the POLER 
programme (Prolonged Preoperative Weight Loss Programme), and were then 
listed for a second attempt at the surgery. These two sham groups were 
excluded from statistical calculation due to the small sample size. 
 
Figure  3-6: Patient distribution chart 
Out of 49 eligible patients, 35 completed the study and 14 withdrew before surgery. 35 patients 
were divided into three groups according to their sexual activity. The first group consisted of 
patients with ED (ED group, n=20), 2 of these were not considered to be true ED because of the 
lack of a partner. The second group consisted of patients without ED (NO-ED group, n=12). The 
third group is the control group (sham), which contained three patients, 2 of whom presented 
true ED (sham ED) and 1 who did not present ED (sham NO-ED). 
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3.2.3 Age range  
Patients age ranged from 30 to 68 years old with mean age of 47.23 ± 8.1 and 
was categorized by decade Figure  3-7. 
An independent sample t-test found that there was no difference in age 
between the ED group (48.9 ±7.0 years) and the NO-ED group (44.1±6.9 years; 
t (29)=2.1;  p=0.10). 
 
Figure  3-7: Age distribution of patients for bariatric surgery audit. 
Age distribution data derived from 35 patients showed that 45.7% of patients were between 40 
and 49, 31.4% between 50 and 59, 14.3% between 30 and 39 and 8.6% were 60 years old and 
above.   
 
 
3.2.4 Bariatric surgery types  
The three types of bariatric surgery chosen in this audit were gastric sleeve 
(45.7% of surgeries), gastric bypass (31.4% of surgeries) and gastric band 
(22.9% of surgeries). Within the ED group the distribution of surgeries was 
gastric sleeve - 44.4%, gastric bypass - 33.3% and gastric band - 22.2%. Within 
the NO-ED group, the distribution was gastric sleeve - 41.6%, gastric bypass - 
25.0% and gastric band - 33.3%. There was no difference between the ED 
group and NO-ED group for any of the surgery types calculated using one way 
ANOVA (F(29)=0.24, p=0.79) (Figure  3-8).  
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Figure  3-8: Distribution of bariatric surgery type among patients groups.  
Data showed no difference between ED (N=18) and NO-ED (N=12); the other groups (Not true 
ED (n=2), Sham-ED (n=2) and Sham-NO-ED (n=1)) were statistically excluded because of the 
small sample size.  
 
3.2.5 Change in body weight associated with bariatric surgery.   
Interrogation of the data indicated that most of the BMI and %EWL data were 
skewed and were not normally distributed as shown in the skewness test 
(Table ‎3-25) and the histogram check (Appendix C), thus nonparametric tests 
were applied. 
3.2.5.1  BMI and EWL in the ED group 
The results showed that BMI and %EWL improved over time (p<0.01) in the ED 
group after the bariatric surgery which was reflected in a decreasing mean rank 
across the time-points measured (Figure  3-9, Figure  3-10 and Table  3-26).  
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3.2.5.2 BMI and EWL in the NO-ED group 
Patients without ED also showed improvement in BMI and %EWL over time 
reflected in a decrease in mean rank over time as shown in (Figure  3-9, 
Figure  3-10 and Table  3-26).  
Moreover, the BMI and %EWL results were compared between T1 (baseline) 
and the other three periods (T2, T3 and T4). Table ‎3-27 shows the significant 
values (p) to highlight if a significant difference exists. For BMI and %EWL there 
was a significant improvement at T2, T3 and T4 compared to the baseline T1 
(p<0.01).   
  
Figure  3-9: Changes in BMI for the ED and NO-ED groups over time.   
BMI data derived from the ED (blue diamonds; n=18) and NO-ED groups (red squares; n=12) 
were significantly improved across time after bariatric surgery (p<0.001). 
*  Significant improvement was found at one month post-op (T2) compared to T1 and continued 
until six months post-op (T4) for patients in the NO-ED group (p=0.002).  
** 
Significant improvement was detected at one month post op (T2) compared to T1 and 
continued until six months post-op (T4) for patients in the ED group (p<0.001). 
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation. 
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Figure  3-10: Changes in %EWL in the ED and NO-ED groups over time.   
The weight at T1 was taken as baseline for %EWL calculations. %EWL values derived from 
patients in the ED (n=18) and NO-ED groups (n=12) were significantly improved over time 
(p<0.001).  
* Significant improvement was found at one month post-op (T2) compared to T1and continued 
until six months post-op (T4) for patients in the NO-ED group (p=0.003).  
** 
Significant improvement was found at one month post-op (T2) compared to T1 and continued 
until six months post-op (T4) for patients with ED (p=0.005). 
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation. 
   
Table  3-26: BMI and %EWL of the ED and NO-ED groups 
across time points.  
 Mean rank  
 
Variables 
 
T1/DOS 
 
T2 
 
T3 
 
T4 
 
Chi-square (X
2
) 
 
p
a
 
 
BMI (ED group)  3.8 3.3 1.9 1.2 68.7 <0.001 
%EWL (ED group)  1.3 1.8 3.1 3.9 49.1 <0.001 
BMI (NO-ED group) 4.0 3.1 1.8 1.2 45.1 <0.001 
%EWL (NO-ED group) 1.9 3.2 3.8 3.9 32.9 <0.001 
a 
Friedman’s test was used. 
T1: one month pre-operation; DOS: day of surgery; T2: one month post-operation; T3: three 
months post-operation; T4: six months post-operation. 
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Table  3-27: The significance of differences for BMI and 
%EWL between time points in the ED and NO-ED groups.  
 Significance level (p) against T1
a 
 
Variables T2 T3 T4 
BMI (ED group)  <0.001 <0.001 <0.001 
%EWL (ED group)  0.005 <0.001 <0.001 
BMI (NO-ED group) 0.002 0.002 0.002 
%EWL (NO-ED group) 0.003 0.002 0.002 
a 
Wilcoxon signed rank test was used. 
T2: one month post-operation; T3: three months post-operation; T4: six months post-operation; 
all times compared with T1 (one month pre-operation, baseline). 
 
3.2.5.3 BMI and EWL according to surgery type 
BMI and %EWL improved over time with no difference between the types of 
surgery used, as shown in Figure  3-11, Figure  3-12, Table  3-28 and Table  3-29. 
The BMI and %EWL results were compared between T1 (baseline) and the 
other three periods (T2, T3 and T4). Table ‎3-30 shows that BMI was 
significantly different between surgery types at T2 compared to the baseline T1 
(p=0.01). %EWL showed no difference between surgery types at all-time points 
compared to the baseline T1 (p>0.05). The comparison between surgery types 
showed a significant difference between gastric sleeve and gastric band at 
baseline T1 (p=0.016) as well as at T2 (p=0.012) and T3 (p=0.016) against T1 
(Table ‎3-31).  
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Figure  3-11: Changes in BMI comparing different surgery types across 
time points. 
BMI data derived from different types of surgery: gastric sleeve (blue diamonds; n=13), gastric 
bypass (red squares; n=9) and gastric band (green triangle; n=8) were all significantly changed 
over time (p<0.001). 
* Significant difference between types of surgery was found at one month post-op (T2) 
compared to T1 (p=0.01), but not continued until six month post op (T4), (Table  3-30). 
** 
Significant difference between the BMI of patients listed for gastric sleeve and gastric band 
was detected at baseline (T1) and  one month post-op (T2) compared to T1 and continued until 
three months post-op (T3) (p<0.02), (Table  3-31). 
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation. 
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Figure  3-12: Changes in %EWL comparing different surgery types across 
time points. 
%EWL data derived from different types of surgery: gastric sleeve (blue diamonds; n=13), 
gastric bypass (red squares; n=9) and gastric band (green triangle; n=8) were all significantly 
changed across time (p<0.001), (Table  3-29). No significant differences were detected between 
the types of surgery on %EWL (Table  3-30). 
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation. 
 
Table  3-28: Changes in BMI comparing types of surgery 
across time points.  
 Mean rank of BMI  
 
Variables 
 
T1/DOS 
 
T2 
 
T3 
 
T4 
 
Chi-square (X
2
) 
 
p
a
 
 
Gastric sleeve  2.9 2.7 2.3 2.1 51.4 <0.001 
Gastric bypass  2.7 2.5 2.4 2.2 46.3 <0.001 
Gastric band 1.8 1.7 1.6 1.4 45.2 <0.001 
a 
Friedman’s test was used. 
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation. 
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Table  3-29: Changes in %EWL comparing types of surgery 
across time points. 
 Mean rank of %EWL  
 
Variables 
 
T1/DOS 
 
T2 
 
T3 
 
T4 
 
Chi-square (X
2
) 
 
p
a
 
 
Gastric sleeve  1.0 2.2 4.3 5.7 51.4 <0.001 
Gastric bypass  1.3 2.1 2.8 4.3 46.3 <0.001 
Gastric band 2.1 2.7 5.5 6.1 45.2 <0.001 
a 
Friedman’s test was used. 
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation. 
 
Table  3-30: The significance of differences for BMI and 
%EWL between time points in different types of surgery. 
 Significance level (p) against T1
a 
 
Variables T2 T3 T4 
BMI   0.01 0.08 0.22 
%EWL  0.61 0.52 0.26 
a 
Wilcoxon signed rank test was used. 
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation. 
 
Table  3-31: Comparison between types of surgery.  
Variable/ 
surgery type 
Gastric  bypass against 
gastric sleeve 
 
Gastric band against 
gastric sleeve 
Gastric  bypass against 
gastric band 
 
Mean 
rank 
Mann 
Whitney 
U test 
p
a 
Mean 
rank 
Mann 
Whitney 
U test 
p
a 
Mean 
rank 
Mann 
Whitney 
U test 
p
a 
BMI-T1 10.8 52.5 0.08 14.9 25.0 0.016 8.6 33.0 0.36 
BMI-T2 11.0 55.0 0.10 7.4 23.0 0.012 8.3 30.0 0.24 
BMI-T3 11.1 56.0 0.11 7.7 25.5 0.016 8.4 31.0 0.28 
BMI-T4 12.0 66.0 0.28 9.4 39.0 0.12 9.3 38.5 0.64 
%EWL-Dos 13.9 87.0 0.96 15.4 41.0 0.15 12.5 24.0 0.09 
%EWL-T2 15.2 75.0 0.52 14.6 47.0 0.29 10.5 40.0 0.74 
%EWL-T3 16.2 64.0 0.23 13.1 59.0 0.76 8.6 33.0 0.39 
%EWL-T4 15.4 73.0 0.46 12.6 62.0 0.92 8.8 34.0 0.44 
a 
Mann Whitney U test was used. 
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation. 
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3.2.6 Change in erectile function following bariatric surgery over 
time  
All patients were asked to complete and answer the IIEF and IPSS 
questionnaires over four weeks prior to the surgery. The results of these 
questionnaires are presented in Table ‎3-32. In all IIEF domains there was a 
significant difference between the ED and NO-ED groups (p<0.05). Data from 
the IPSS questionnaire have shown statistically significant differences between 
the ED and NO-ED groups in five domains; incomplete emptying, urgency, weak 
stream, QoL and IPSS total score (p<0.05). While four domains; frequency, 
intermittency, straining and nocturia showed no significant difference between 
groups (p>0.05). 
Table  3-32: The difference in IIEF and IPSS scores in the ED 
and NO-ED groups at baseline (T1).  
 
Variables 
ED (n=18) NO-ED (n=12)  
p
a 
Median (IQR)
 
Median (IQR)
 
IIEF- erectile function 13.0 (2.0, 25.0) 29.0 (27.0, 30.0) <0.001 
IIEF- orgasm function 8.0 (1.0, 10.0) 10.0 (6.0, 10.0) 0.03 
IIEF- sexual desire 6.0 (2.0, 8.0) 8.5 (4.0, 10.0) 0.005 
IIEF- intercourse satisfaction 6.0 (0.0, 13.0) 12.5 (6.0, 15.0) 0.001 
IIEF- overall satisfaction 5.5( 2.0, 10.0) 9.0 (4.0, 10.0) 0.002 
IPSS- incomplete emptying 1.5 (0.0, 5.0) 0.0 (0.0, 2.0) 0.004 
IPSS- frequency 2.0 (0.0, 5.0) 0.5 (0.0, 5.0) 0.12 
IPSS- intermittency 1.5 (0.0, 5.0) 0.0 (0.0, 4.0) 0.14 
IPSS- urgency 2.0 (0.0, 5.0) 0.0 (0.0, 3.0) 0.003 
IPSS- weak stream 1.0 (0.0, 2.0) 0.0 (0.0, 2.0) 0.012 
IPSS- straining 0.0 (0.0, 2.0) 0.0 (0.0, 1.0) 0.85 
IPSS- nocturia 1.0 (0.0, 5.0) 1.0 (0.0, 3.0) 0.60 
IPSS- Q o L 3.0 (0.0, 6.0) 2.0 (0.0, 3.0) 0.010 
IPSS total score 12.5 (0.0, 28.0) 4.5 (1.0, 14.0) 0.007 
a 
Mann-Whitney U test was used. 
 
3.2.6.1 ED group: overall improvement 
Data from the IIEF questionnaires were not normally distributed therefore a 
Friedman’s test was used to analyse the data (Table  3-25). Eighteen patients 
were classified as having ED.  Using Friedman’s test, a significant change was 
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observed in all domains from pre- to post-surgery (Figure  3-13, Figure  3-14 and 
Table  3-33).  
The difference between time points was evaluated using Wilcoxon signed rank 
test in order to find out at what time point IIEF scores improved compared to 
baseline (T1). For erectile function domain there was a significant improvement 
at T2 compared to baseline (T1; p<0.05), a significant improvement in orgasmic 
function was observed at T4 (p<0.01), and sexual desire at T3 (p<0.01). For 
intercourse satisfaction the significant change occurred at T2 and overall 
satisfaction was significantly improved at T3 (p<0.01) (Table  3-34). 
 
Figure  3-13: Changes in erectile function and sexual desire domains- IIEF 
for ED group through time.  
IIEF questionnaire data derived from patients with ED (n=18) were significantly improved for all 
domains cross the time (p<0.001).  
* Significant improvement for erectile function (p=0.02) domain was found at T2 compared to T1 
and continued until T4. 
** Sexual desire (p=0.002) reached significance at T3 compared to T1 continued until T4 (p 
≤0.002).  
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation. 
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Figure  3-14: Changes in overall satisfaction, orgasmic function and 
intercourse satisfaction –IIEF domains for ED group through time 
IIEF questionnaire data derived from patients with ED (n=18) were significantly improved for all 
domains cross the time (p<0.001).  
* Significant improvement for intercourse satisfaction (p=004) domain was found at T2 
compared to T1 and continued until T4. 
** Overall satisfaction (p=0.001) reached significance at T3 compared to T1 continued until T4 
(p ≤0.002).  
*** Orgasmic function reached significant level at T4 (p=0.004).  
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation. 
For clarity, the chart was split into two parts (Figure  3-13 and Figure  3-14) and different error 
bars were used (negative error bars for overall satisfaction, positive error bars for orgasmic 
function and intercourse satisfaction). These are two separate graphs; their figure legends 
should be separate.  
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Table  3-33: IIEF scores of patients from the ED group over 
time.  
 
Variables 
Mean rank   
 
T1 
 
T2 
 
T3 
 
T4 
 
Chi-square (X
2
) 
 
p
a
  
Erectile function  1.3 1.9 3.2 3.5 37.8 <0.001 
Orgasmic function  2.3 1.7 2.6 3.5 23.1 <0.001 
Sexual desire 1.6 1.8 2.9 3.6 30.9 <0.001 
Intercourse 
satisfaction 
1.5 2.1 2.9 3.5 32.7 <0.001 
Overall satisfaction 1.6 1.8 3.1 3.5 36.4 <0.001 
a 
Friedman’s test was used. 
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation. 
 
Table  3-34: The significance of differences in IIEF scores 
between time points in the ED group  
 
Variables 
Significance level (p) against T1
a 
 
T2 T3 T4 
Erectile function 0.02
 
<0.001
 
0.001
 
Orgasmic function 0.27 0.07 0.004
 
Sexual desire 0.42 0.002
 
<0.001
 
Intercourse satisfaction 0.004
 
0.001
 
0.001
 
Overall satisfaction 0.15 0.001
 
0.001
 
a 
Wilcoxon signed rank test was used. 
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation. 
 
3.2.6.2 NO-ED group: overall improvement 
The IIEF questionnaires data of the 12 patients in the NO-ED group were not 
normally distributed (Table ‎3-25); therefore Friedman’s test was used to test 
whether the erectile function improved over time. The test results showed that 
there was indeed a significant overall improvement in total IIEF score 
(X2(3,18)=14.1, p=0.003). The mean rank for erectile function domain was 
shown to drop at T2 then it was similar at T3 and T4. No significant effect was 
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found on orgasmic function (X2(3,18)= 3.9, p=0.27) the mean rank was shown 
to be similar across all times (Figure ‎3-15; Figure  3-16; Table ‎3-35).  The sexual 
desire domain significantly improved over time (X2(3,18)=11.28, p=0.01), but 
showed a decrease at T2. Intercourse satisfaction also showed a significant 
improvement over time (X2(3,18)=14.35, p=0.002 but again the mean rank 
dropped at T2 and then increased with T3 and T4. The mean rank for overall 
satisfaction appeared to drop in T2 and then was found to be similar in T3 and 
T4, (X2(3,18)=13.65, p=0.003)  (Table ‎3-36). 
 
Figure ‎3-15: Changes in erectile function and sexual desire- IIEF domains 
for the NO-ED group over time. 
IIEF questionnaire data derived from patients without ED (n=12) were significantly improved in 
all domains except orgasmic function over time (p≤0.01).  
* Significant improvement for sexual desire (p=0.02) domain was found at T4 compared to T1. 
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation. 
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Figure  3-16: Changes in orgasmic function, intercourse satisfaction and 
overall satisfaction- IIEF domains for the NO-ED group over time. 
IIEF questionnaire data derived from patients without ED (n=12) were significantly improved in 
all domains except orgasmic function over time (p≤0.01).  
*
 
Significant improvement for the overall satisfaction (p=0.03) domain was found at T2 
compared to T1 but not continued at T3 and T4. 
** Significant improvement for intercourse satisfaction (p=0.01) domain was found at T4 
compared to T1. 
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation. 
For clarity, the chart was split into two parts (Figure  3-15 and Figure  3-16) and different error 
bars were used (negative error bars for overall satisfaction, positive error bars for orgasmic 
function). 
 
Table  3-35: IIEF scores of the NO-ED group over time. 
 
Variables 
Mean rank    
 
T1 
 
T2 
 
T3 
 
T4 
 
Chi-square (X
2
) 
 
p
a 
Erectile function 2.17 1.67 3.00 3.17 14.08 0.003 
Orgasmic function 2.25 2.25 2.92 2.58 3.94 0.27 
Sexual desire 2.13 1.96 2.71 3.21 11.28 0.01 
Intercourse satisfaction 2.00 1.83 2.79 3.38 14.35 0.002 
Overall satisfaction 2.25 1.71 3.00 3.04 13.65 0.003 
a 
Friedman’s test was used. 
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation. All times compared with T1 (one month pre-operation, baseline). 
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Table  3-36: The significance level of differences between 
time points in IIEF scores in the NO-ED group. 
 
Variables 
Significance level (p) against T1
a
  
T2 T3 T4 
Erectile function 0.15 0.29 0.14 
Orgasmic function 0.73 0.14 0.44 
Sexual desire 0.53 0.16 0.02
 
Intercourse satisfaction 0.38 0.08 0.01
 
Overall satisfaction 0.03
 
0.10 0.06 
a 
Wilcoxon signed rank test was used. 
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation. 
 
3.2.7 Change in urological function following bariatric surgery over 
time 
3.2.7.1 ED group: overall improvement  
IPSS questionnaire data were not normally distributed, therefore Friedman’s 
test was used to analyse the data (Table ‎3-25). Twelve patients were classified 
to have NO-ED. Using Friedman’s test, a significant change was observed in all 
domains from pre- to post- surgery (p <0.005), except in one domain (straining) 
in which no significant effect was found (Figure  3-17; Figure  3-18; Figure  3-19; 
Figure  3-20; Table  3-37). The difference between time points was evaluated 
using Wilcoxon signed rank test in order to find out at what time point IPSS 
scores improved compared to the baseline (T1). There was a significant 
improvement at T2 compared to the baseline (T10 (p<0.05) for frequency, 
intermittency, weak stream, nocturia and quality of life (Qol) domains. The 
significant improvement in incomplete emptying and urgency domains were 
observed in T3 compared to the baseline (T1) (p≤0.01), and for straining no 
significant improvement was observed over time (Table ‎3-38).  
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Figure  3-17: Changes in frequency, intermittency and straining - IPSS 
domains for the ED group over time. 
IPSS questionnaire data derived from patients with ED (n=18) were significantly improved in all 
domains over time (p≤0.004), exception of straining (p=0.10). 
*
 Significant improvements in frequency (p=0.02) and intermittency (p=0.01) domains were 
found at T2 compared to T1 and continued until T4. 
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation.  
For clarity, the chart was split into four parts (Figure  3-17; Figure  3-18; Figure  3-19; Figure  3-20) 
and different error bars were used (positive error bars for frequency, incomplete emptying and 
urgency and negative error bars for straining and weak stream). 
 
 
 
Figure  3-18: Changes in urgency, weak stream and Qol - IPSS domains for 
the ED group over time.  
IPSS questionnaire data derived from patients with ED (n=18) were significantly improved in all 
domains over time (p≤0.004), exception of straining (p=0.10). 
*
 Significant improvements in weak stream (p=0.01) and quality of life (Qol) (p=0.03) were found 
at T2 compared to T1 and continued until T4. 
** 
Significant improvement in urgency (p=0.003) was found at T3 compared to T1 and continued 
until T4. 
0.00
0.50
1.00
1.50
2.00
2.50
T1 T2 T3 T4
A
ve
ra
ge
 o
f 
IP
SS
 s
co
re
s 
Time points-ED group 
Frequency Intermittency Straining
* 
* 
* * 
* 
* 
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
T1 T2 T3 T4
A
ve
ra
ge
 o
f 
IP
SS
 s
co
re
s 
Time points-ED group 
Urgency Weak stream QoL
* 
* 
* 
* 
* * 
** 
** 
143 
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation.  
For clarity, the chart was split into four parts (Figure  3-17; Figure  3-18; Figure  3-19; Figure  3-20) 
and different error bars were used (positive error bars for frequency, incomplete emptying and 
urgency and negative error bars for straining and weak stream). 
 
  
 
Figure  3-19: Changes in nocturia and incomplete emptying - IPSS 
domains for the ED group over time.  
IPSS questionnaire data derived from patients with ED (n=18) were significantly improved in all 
domains over time (p≤0.004), exception of straining (p=0.10). 
*
 Significant improvements in nocturia (p=0.002) was found at T2 compared to T1 and continued 
until T4. 
** 
Significant improvement in incomplete emptying (p=0.01) was found at T3 compared to T1 and 
continued until T4. 
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation.  
For clarity, the chart was split into four parts (Figure  3-17; Figure  3-18; Figure  3-19; Figure  3-20) 
and different error bars were used (positive error bars for frequency, incomplete emptying and 
urgency and negative error bars for straining and weak stream). 
 
 
Figure  3-20: Changes in IPSS total score for the ED group over time.  
IPSS questionnaire data derived from patients with ED (n=18) were significantly improved in all 
domains over time (p≤0.004), exception of straining (p=0.10). 
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*
 Significant improvements in IPSS total score domain (p=0.002) was found at T2 compared to 
T1 and continued until T4. 
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation.  
 
Table  3-37: IPSS scores of the ED group over time. 
 
Variables 
 
T1 
Mean rank 
T2 
 
T3 
 
T4 
 
Chi-square (X
2
) 
 
p
a 
Incomplete emptying 3.11 2.86 2.22 1.81 20.46 <0.001 
Frequency 3.19 2.69 2.39 1.75 17.55 0.001 
Intermittency  3.17 2.58 2.14 2.11 13.57 0.004 
Urgency 3.25 2.94 2.08 1.72 22.48 <0.001 
Weak stream  3.47 2.86 2.06 1.61 32.87 <0.001 
Straining 2.72 2.78 2.28 2.22 6.22 0.10 
Nocturia 3.42 2.50 2.14 1.94 23.68 <0.001 
Q o L  3.28 2.31 2.31 1.44 31.29 <0.001 
IPSS total score 3.58 2.69 2.06 1.67 24.19 <0.001 
a 
Friedman’s test was used. 
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation.  
 
Table  3-38: The significance of differences in IPSS scores 
between time points in the ED group. 
Variables Significance level (p) against T1
a
  
 
T2 T3 T4 
Incomplete emptying 0.08 0.01 0.004 
Frequency 0.02 0.06 0.02 
Intermittency  0.01 0.01 0.01 
Urgency 0.07 0.003 0.002 
Weak stream  0.01 0.002 <0.001 
Straining 1.00 0.11 0.29 
Nocturia 0.002 0.002 0.002 
Q o L 0.03 0.007 0.001 
IPSS total score 0.002 0.02 0.001 
a 
Wilcoxon signed rank test was used. 
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation; all times compared with T1 (one month pre-operation, baseline). 
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3.2.7.2 NO-ED group: overall improvement 
IPSS questionnaire data were not normally distributed therefore a Friedman’s 
test was used to analyse the data (Table ‎3-25). Friedman’s test presented a 
significant effect over time in two domains (nocturia and quality of life due to 
urological function) and the total IPSS score (Table ‎3-39). Thus, the mean rank 
showed decreased symptoms over time (p <0.05). However, no significant 
effects were found on incomplete emptying, frequency, intermittency, urgency, 
weak stream or straining (p>0.05) (Figure  3-21; Figure  3-22; Figure  3-23; 
Figure  3-24). No significant differences were observed between IPSS domains 
compared to the baseline (T1) (p>0.05). However, QoL was significantly 
improved at T2 compared to baseline (T1) but did not continue until six months 
post-operation. The IPSS total score and nocturia were significantly different at 
T4 compared to the baseline (T1) (p<0.05; Table ‎3-40).  
 
Figure  3-21: Changes in intermittency, nocturia and Qol -IPSS domains for 
the NO-ED group over time.  
IPSS questionnaire data derived from patients without ED (NO-ED; n=12) were significantly 
improved in nocturia (p=0.01) and quality of life (Qol) (p=0.03) domains over the time. 
* Significant improvement for Qol (p=0.047) domain was found at T2 compared to T1 but not 
continued until T4. 
** Significant improvement for Nocturia (p=0.03) domain was found at T4 compared to T1. 
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation.  
For clarity, the chart was split into four parts (Figure  3-21; Figure  3-22; Figure  3-23; 
Figure  3-24).  
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Figure  3-22: Changes in straining, incomplete emptying and urgency -
IPSS domains for the NO-ED group over time.  
IPSS questionnaire data derived from patients without ED (NO-ED; n=12) were no significant 
detected in straining, incomplete emptying and urgency domains over the time (p>0.05). 
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation.  
For clarity, the chart was split into four parts (Figure  3-21; Figure  3-22; Figure  3-23; 
Figure  3-24).  
 
 
 
Figure  3-23: Changes in frequency and weak stream -IPSS domains for the 
NO-ED group over time.  
IPSS questionnaire data derived from patients without ED (NO-ED; n=12) were no significant 
detected in frequency and weak stream domains over the time (p>0.05). 
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation.  
For clarity, the chart was split into four parts (Figure  3-21; Figure  3-22; Figure  3-23; 
Figure  3-24).  
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Figure  3-24: Changes in IPSS total score domain for the NO-ED group 
over time.  
IPSS questionnaire data derived from patients without ED (NO-ED; n=12) was significantly 
improved in IPSS total score (p=0.01) domain over the time. 
* Significant improvement for IPSS total score (p=0.049) domain was found at T4 compared to 
T1.  
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation.  
For clarity, the chart was split into four parts (Figure  3-21; Figure  3-22; Figure  3-23; 
Figure  3-24). 
 
 
Table  3-39: IPSS scores for the NO-ED group over the time. 
 
Variables 
 
T1 
Mean rank 
T2 
 
T3 
 
T4 
 
Chi-square (X
2
) 
 
p
a 
Incomplete emptying 2.01 2.00 1.98 1.82 2.28 0.52 
Frequency 2.02 2.00 1.85 1.74 6.03 0.11 
Intermittency  3.00 2.50 2.14 2.10 7.76 0.05 
Urgency 2.25 2.10 2.08 1.98 1.64 0.65 
Weak stream  2.45 2.22 2.06 1.99 2.23 0.52 
Straining 2.70 2.55 2.27 2.20 2.78 0.43 
Nocturia 2.30 2.02 2.00 1.93 11.41 0.01 
Q o L  3.20 2.10 2.01 1.94 8.79 0.03 
IPSS total score 2.51 2.32 2.03 1.67 11.93 0.01 
a 
Friedman’s test was used. 
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Table  3-40: Wilcoxon signed rank test comparing IPSS 
scores in the NO-ED group over multiple time-points. 
 
Variables 
Significance level against T1
a 
T2 T3 T4 
Incomplete emptying 
0.26 1.00 0.71 
Frequency 
0.48 0.71 0.14 
Intermittency  
0.76 0.06 0,10 
Urgency 
0.41 1.00 1.00 
Weak stream  
0.48 0.56 0.16 
Straining 
0.16 1.00 0.41 
Nocturia 
0.71 0.05 0.03 
Q o L 
0.047 0.74 0.59 
IPSS total score 0.81 0.58 0.049 
a 
Wilcoxon signed rank test was used. 
T2; one month post-operation, T3; three months post operation, T4; six months post-operation, 
all times compared with T1 (one month pre operation, baseline). 
3.2.8 Change in metabolic biomarkers following bariatric surgery 
over time 
Fasting blood glucose (FBG) and HbA1c values were largely not normally 
distributed (Table ‎3-25). The median and IQR of FBG for ED and NO-ED 
groups were 5.3 (4.6, 8.3) mmol/L and 5.4 (4.4, 14.0) mmol/L) respectively at 
T1. The median and IQR values for HbA1c were 43.5 (37.0, 58.0) mmol/mol 
and 44.0 (32.0, 95.0) mmol/mol, respectively at T1. There was no significant 
difference between the ED and NO-ED groups at the baseline (T1; Table ‎3-41). 
Table  3-41: The difference in fasting blood glucose and 
HbA1c values in the ED and NO-ED groups at baseline (T1). 
 
Variables 
ED (n=18) NO-ED (n=12)  
p
a 
Median (IQR)
 
Median (IQR)
 
Fasting blood glucose 5.3 (4.6, 8.3) 5.4 (4.4, 14.9) 0.71 
HbA1c 43.5 (37.0, 58.0) 44.0 (32.0, 95.0) 0.81 
a 
Mann-Whitney U test was used. 
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Moreover, 38.9% of patients with ED had FBG levels above the normal range 
(above 5.8 mmol/L) and 61.1% of patients had HbA1c levels above the normal 
range (42 mmol/mol), while 41.7% of patients without ED (NO-ED) had FBG 
levels and 50.0% of patients had HbA1c levels above the normal range.   
 
Figure  3-25: Percentage of patients’ fasting blood glucose above or within 
the normal range.  
Data showed that 38.9% of patients with ED (n=18) had fasting blood glucose (FBG) levels 
above the normal range (above 5.8 mmol/L) and 61.1% of patients presented value within the 
normal range (3.9-5.8 mmol/L). Also 41.7% of patients without ED (NO-ED; n=12) had levels 
above the normal range while 58.3% fell within normal range. There was no significant 
difference between ED and NO-ED groups in FBG (p>0.05) (Table  3-41). 
 
Using Friedman’s test showed an improvement over time in FBG and HbA1c in 
the ED and NO-ED groups (p<0.01; Figure  3-26, Figure  3-27 and Table  3-42.  
The difference between the time points was evaluated using Wilcoxon signed 
rank test compared to the baseline (T1). The results of FBG and HbA1c in the 
ED group were X2(3,18)= 32.6 (p<0.001) and X2(3,18)=44.48, (p=<0.001) 
respectively. This showed an improvement at T2 compared to T1 and continued 
until T4.  
The results of the NO-ED group showed an improvement in HbA1c at T2 
compared to T1 and continued to T4 (p <0.005). However, FBG results showed 
improvement at only T4 compared to T1 (p=0.047) (Table ‎3-43).  
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Figure ‎3-26: Changes in fasting blood glucose level in the ED and NO-ED 
groups over time.  
Fasting blood glucose data derived from patients from the ED (n=18) and NO-ED (n=12) groups 
were significantly improved over the time (p≤0.001 and p=0.01, respectively).   
*Significant improvement for fasting blood glucose level in the ED group (p<0.001) was found at 
T2 compared to T1 and continued until T4. 
** Significant improvement was found at T4 compared to T1 for NO-ED group (p=0.047). 
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation. 
For clarity, different error bars were used (negative error bars for the ED group, positive error 
bars for the NO-ED group).  
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Figure  3-27: Changes in HbA1c level in the ED and NO-ED groups over 
time. 
HbA1c data derived from patients in the ED (n=18) and NO-ED (n=12) groupswere significantly 
improved over time (p≤0.001 and p=0.001, respectively). 
* Significant improvement for HbA1c levels in the ED (p<0.001) and NO-ED groups (p=0.004) 
were detected at T2 and continued until T4.  
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation. 
 
Table  3-42: Fasting blood glucose level and HbA1c in the 
ED and NO-ED groups over time.  
 
Variables 
Mean rank      
T1 T2 T3 T4 Chi-square (X
2
) p
a 
Fasting blood glucose 
level  (ED group)  
3.94 2.08 2.14 1.83 32.6 <0.001 
HbA1c (ED group)  4.00 2.36 2.39 1.25 44.48 <0.001 
Fasting blood glucose 
level (NO-ED group) 
3.17 2.83 2.29 1.71 11.14 0.01 
HbA1c (NO-ED group) 3.38 2.50 2.50 1.63 12.60 0.001 
a 
Friedman’s test was used. 
T1: one month pre-operation; T2: one month post-operation; T3: three months post-operation; 
T4: six months post-operation. 
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Table  3-43: The significance of differences between time 
points for fasting blood glucose level and HbA1c in the ED 
and NO-ED groups. 
 
Variables 
significance level against T1
a 
T2 T3 T4 
Fasting blood glucose level  (ED group)  <0.001 <0.001 0.003 
HbA1c (ED group)  <0.001 <0.001 <0.001 
Fasting blood glucose level (NO-ED 
group) 
0.051 0.056 0.047 
HbA1c (NO-ED group) 0.004 0.001 0.001 
a 
Wilcoxon signed rank test was used. 
T2; one month post-operation, T3; three months post-operation, T4; six months post-operation, 
all times compared with T1 (one month pre-operation; baseline). 
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4 DISCUSSION  
This chapter interprets the audit findings in light of the existing literature. In 
sections ‎4.1 and ‎4.2, the results associated with each of the two research 
questions are contextualised and discussed, as are any broader implications.  
The end of each section concludes with the limitations of the present audit 
which should be borne in mind.  
The aim of this project, as described in section ‎1.5, was to evaluate the baseline 
characteristics of patients with an erectile dysfunction, and to determine the 
impact of bariatric surgery on erectile and urological function in morbidly obese 
men. This information would then be used to investigate on a large scale, the 
hypothesis that obesity is a hidden factor responsible for urogenital dysfunction. 
The information gained would also be validated for use in the design of a multi-
centre observational longitudinal cohort study.   
The objectives of the audit were as follows:  
1. To conduct an audit to investigate the baseline characteristics of men 
over 18 years of age who were attending the urological clinic, using 
IIEF and IPSS questionnaires. 
2. To perform a study to explore the effect of BMI on the urogenital 
function of men over 18 years of age attending the urological clinic, 
using IIEF and IPSS questionnaires. 
3. To collate and analyse other baseline characteristics such as age, 
smoking and medical history. 
4. To conduct a second audit to investigate the effect of bariatric surgery 
on the urogenital function and BMI of morbidly obese men over 30 
years of age with a body mass index of 35 or over. 
5. To utilise and obtain urogenital function and biomarker data from the 
second audit on morbidly obese men undergoing elective bariatric 
surgery. 
6. To analyse and present the data and recommend further work based 
on the results. 
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The following two sections discuss the results of the work carried out to achieve 
each of these six objectives. 
4.1 Baseline characteristics audit   
In accordance with NICE (National Institute for Health and Care Excellence) 
and the Healthcare Commission, and in order to complete the objectives of this 
audit, participants were selected according to specific criteria by the surgeons 
working for the NHS trust.  
The methods used in selecting and recruiting these participants, as described in 
section ‎2.1.3, were based on prior experience of the clinical team and the 
literature on clinical audits (Kupelian et al. 2006, Demir et al. 2009, Tsao et al. 
2008, Copeland 2005).  
The audit was conducted using a multidimensional scale for the assessment of 
erectile dysfunction (the International Index of Erectile Function (IIEF)) (Rosen 
et al. 1997) as described in section ‎1.2.5 and the International Prostate 
Symptom Score (IPSS) (Plante et al. 1996), as described in section ‎1.3.6.  
Additional information such as medical history and blood tests, were also 
acquired from patients’ records using the UCLH database and following the 
guidelines of UCL data protection (UCL Library Services 2015).  
Furthermore, the audit was conducted over a nine month period during 2014, 
involving sixty patients with any urological condition. According to the responses 
from answering the IIEF erectile function domain, the patients were divided into 
two groups: ED and NO-ED. A cut-off score of 25 or less was used for the 
diagnosis of ED (Cappelleri et al. 1999).  
Overall, it can be stated that the recruiting method that was used was 
successful in recruiting forty eight patients with erectile dysfunction (ED) and 
twelve patients with NO-ED for the study, during nine months covering one 
urology clinic per week. This was achieved mainly by following good local 
clinical audit criteria from the NHS trust (Cappelleri et al. 1999) which is 
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endorsed by NICE and the healthcare commission in the United Kingdom (NICE 
2015).  
4.1.1 Correlations in the baseline characteristics audit 
The aim of the correlations presented in this section was to observe sexual 
function among participants with obesity in particular. Sexual dysfunction is 
highly predominant in the general population and is associated with a lower 
quality of life (Sarwer et al. 2012). Obesity is clearly linked with sexual 
dysfunction in men (Feldman et al. 2000, Esposito et al. 2005).  
4.1.1.1 Age  
The average age of the patients was 46.2 ±13.7 years old, which is 
representative of patients at urology clinics and in line with the literature 
(Feldman et al. 1994, Johannes et al. 2000). The average age of ED patients 
was 47.1 ±13.1 years. Although age is a primary risk factor for erectile 
dysfunction and ED is usually associated with older age (Kirby et al. 2014), 
several studies have reported ED in the younger male population for those ≤60 
years old (Feldman et al. 1994, Cappelleri et al. 2005). 
The literature shows a clear relationship between age and ED (Prins et al. 
2002). Although there was no apparent significant difference in age between the 
ED and NO-ED groups, there were significant correlations in the audit 
population between age and IIEF domains; erectile function, orgasmic function 
and sexual desire.  
The most significant finding from this study is that ED occurs in 80% of the audit 
population, and in men younger than 60 years, although there is no definite 
explanation of why this phenomenon occurs in younger men (Prins et al. 2002, 
Camacho et al. 2013). Some studies suggest that erectile dysfunction has a 
biological reason behind it (Thrower et al. 2013, Camacho et al. 2013). It is still 
a matter of argument whether age-related changes in androgen levels play a 
role in the decline of sexual function in ageing men, despite sexual activity 
declining even in old men who are healthy and have partners (Sariyildiz et al. 
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2013).  Moreover, several studies suggest that testosterone levels in men 
decline significantly with increasing age as part of the natural biological process 
(Prins et al. 2002, Camacho et al. 2013). The testosterone results from the audit 
further support the possible involvement of androgens in development of ED in 
men younger than 60 years old which will be further discussed. 
4.1.1.2 Height 
There was a statistically significant difference in the height between ED and 
NO-ED groups. The audit suggests that taller men have a higher incidence of 
ED, although height is not considered to be a classical risk factor for ED. 
However, Cappelleri, et al (1999) evaluated the erectile function domain of IIEF 
as a diagnostic tool to differentiate between men with and without ED. The 
study showed the baseline characteristics including physical measures such as 
height, weight and age of 1035 men who reported ED and 116 controls. The 
authors showed that the ED group was taller than the control group, although 
this finding was not supported by any explanations in this study (Cappelleri et 
al. 1999).  
4.1.1.3 Medical conditions  
The presence of more than two medical conditions may create a higher risk of 
having ED, and this is compatible with a previous study by (Johannes et al. 
2000). Moreover, an Italian study conducted by urologists, surveyed over 2,000 
men aged 18 years or over. This study showed that multiple medical conditions 
such as diabetes combined with heart disease increased the risk of developing 
ED eight-fold (Parazzini et al. 2000). Also, the results from a Massachusetts 
male ageing study concluded that ED was directly and strongly correlated with 
the presence of several medical conditions such as diabetes, heart disease, 
hypertension and depression (Feldman et al. 1994).   
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4.1.1.4 Clinical biomarkers  
4.1.1.4.1 Testosterone   
The objective of the work presented in section ‎3.1.7.5 was to observe the 
impact of clinical biomarkers that influence sexual and urological functions. 
From the literature, it had been shown that testosterone is the hormone most 
widely associated with erectile function, but its role in the treatment of erectile 
dysfunction has been debated (Shamloul et al. 2013, Corona et al. 2010, 
Feldman et al. 2002). The average testosterone serum levels in ED and NO-ED 
groups were 16.2 nmol/L and 18.1 nmol/L respectively; the difference was 
significant. The impact of testosterone was revealed in the audit (see Table ‎3-7) 
to be the main difference between ED and NO-ED groups, and was confirmed 
by the significant correlation with IIEF domains: erectile function, orgasm 
function, sexual desire and intercourse satisfaction.  
The role of testosterone in men’s sexual function and its role in treatment of ED 
has been subject of debate (Feldman et al. 1994, Feldman et al. 2002, Rhoden 
et al. 2002, Mikhail 2006).One of the debated topics in this field is whether 
elderly men should be given  testosterone as a prophylactic . Shores et al 
(2012), concluded from their observational study of mortality in testosterone-
treated compared with untreated men aged older than 40 years that 
testosterone treatment was associated with decreased mortality compared with 
no testosterone treatment between January 2001 and December 2002 (Shores 
et al. 2012). Moreover, Isidori et al (2005) conducted a systematic review and 
meta-analysis of available studies on the useful effect of testosterone treatment 
for erectile function. The results from the meta-analysis indicate that 
testosterone treatment might be useful for improving ED in patients with low or 
normal testosterone levels. However, the evidence for the long-term safety data 
is not available (Isidori et al. 2005). 
Another argument suggests that testosterone should not be given to men 
unless there are important needs, for example according to a letter published in 
the British Medical Journal (BMJ) (2012) regarding reflections on testosterone. 
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Over the last two decades, the BMJ has pointed out that physicians should be 
wary of the harm that the androgens can do to patients by unnecessarily 
worrying them of side effects for which there is no evidence or raising spurious 
parallels to other unrelated disease areas (Gan et al. 2012). Moreover, the 
British Society for Sexual Medicine (BSSM) has issued guidelines on the 
management of sexual problems in men. The role of testosterone in maintaining 
wellbeing in men is well established, and men with confirmed ED and 
documented testosterone deficiency are candidates for testosterone therapy. 
The guidelines also state that failure to benefit within a reasonable time interval 
(up to six months) should result in discontinuation of treatment due to the risk of 
side effects (Hackett et al. 2008).  
The Food and Drug Administration (FDA) has approved testosterone products 
as replacement therapy in men with hypogonadism (where the body doesn't 
produce enough testosterone) (Nguyen et al. 2015). Recently, testosterone use 
has increased noticeably among middle-aged and elderly men for age-related 
hypogonadism (Nguyen et al. 2015). The FDA refer to this condition as “late-
onset hypogonadism,” which  is identified in men who have no reason other 
than older age and testosterone concentrations below the normal range 
compared with healthy young men. An analysis by the FDA showed that more 
than 80% of prescription testosterone users are men between 40 and 74 years 
of age and 28% of men who received a new testosterone prescription had no 
evidence of a prior testosterone measurement (Nguyen et al. 2015). The FDA 
concluded in September 2014 that an indication for testosterone therapy only in 
men with classic hypogonadism and testosterone treatment had not been 
established for age-related hypogonadism. Also, the FDA recommends adding 
a statement to drug labels about the need to confirm low testosterone 
concentrations before initiating treatment.  The FDA also recommends that a 
controlled clinical trial should be considered rather than observational studies 
(Nguyen et al. 2015).  
In this study, free and bioavailable testosterone results have not shown any 
significance when compared with IPSS scores among patients with ED. 
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However, free and bioavailable testosterone has demonstrated a significant 
correlation with hypertension and low testosterone correlated with high blood 
pressure. Ziemens et al., (2013) suggest an association between total 
testosterone and hypertension in women; also they suggest that high total 
testosterone levels are a risk factor for increased blood pressure, as well as 
prevalent hypertension, in women (Ziemens et al. 2013). 
Likewise, free testosterone has demonstrated a significant correlation with 
psoriatic arthritis (Saber et al. 2010). However, this finding seems to be a 
chance occurrence due to the power of the sample size effect, as only two 
participants reported psoriatic arthritis from the sixty participants in total. 
Moreover, there are no links between free testosterone and psoriatic arthritis in 
the literature.  
The small sample size may also have an effect on bioavailable testosterone and 
depression, where the results show a positive significant correlation. Other 
studies suggest a significant link between bioavailable testosterone and 
depression (Barrett-Connor et al. 1999, McIntyre et al. 2006).  
Moreover, the free testosterone results in this audit suggest a significant 
correlation with being overweight (BMI>25 kg/m2) with higher BMI leading to 
lower testosterone. Epidemiological studies support the relationship between 
serum testosterone and obesity (MacDonald et al. 2010, Brand et al. 2014). 
Adipose tissue affects testosterone levels by increasing the aromatisation of 
testosterone to oestradiol, for the reason that the aromatase enzyme is 
concentrated in fat cells (adipocytes) and decreases testosterone levels (Cohen 
1999, Cohen 2001). The oestradiol produced by aromatisation reduces 
testosterone production in the Leydig cells in the testicles (they produce 
testosterone in the presence of luteinizing hormone (LH)) (Cohen 2001, 
Dandona et al. 2010). Moreover, increasing adipose tissue leads to increased 
insulin resistance, which affects the Leydig cells, in addition to inhibiting the 
release of luteinizing hormone (LH) through the release of adipokines 
(inflammatory cytokines) such as TNF-a (Cohen 2001, Dandona et al. 2010, 
Pitteloud et al. 2013). 
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Moreover, central obesity predicts low testosterone levels. A high BMI is 
associated with low testosterone and SHBG levels. This is due to obesity 
suppressing SHBG. Changes in SHBG confound the relationship between 
testosterone and obesity (MacDonald et al. 2010, Brand et al. 2014, Laaksonen 
et al. 2005).  
Furthermore, there was no correlation detected in this audit between 
testosterone and age. This might be due to the fact that 80% of the audit 
population with ED was younger than 60 years. As discussed in section ‎4.1.1.1 
numerous studies suggest that testosterone levels in men decline significantly 
with the increase of age as part of the natural biological process (Prins et al. 
2002, Camacho et al. 2013).  
4.1.1.4.2 Eosinophil  
A significant correlation between blood eosinophil levels and two IIEF domains 
(erectile function and intercourse satisfaction) was found, although nothing was 
found during the literature review to support this finding. The functions of the 
eosinophil are varied, and it is involved in many inflammatory processes 
including bacterial and viral infections (Humbles et al. 2004). The responses of 
eosinophils are also important for their involvement in the acute pathogenesis of 
allergic diseases (Weller et al. 1996). Allergic inflammation is an important 
pathophysiological feature of several medical conditions such as allergic rhinitis 
and allergic asthma (Weller et al. 1996). Allergic reactions may usually be 
divided into two phases; the early phase which occurs within a short time 
(minutes) after allergen exposure; the late phase which occurs within hours (8-
12 hours) (Rothenberg et al. 2006). Characteristically, the sensitive cells 
detected in allergic reactions contain a high proportion of eosinophil 
(Rothenberg et al. 2006). It should be also noted that the eosinophil counts 
were within normal range in all patients.  
4.1.1.4.3 Fasting blood glucose and HbA1c  
The results show no abnormalities in the average of FBG and HbA1c, which are 
the risk factors in ED and urological function (Fedele 2005, Parsons 2010, 
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Demir et al. 2009, Kaya et al. 2015). However, these findings are compatible 
with Demir et al., (2009) study, while they disagree with previous literature 
(Hatzimouratidis et al. 2009, Bansal et al. 2005, Corona et al. 2009) . This 
disagreement might have arisen from two important factors; the small size of 
the audit population was a major influence on the statistical calculations;  only 
eight patients out of sixty reported abnormalities in their FBG and HbA1c; the 
other reason is the nature of the audit since it is an observational, single time 
point study.    
4.1.1.5 Sexual function (IIEF) 
As expected from the comparison of the presence of sexual dysfunction 
between the ED and NO-ED groups, there were statistically significant 
differences between the two groups in the IIEF domains scores: erectile 
function, orgasm function, sexual desire, intercourse satisfaction and overall 
satisfaction (p≤003). This finding is supported a study by Rosen et al (1997) 
which compared two groups - patients with ED and a control group. The results 
presented and discussed in the study show that all IIEF domains were 
significantly different between the two groups (p≤0.01)(Rosen et al. 1997).  
4.1.1.6 Urological function (IPSS) 
The results previously presented in section ‎3.1.7.3 reveal no significant 
correlation between ED and IPSS domains, while the literature suggests the 
presence of ED is significantly associated with LUTS (Tsao et al. 2008). This 
disagreement could be due to the small sample size in the audit, which was 48 
patients, compared, for example, with Tsao et al’s. (2008) study, where the 
sample size was 398 patients. Similar findings have been reported in another 
large observational, population-based, cross-sectional internet survey to assess 
the prevalence of LUTS in the USA, the UK and Sweden. The results showed 
that ED is significantly associated with LUTS, while the analysis included 
14,139 male participants (Coyne et al. 2009). Other relevant epidemiologic 
studies of the correlation between LUTS and ED were reported by Martinez-
Salamanca et al., (2011) and Rosen and Breyer, (2014).  For example, Braun et 
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al., (2000) reported strong correlations between LUTS and ED for 4,489 
German patients who participated in this study (Braun et al. 2000).  Similar 
findings were suggested in 2003 by different authors: Rosen et al., Vallancien et 
al. and Boyle et al. The sample size for these studies was 12,815, 1,274 and 
4,800 respectively (Vallancien et al. 2003, Rosen et al. 2003, Boyle et al. 2003).  
Moreover, in this audit there were significant correlations between some of the 
IPSS domains (incomplete emptying, urgency and weak stream) and IIEF-
sexual desire domain, as seen in Table  3-17. This finding is compatible with a 
large-scale study by Lukacs et al. (1996) who reported strongly correlations 
between LUTS and sexual desire (Lukacs et al. 1996).  
4.1.1.7 Obesity (BMI) 
Epidemiological studies suggest that a balanced healthy life style (Knoops et al. 
2004, Kirby et al. 2006) with three regular meals a day, such as the 
Mediterranean diet which is largely based on vegetables, fruits, nuts, beans, 
cereal grains, olive oil and fish (NHS Choices 2015b), as well as including 
physical activity and not smoking (Knoops et al. 2004) might decrease mortality 
due to obesity by more than half (Knoops et al. 2004, Kirby et al. 2006). This 
life-style is associated with a reduced risk of ED, and modest improvements in 
sexual function have been previously documented from a reduction in weight 
(Dallal et al. 2008, Esposito et al. 2005).  
4.1.1.7.1 IIEF/BMI 
The results displayed in Table ‎3-13, showed that IIEF- sexual desire domain 
was correlated with BMI, but not the other domains. These results appear to be 
in parallel with other epidemiological studies which show that obesity could be 
one of the main causes of sexual dysfunction in men (Dallal et al. 2008, 
Esposito et al. 2004, Sarwer et al. 2012). As the relationship between obesity 
and ED is not entirely clear, Esposito et al, (2004) suggest that central adiposity 
plays an important role; this may contribute towards increased cardiovascular 
risk in the population (Esposito et al. 2005). Moreover, as described in 
section ‎4.1.1.4.1, adipose tissue leads to a decrease in testosterone levels by 
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increasing the aromatisation of testosterone to oestradiol (Cohen 2001). The 
patients with low testosterone levels have progressively lower levels of sexual 
desire than those who have normal testosterone levels (Corona et al. 2010). 
Additionally, the most testosterone dependent aspects of male sexual behaviour 
are sexual thoughts and motivations (Corona et al. 2010). Psychosocial status 
is a hidden reason that might contribute towards the relationship between 
obesity and impaired sexual functioning such as sexual desire (Sarwer et al. 
2012). There are several psychosocial factors that may negatively impact upon 
sexual behaviour, for example depression may be one of the most common 
factors (Keddie 2011). Another factor that may be considered is body image 
dissatisfaction which is linked to sexual function in both men and women (Dixon 
et al. 2002). Likewise, physical limitations, especially due to extreme obesity, 
may make sexual activity unpleasant, problematic and painful (Sarwer et al. 
2012, Dixon et al. 2002).  
4.1.1.7.2 IPSS/BMI 
There has been no correlation observed between obesity and any IPSS 
domain, as seen in Table ‎3-15. However, the literature reveals a link between 
obesity (BMI >30kg/m2) and LUTS. Patients with a higher BMI tend to have 
more severe symptoms (Lee et al. 2012, Kuruba et al. 2007).  This 
disagreement between the current results and the previous studies might be 
due to the small sample size of the study groups in this audit. Moreover, Kuruba 
et al (2007) analysed 201 patients with BMI 48±7 kg/m2, while in Lee et al’s 
(2012) study the sample size was 409 patients and BMI average was 37.2 
kg/m2.  
4.1.1.8 IIEF and IPSS      
As previously discussed in section ‎3.1.7.3, ED and LUTS were assessed using 
the IIEF and IPSS respectively. The results show significant correlations 
between IPSS domains (incomplete emptying, urgency and weak stream) and 
IIEF-sexual desire as displayed in Table ‎3-17. These results are in accordance 
with previously published reports, and similar research has demonstrated that 
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LUTS is associated with ED (Tsao et al. 2008). Although the cause of this 
correlation remains unclear (Tsao et al. 2008), many theories have been 
proposed to explain the association between ED and LUTS (Rosen et al. 2014, 
Li et al. 2005b, Rosen et al. 2003, Glasser et al. 2007). 
4.1.2 Limitation of the audit   
The audit was carried out on 60 patients attending urological clinics at the 
UCLH to detect the baseline characteristics of their urogenital function. The 
audit suffers from several limitations, which are as follows: 
First, it constitutes a single-institution, with prospective experience. It represents 
a high volume, tertiary-care practice whose patient composition may not 
correlate with that of the general community.  
Second, patients showed little interest in taking part in this audit for several 
environmental and personal reasons; for example, the audit was undertaken in 
a busy clinic and many research studies were being run in the same waiting 
area.   
This appears to contradict the widely held expectation that patients might want 
to directly benefit from such research.  
Third, the audit did not analyse the severity or duration of diabetes or 
hypertension as a function of domain scores.  
Another important consideration is that the audit patients may not be a random 
sample of the male population with urogenital dysfunction and the sample size 
is considered small. Increasing the sample size can give greater power to 
detect differences (Petrie et al. 2013).  
The audit patient population revealed some previous history of tobacco abuse, 
but the amount of tobacco products consumed over time varied between 
patients. This shows the complex nature of statistically assessing the impact of 
smoking.   
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Another possible limitation concerns the use of self-report questionnaires for 
assessing sexual dysfunction (IIEF) and LUTS (IPSS). This presents a possible 
bias in responses, as participants may overstate or inaccurately report their 
sexual dysfunction or urinary symptoms. However, the questionnaires selected 
for the present audit (IIEF and IPSS) had all been previously validated on 
clinical (patients) and nonclinical (volunteers) participants (Plante et al. 1996, 
Rosen et al. 1997)  and are widely used in research and practice. Also, it is 
claimed that sexual dysfunction and LUTS are fundamentally subjective in 
nature. The primary measure of these disorders is patient self-reporting which is 
biased by nature (Dallal et al. 2008).  
4.2 Bariatric surgery audit   
The objective of the work presented in section ‎1.5.2 was to observe the effect of 
bariatric surgery and if there is an improvement shown in the urogenital 
functions of morbidly obese men. The hypothesis was that the surgical 
intervention of bariatric surgery will have a direct effect on urogenital function, 
especially ED before weight loss.  
In order to study the effect of bariatric surgery on urogenital function, the first 
variable that was considered was how to evaluate erectile function. From the 
literature review carried out, different questionnaires have been shown to be the 
most widely used method used for the evaluation of ED and they are the most 
widely method used in clinical practice. The IIEF questionnaire is brief yet 
reliable, with sensitivity shown and specificity for detecting treatment related 
changes in patients with ED (Rosen et al. 1997, Rosen et al. 2008), as 
described in section ‎1.2.5. The second variable considered was how to evaluate 
urological function. According to the literature review, an IPSS questionnaire is 
usually used for this purpose (Plante et al. 1996, Barry et al. 1992), as 
described in section ‎1.3.6. The third variable was evaluating weight loss after 
surgery; BMI was considered appropriate since, as described previously in the 
literature review (Lee et al. 2012, Kuruba et al. 2007, Ranasinghe et al. 2011), 
and as described in section ‎1.1.  Moreover, BMI is the best method available for 
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measuring the prevalence of obesity at the population level. No specialised 
equipment is needed and therefore it is easy to measure accurately and 
consistently across large populations. It is also widely used around the world, 
not only in the UK, which enables comparisons between countries, regions and 
populations of sub-groups (NHS Choices information 2013).  
In order to assess the effect of bariatric surgery on body weight, two parameters 
were included: BMI and %EWL. %EWL is a common metric for reporting weight 
loss after bariatric surgery (Montero et al. 2011). However, one of the obstacles 
to using the %EWL is that it can vary depending on the definition of ideal body 
weight (IBW) used and preoperative weight (Montero et al. 2011). The UK- 
National Bariatric Surgery Registry suggests the use of the term percentage 
excess weight loss (%EWL) to describe weight loss after bariatric surgery 
(Welbourn et al. 2014). It was suggested to use 25 kg/m2 as the upper limit for 
normal BMI (Welbourn et al. 2014). Moreover, it was also highlighted that 
%EWL data must be understood with the fact that the patient with a high BMI 
may lose many kilogrammes, but their %EWL will be less than the patient with a 
lower BMI who loses the same number of kilogrammes (Welbourn et al. 2014). 
On the other hand, Deitel et al. (2007) reported that for obesity surgery BMI is 
preferred, as well as for a comparison of weight loss within a study or between 
studies. Also, Deitel et al. (2007) reported that %EWL has been used in many 
past studies, so this measure may still be acceptable to enable comparison 
(Deitel et al. 2007).  
4.2.1 Effect of surgery type, sexual function (IIEF) and obesity (BMI) 
The three most commonly performed bariatric surgery procedures in the UK are 
adjustable gastric banding, gastric bypass and sleeve gastrectomy respectively 
(National Obesity Observatory, 2010). The data from the audit is in parallel with 
the literature, as the three types of surgery used in this audit were gastric band 
(22.9%), gastric bypass (31.4%) and gastric sleeve (45.7%). The results show 
that the types of surgery have no effect on ED and NO-ED groups. Moreover, to 
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the researcher’s knowledge, similar findings are not available in current 
literature.  
The effect of surgery types on obesity presented by %EWL in this audit is 
comparable with the United Kingdom National Bariatric Surgery Registry 
(UKNBSR) of 2014. The highest %EWL at six month post-op in this audit of 
gastric sleeve was 46% while for the UKNBSR it was 48.3%. Gastric bypass 
and gastric band in the audit compared to the registry were 49.7% compared to 
55.2% and 41.3% compared to 30.8% respectively, considering the difference 
in the sample size between the two comparisons as a major factor for the 
differences.     
4.2.2 Effect of bariatric surgery on body weight (BMI) 
The data presented in section ‎3.2.5 on the change in body weight following 
bariatric surgery showed a significant decrease in BMI and EWL over time 
points and the significance reached at time two (T2; 1 month post-operative) 
compared to time one (T1; 1 month pre-operative); this decrease was observed 
in both ED and NO-ED groups, as expected from prior evidence in the literature 
(Buchwald et al. 2004, Nijamkin et al. 2012, Deitel et al. 2002, Anderson et al. 
2007). However, the different weight loss amounts between groups (ED and 
NO-ED) presented a differential response to bariatric surgery, while both groups 
presented a statistically significant decrease in BMI and EWL.  To the 
researcher’s knowledge, the differential weight loss noted above is the first 
description at one month post-operative for morbidly obese men (Karamanakos 
et al. 2008, Demaria et al. 2010). The previous studies have reported that the 
weight loss reached significant levels at three months (Anderson et al. 2007) 
and six months post-operatively (Nijamkin et al. 2012, Karamanakos et al. 
2008). Moreover, BMI was significantly different between surgery types at T2 
compared to the baseline T1 (p=0.01). %EWL showed no difference between 
surgery types at all-time points compared to the baseline T1 (p>0.05). The UK-
NBSR suggested that %EWL data must be understood with the fact that 
patients with a high BMI may lose many kilogrammes, but their %EWL will be 
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less than the patient with a lower BMI who loses the same number of 
kilogrammes.  Moreover, bariatric surgery parameters for example the % 
Excess Weight Loss (%EWL), the Body Mass Index (BMI) and the ideal body 
weight (IBW) are different methods for reporting weight loss after bariatric 
surgery (Dixon et al. 2005). However, weight loss measurement has not been 
standardized yet (Buchwald et al. 2009, Baltasar et al. 2011). Baltasar et al. 
(2011) recommended further studies should be made with a larger sample size 
of patients, enough follow-up and several bariatric surgery centres (Baltasar et 
al. 2011). The findings of the audits highlight the need for a standardized weight 
loss measurement, a larger sample size of patients for future studies, sufficient 
number of follow-ups and multiple bariatric surgery centres.   
4.2.3 Effect of bariatric surgery on sexual function (IIEF) 
The outcomes of the work presented in section ‎1.5.1 were to observe the effect 
of bariatric surgery in the short term (four weeks post-operative):  
First outcome: if the recovery of erectile function occurs early (before weight 
loss) in parallel with normalised blood glucose, this proposes that the 
improvement of blood glucose has greater impact than body weight on the 
pathophysiology of urogenital dysfunction.  
Second outcome; if the recovery of EF occurs later (in parallel with weight loss), 
this suggests that body weight is as important as, if not more than, the 
normalisation of blood glucose. 
There are limited studies that have focused on erectile function (EF) in morbidly 
obese patients, and a very limited number are focusing on EF after weight loss 
(Reis et al. 2010). This is the first prospective study, to the researcher’s 
knowledge, that copmares the impact of weight loss on sexual and urogical 
function in morbidly obese men at one month post-operative. As summarised in 
Table ‎4-1 there have been five studies which investigated the effect of bariatric 
surgery on erectile function. This study differs from the five studies in Table ‎4-1 
as the only study which has investigated the effect at 1 month post-operatively. 
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Table  4-1: Comparison in sexual function between the audit 
and the literature. 
Reference Surgery 
type 
Improvement in sexual 
function 
Time points Sample 
size of the 
study 
Time of 
improve
ment 
(Dallal et al. 
2008) 
Roux-en-Y 
gastric 
bypass 
- All sexual function domains 
improved after surgery 
(p≤0.002). 
-The Brief Male Sexual 
Inventory (BMSFI) 
questionnaire was used. 
It  consists of 11questions 
comprising 5 sexual function 
domains: sexual drive (2 
items), erectile function (3 
items), ejaculatory function (2 
items), sexual problem 
assessment 
(3 items), and sexual 
satisfaction 
(1 item). 
-Baseline: (1-3 
months pre-op) 
-Time 1: once 
after surgery (at 
least 6 months 
follow-up). 
- Mean 
postoperative 
follow-up length 
was 19 months 
(range 6 to 
45 months) 
 
97 patients 24 
months 
(Mora et al. 
2013) 
Roux-en-Y 
gastric 
bypass 
and 
Laparosc-
opic sleeve 
gastrectom
-y sleeve 
-IIEF improved after surgery 
(p=0.023) 
-Baseline 
-Time 1: 12 
months post-
operation. 
39 patients 12 
months 
(Reis et al. 
2010) 
 
Roux-en-Y 
gastric 
bypass 
-Sexual function improves 
after surgery at (p=0.0469). 
- IIEF-5 questionnaire was 
used. 
 
-Baseline 
-Time 1: 4 
months post-
operation. 
-Time 2: 24 
months post-
operation. 
20 patients 
(10 
underwent 
surgery 
and 10 
control 
(exercise 
and diet) 
24 
months 
(Hammoud 
et al. 2009)  
Roux-en-Y 
gastric 
bypass 
-Sexual quality of life was 
improved (p=0.038). 
-The IWQOL-Lite 
questionnaire was used. It is a 
validated 31-item self-report 
questionnaire designed to 
assess the impact of weight on 
quality of life in obese 
individuals. The IWQOL-Lite 
assesses five domains, 
including a sexual life domain. 
-Baseline 
-Time 1: 24 
months post-
operation. 
22 patients 24 
months 
(Ranasinghe 
et al. 2011) 
Laparosc-
opic gastric 
banding 
-There was no improvement in 
sexual function after surgery. 
-Erectile index and orgasmic 
function worsened. 
-Over the last 10 
years (2001-
2009) 
 
145 male 
patients 
 
N/A
* 
*N/A: not available. 
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A review of the literature as presented in section ‎1.4.1.1 shows numerous 
studies evaluating the sexual function after bariatric surgery (Reis et al. 2010, 
Dallal et al. 2008, Ranasinghe et al. 2011, Hammoud et al. 2009, Mora et al. 
2013).  
Dallal and colleagues (2008) examined 97 men with an average age of 48 and 
average BMI of 51 all of which went through gastric bypass surgery. The brief 
male sexual inventory (BMSFI) was given out to examine the sexual function of 
the patients twice before surgery (between one and three months prior to the 
surgery) and after the surgery by six months (Dallal et al. 2008). The objective 
of Dallal and colleagues study was to measure the sexual function in morbidly 
obese men before and after significant weight loss achieved by gastric bypass 
(Dallal et al. 2008). The study concluded with an improvement in sexual function 
at two years after gastric bypass surgery. Dallal and colleagues suggested that 
the improvement in sexual function was due to weight reduction, while the 
mechanism is multifactorial. The changes in glucose metabolism or the 
presence of cardiovascular disease may not be the main cause of obesity- 
associated erectile dysfunction (Dallal et al. 2008).  
Mora and colleagues (2013) showed an improvement in sexual function in 39 
men with the age range between 18- 65 years. The patients underwent gastric 
sleeve surgery or Roux-en-Y gastric bypass, using the full version of the IIEF 
questionnaire (IIEF) before surgery and at one year after surgery (Mora et al. 
2013). Mora and colleagues suggested that the improvement in sexual function 
focused on; EF, SD, and OS scores, whereas OF and IS scores did not change 
significantly. It was suggested that this was, due to the weight reduction 
occurring after bariatric surgery further than the parallel improvement in 
testosterone level and metabolic profiles such as insulin sensitivity, C-reactive 
protein and lipid profile. Additionally, the post-operative improvement in sexual 
function accounted for improvements in EF, SD, and OS scores, whereas OF 
and IS scores did not change significantly. The results showed weight loss as a 
major contributor to the improved sexual function after bariatric surgery. While, 
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IS and OF domains seemed to depend on factors other than weight loss and 
hormonal or metabolic changes after bariatric surgery (Mora et al. 2013). 
Reis and colleagues (2010) measured erectile function and hormonal changes 
after significant weight loss either surgically or non-surgically in morbidly obese 
males (Reis et al. 2010). All twenty patients completed the IIEF-5 questionnaire 
and blood chemistry values were taken (Reis et al. 2010). Reis and colleagues 
showed an improved sexual function in two year follow-up. Reis suggested the 
role that oestrogens play in erectile function remains unknown. More clinical 
studies are needed with the concern of the role of oestrogen in EF. While the 
sexual hormones were in the normal range before surgery they increased 
significantly with BMI reduction. It is possible to hypothesize that this effect is 
related to the increased tonic stimulation of the testes by the pituitary after 
reduction of the fat mass. This study suggested that erectile dysfunction is 
considered to be a reversible complication of obesity (Reis et al. 2010). It was 
suggested that new studies should include more patients, which could permit a 
more detailed analysis (Reis et al. 2010). 
Hammoud and colleagues (2009) showed an improvement in sexual function 
after gastric bypass surgery, by using the Impact of Weight on Quality of Life- 
Lite (IWQOL-L) questionnaire (Hammoud et al. 2009). However, the study did 
not find an association between change in body fat and hormonal and sexual 
quality of life parameters, despite a correlation between these and change in 
weight (Hatzimouratidis et al. 2009). 
Ranasinghe and colleagues (2011) found no improvement in sexual function 
despite a significant weight loss (p <0.0001) after the gastric band (Ranasinghe 
et al. 2011). There was no improvement in any of the domains of IIEF when 
adjusted for weight loss. Unexpectedly, there was a trend towards decreasing 
erectile function and orgasmic function with time but not with age. Thus, the 
initial findings from this study do not support the suggestion that bariatric 
surgery is associated with the improvement of sexual function in morbidly obese 
men in the short term. Ranasinghe suggested these findings might be caused 
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by time and the ageing process. The study nature was retrospective over ten 
years (Ranasinghe et al. 2011).   
The disagreement between Dallal’s, Mora’s, Reis’s, Hammoud’s studies and 
Ranasinghe’s study might be due to the variations in the tools used in the 
studies, such as the biomedical tests, questionnaires, period of the study, and 
the number of participants that took part in the study (Reis et al. 2010, Dallal et 
al. 2008, Mora et al. 2013). Also, there is possible influence from the study 
design and the medical centre type: primary, secondary or tertiary and the 
number of medical centres participating (single or multi-centre). Overall, the 
evidence for the improvement of erectile function in males after bariatric surgery 
is debatable.  
A strong correlation between BMI and EF was shown and confirmed by 
previously reported data (Kratzik et al. 2005). Dallal et al., (2008) also described 
the overall improvement in sexual function after gastric bypass surgery after 
twenty four months post-operation (Dallal et al. 2008). Moreover, in a 
randomised controlled trial of 110 obese men (BMI > 30 kg/m2) who had erectile 
dysfunction, patients who ate a very low calorie diet reported improvement in 
erectile function with average IIEF-EF scores that improved from 13.9 to 17. 
This improvement in erectile function was independently associated with a 
decrease in BMI; however, it was a two year follow-up (Esposito et al. 2004).  
The results displayed in section ‎3.2.6, show that eighteen obese men (BMI > 35 
kg/m2) noted an overall significant improvement in all IIEF domains, which is 
comparable with previous studies (Dallal et al. 2008, Esposito et al. 2004).  
However, the results reveal significant improvement in erectile function (EF)  
and intercourse satisfaction (IS) with IIEF scores at one month post-operation, 
while sexual desire (SD) and overall satisfaction (OS) scores improved at three 
months post-operation, and significant improvement in orgasmic function was 
reached at six months post-operation. These results are the first of their kind to 
reveal the situation one month post-operatively, according to the researcher’s 
knowledge. The significant improvement in EF at one month post-operative is 
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likely to be multifactorial. Although, it might be explained by the strong 
correlation of BMI to EF which is confirmed by previous studies (Reis et al. 
2010, Dallal et al. 2008, Mora et al. 2013). Another factor suggested for this 
improvement is the short-term remission of FBG (Reis et al. 2010), while there 
was improvement in FBG parallel to weight loss and improvement of sexual 
function. A correlation of testosterone and other hormone levels to EF was 
shown and suggested by previous studies (Feldman et al. 1994, Feldman et al. 
2002, Isidori et al. 2005), although these parameters were not obtained before 
and after the weight loss in this audit. Likely, the short-term improvement in IS 
after one month post-operative might be due to psychosocial status, which 
improved after the weight loss (Sarwer et al. 2012, Keddie 2011).  
Furthermore, no changes in any of the IIEF domains for twelve obese men with 
NO-ED are revealed, except for SD and IS at six months post-operative. These 
patients had SD and IS-domain scores within the normal range before and after 
the surgery. Some improvement in the scores was shown for these domains 
after six months post-operative, although they remained within the normal 
range, but it may be suggested that this improvement was simply a chance 
occurrence. Also, the primary measure of these domains is patient self-
reporting, which means that the results may have been affected by bias.  
These results suggest that the recovery of EF could occur in parallel with weight 
loss, as other studies suggest that obesity could be one of the causes of sexual 
dysfunction in men and that significant weight loss normalises sexual function in 
the morbidly obese male (Dallal et al. 2008, Sarwer et al. 2012, Ranasinghe et 
al. 2011, Efthymiou et al. 2014). As described in section ‎1.5.1, there are two 
outcomes expected from this study, as follows. First outcome:  if the recovery of 
erectile function occurs early in parallel with normalised blood glucose, this 
suggests that the improvement in blood glucose has a greater impact than body 
weight on the pathophysiology of urogenital dysfunction.  Second outcome: if 
the recovery of EF occurs later, this suggests that body weight is as important 
as, if not more than, the normalisation of blood glucose. The results show there 
was a statistically significant decrease in BMI at one month post-operative in 
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parallel with glycaemic improvement. Also, sexual function in the ED group was 
significantly improved parallel to weight reduction and glycaemic improvement 
at one month post-operative. These findings suggest that body weight is 
important factor in improving sexual function in the early stages, at one month 
post-operative. However the study has unable to test the hypothesis since the 
weight loss occurred at one-month postoperatively which was unexpected. 
Oral PDE5-inhibitors (PDE5-Is) are considered to be the first line of treatment 
for erectile dysfunction (Konstantinos et al. 2009). The main advantage of 
PDE5-Is lies in the improvement in sexual function but not sexual desire 
(Wespes et al. 2002).  These medications are used with caution in patients with 
cardiovascular disease. Moreover, diabetes mellitus is considered a common 
cause for the failure of PDE5-inhibitors (Kendirci et al. 2006).  
On the other hand, the results of this audit and a review of the literature showed 
that bariatric surgery can improve sexual function, including sexual desire (Reis 
et al. 2010, Dallal et al. 2008). Also, the literature has shown remission in 
diabetes after bariatric surgery (Pories et al. 1995), while the main reason for 
bariatric surgery is weight reduction in morbidly obese patients (Padwal et al. 
2011).  
Whilst both interventions showed some kind of improved effect on ED, PDE5-
inhibitors are the only one given as a treatment. Even though bariatric surgery 
showed that it has some improved effect on ED it is not considered as a 
treatment for it. Sexual dysfunction is suggested as being one of several 
potentially reversible complications of obesity. Further research should be 
considered in larger studies. 
4.2.4 Effect of bariatric surgery on urological function (IPSS)  
This audit attempts to further examine the link between obesity and LUTS using 
the IPSS questionnaire as the main measuring tool. Obese patients are inclined 
to have more severe symptoms, with a higher total IPSS score (20 – 35) (Lee et 
al. 2012). Some studies have also provided evidence that obesity might be 
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considered a reason for the severity of urinary symptoms (Çinar et al. 2008, Kim 
et al. 2010). 
Bariatric surgery has been shown to produce durable and maintainable weight 
loss, improvement in quality of life, and improvement or resolution of co-
morbidities (Kuruba et al. 2007).  
The IPSS questionnaire is an easy, reliable, and sensitive measure of urinary 
function and has been validated in previous studies (Plante et al. 1996). The 
results displayed in section ‎3.2.7 suggested that the ED group saw significant 
improvement in most of their urinary functions (frequency, intermittency, weak 
stream, nocturia, Qol and IPSS total score) at one month post-operative. 
Moreover, incomplete emptying and urgency improved at three month post-
operative, while, straining did not significantly improve in both groups (ED and 
NO-ED). These improvements in the IPSS domains are in parallel with the 
weight reduction after bariatric surgery. Obesity plays an important role in the 
aetiology of LUTS, possibly by increasing the intra-abdominal pressure (Kuruba 
et al. 2007). A study by Bump et al. (1992) showed that weight reduction 
improves urinary incontinence by reducing abdominal pressure, thus improving 
the transmission of mechanical stress to the urethra (Bump et al. 1992). 
Likewise, Subak et al. (2009) indicated that obesity plays an important role in 
urinary symptoms, including incontinence, in women and men (Subak et al. 
2009). Moreover, abdominal obesity has been associated with a 1.5 fold 
increase in LUTS (Rohrmann et al. 2004). It is also suggested that being obese 
in young adulthood may be associated with a higher prevalence of LUTS later in 
life (Rohrmann et al. 2004). Another reason that might be indicated with this 
improvement is sexual function improvement after bariatric surgery. The 
association between LUTS and sexual dysfunction has been investigated in 
community-based studies and it is suggested that these improvements run 
parallel to each other (Li et al. 2005b, Glasser et al. 2007, Frankel et al. 1998, 
Elliott et al. 2004).   
Nonetheless, not all IPSS domains improved over the time points with NO-ED 
patients after surgically induced weight loss. The IPSS results present a 
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statistically significant correlation with post-operative BMI and percentage of 
excess body weight lost. These findings correspond with the published studies 
that suggest there are overall significant improvements in most IPSS domains 
after bariatric surgery (Lee et al. 2012, Kuruba et al. 2007, Ranasinghe et al. 
2011). In addition, the results present an improvement in most IPSS domains 
with significant improvement in weight loss at one month post-operative; these 
findings have not been published previously according to the researcher’s 
knowledge. This seems to confirm the impact of weight loss on urological 
function after bariatric surgery. It is hypothesised that this might be caused by a 
reduction in intra-abdominal pressure, as suggested by previous studies (Rosen 
et al. 2014, Bump et al. 1992, Cummings et al. 2000).   
A review of the literature as presented in section  1.4.1.2 showed numerous 
studies evaluating the urological function after bariatric surgery (Kuruba et al. 
2007, Ranasinghe et al. 2011, Burgio et al. 2007, Laungani et al. 2009). 
Kuruba and colleagues (2007) prospectively collected data from 201 patients 
between 2004 and 2006 that underwent bariatric surgery. The patients were 
administered the questionnaires after bariatric surgery by telephone interview 
and/or during the three months post-operative visits in the first year. Out of the 
201 patients 65 reported urinary incontinence (UI) and 45 out of the 65 patients 
with UI underwent bariatric surgery during the study period.  This study showed 
that urinary incontinence was improved in 82% of patients after bariatric surgery 
and weight loss suggesting that weight loss after bariatric surgery played an 
important role in the aetiology of UI by inducing weight loss causing reduction 
intra-abdominal pressure (Kuruba et al. 2007). About 13% of the study patients 
reported improvement in UI by subjective measures with no significant change 
that was reported in post-operative severity index scores. Kuruba suggested 
this was due to the documented sensitivity of severity index scores. Moreover, 
no significant correlations were found between age, BMI, %EWL and 
improvement in UI, the small sample size might be the reason behind that 
(Kuruba et al. 2007).   
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Ranasinghe and colleagues (2011) examined, in a retrospective study, the 
effects of weight loss following laparoscopic gastric banding surgery (LGB) on 
urinary incontinence in both male and female patients. Moreover, post-operative 
weight loss improved overall UI, quality of life and stress incontinence in 
women, this improvement was suggested due to a reduction in intra-abdominal 
pressure (Ranasinghe et al. 2011). However, no improvement in urinary 
function, despite weight loss after LGB, was observed in males, although 
23.54% of males reported UI before bariatric surgery, the study did not identify 
an association between weight loss and UI. Therefore, Ranasinghe suggested 
that raised intra-abdominal pressure may not contribute to UI in males. Also, the 
retrospective nature of the study and poor response rate from the patients might 
have allowed recall bias, and the use of questionnaires based on subjective 
assessment could have also reflected factors such as individual patient 
satisfaction with the surgery (Ranasinghe et al. 2011).  
Burgio and colleagues (2007) examined, the changes in UI in morbidly obese 
women who underwent laparoscopic Roux-en-Y gastric bypass between 
October 2003 and February 2005 and were followed up to six and twelve 
months post-surgery. The Urogenital Distress Inventory (short form) and the 
Incontinence Impact Questionnaire (short form) were used in this study. 
Significantly BMI decreased after six months post-operative and the prevalence 
of UI decreased significantly at 6 months and continued to twelve months post-
operative. Burgio suggested that the reduction in prevalence of the UI was 
significantly associated with decreases in BMI. Although the mechanism of 
improvement is unknown, it may be due to the relief of chronic pressure on the 
pelvic floor that may weaken the urinary continence mechanism (Burgio et al. 
2007).  
Lanugani and colleagues (2009) evaluated 470 morbidly obese women who 
underwent laparoscopic gastric bypass for urinary incontinence with the 
International Consultation on Incontinence Questionnaire Short Form at three 
and twelve months post-surgery.  The UI had been resolved in more than 50% 
of the patients and improved overall in most of them.  The significant 
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improvement in UI was reported within three months post-operative and 
continued to one year in parallel with weight loss (Laungani et al. 2009).  
Lanugani suggested as previous studies did (Kuruba et al. 2007, Ranasinghe et 
al. 2011, Burgio et al. 2007), that the mechanism of improvement might be due 
to weight loss and the decrease in intra-abdominal pressure (Laungani et al. 
2009). 
In summary, the occurrence and development of urological diseases depends 
on numerous factors, including obesity (Mydlo 2004), which has been shown to 
be a risk factor for urinary function (Kuruba et al. 2007). Similarly, Burgio et al 
(2007) showed that urinary function improved after weight reduction (Burgio et 
al. 2007) although, both studies were on female patients (Table ‎4-2). This 
reflects the need of more specialised studies examining the effect of obesity in 
depth.   
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Table  4-2: Comparison in urological function between the 
audit and the literature. 
Reference Surgery 
type 
Improvement in 
urological function 
Time points Sample size 
of the study 
Time of 
improve
ment 
(Kuruba et 
al. 2007) 
Roux-en-Y 
gastric 
bypass 
- Significant 
improvement or 
resolution was reported 
after a mean duration 
of 4 months or 
a 50-lb weight loss. 
-Validated urinary 
incontinence 
questionnaire used to 
screen 201 consecutive 
prospective bariatric 
patients before and 
after weight loss 
surgery. 
  
 
-Baseline: (1-3 
months pre-op) 
-Time 1: 3 months 
post-op. 
Time 2: 6 months 
post-op. 
Time 3: 12 months 
post-op. 
-The median follow-
up of 12 
months (range 6–
23) 
201 patients 
(38 patients 
completed the 
study and 
previously 
reported 
urinary 
incontinence) 
4 
months 
(Ranasinghe 
et al. 2011) 
Laparosc-
opic gastric 
banding 
- Short Form (ICIQ-SF) 
and IPSS 
questionnaires were 
mailed to all study 
patients. 
- No significant 
improvement in UI with 
weight loss after 
bariatric surgery in 
males. 
- Surgical weight loss 
improved overall UI, 
quality of life and stress 
incontinence in women. 
 
 
-Over the last 10 
years (2001-2009) 
145 male 
patients 
(36 
responded) 
 
N/A
* 
(Burgio et al. 
2007) 
Roux-en-Y 
gastric 
bypass 
- Significant 
improvement in UI with 
weight loss after 
bariatric surgery. 
-The Urogenital 
Distress Inventory 
(short form) and the 
Incontinence Impact 
Questionnaire (short 
form) were used in this 
study 
-Baseline 
-Time 1: 6 months 
post-op. 
-Time 2: 12 months 
post-op. 
 
101 
Female 
patients 
6 
months 
(Laungani et 
al. 2009) 
laparoscop
ic gastric 
bypass 
- Significant 
improvement in UI and 
quality of life with 
weight loss after 
bariatric surgery 
-The Incontinence 
Impact Questionnaire 
(short form) was used. 
Baseline 
-Time 1: 3 months 
post-op. 
-Time 2: 12 months 
post-op. 
 
309 Female 
patients 
3 
months 
*N/A: not available. 
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4.2.5 Effect of bariatric surgery on biomarkers  
As previously stated, the objectives of the audit were to observe the effect of 
bariatric surgery on fasting blood glucose (FBG) and HbA1c post-operatively.  
The expectation was that the surgery would have a direct effect on fasting blood 
glucose, corresponding with the published research which suggests the use of 
bariatric surgery as a treatment for obesity and T2DM (Wickremesekera et al. 
2005, Pournaras et al. 2010, Isbell et al. 2010). However, the mechanism of the 
bariatric surgery on diabetes and the improvement of fasting blood glucose 
following surgery remains largely unclear (Proczko-Markuszewska et al. 2011, 
Pournaras et al. 2010). The results of the present study show no difference 
between ED and NO-ED groups for FBG and HbA1c before the surgery. 
4.2.5.1 Fasting blood glucose  
The data presented in section  3.2.8 for FBG show a significant improvement 
over time in both ED and NO-ED groups. The results suggest an improvement 
at one month post-operative with the ED group. However, the NO-ED group 
showed an improvement at six months post-operative and this improvement is 
compatible with the literature as presented in Table ‎1-7 (Wickremesekera et al. 
2005, Pournaras et al. 2010, Torquati et al. 2005, Garrido-Sanchez et al. 2012, 
Mingrone et al. 2012).  
In this audit FBG improvement was parallel with weight loss at one month post-
operative. However, this improvement might be weight loss independent 
(Pournaras et al. 2010), because this observation was not reported immediately 
but was measured one month after the surgery.  Moreover, Umeda et al., 
(2011) note that the first improvement in BMI and FBG was observed one 
month after bariatric surgery, while a fasting insulin and homeostasis model 
assessment of insulin resistance (HOMA-IR) index was observed seven days 
after surgery (Umeda et al. 2011). In addition, the immediate improvement in 
blood glucose level in the post-operative period is weight loss independent, 
because immediately improved insulin secretion and reduced insulin resistance 
have been observed between the second and seventh day after a gastric 
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bypass (Pournaras et al. 2010). This increase was associated with an improved 
GLP-1 response (Pournaras et al. 2010), which may partly be explained by L-
cell stimulation from bile acids (Pournaras et al. 2012).  Furthermore, the results 
reveal prolonged improvements (six month post-operative) in FBG for most of 
the audit patients that underwent gastric sleeve or gastric bypass, and only two 
patients who were diagnosed with T2DM underwent a gastric bypass.   
However, these prolonged improvements could be explained by the substantial 
and maintained weight loss. A reduced appetite may be partly explained by 
enhanced satiety gut hormones from the endocrine L cell, such as GLP-1 (Le 
Roux et al. 2006).  Moreover, Pournaras et al., (2012) suggest that the changed 
anatomy after bariatric surgery (not gastric band) affects bile delivery to the 
terminal ileum and leads to elevated plasma bile acids resulting in increased 
satiety gut hormone responses, reduced food intake, and weight loss 
(Pournaras et al. 2012). 
4.2.5.2 HbA1c  
As previously presented in ‎4.2.5.1, the data shown in section  3.2.8 of HbA1c 
reveals a significant improvement within one month post-operative in the ED 
and NO-ED groups. This improvement in HbA1c is compatible with some of the 
literature (Proczko-Markuszewska et al. 2011, Umeda et al. 2011), but not all 
(Wickremesekera et al. 2005, Basso et al. 2011, Rizzello et al. 2010).  
In this audit, a significant improvement in HbA1c was parallel to weight loss at 
one month post-operative. However, this improvement might be weight loss 
independent; Pournaras et al. (2010) reported an improvement of HbA1c at one 
week post-operative independent of weight loss (Pournaras et al. 2010). The 
audit cannot guarantee that the improvement is independent of weight loss due 
to the HbA1c results not being measured immediately but measured one month 
after surgery.  
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4.2.6 Limitation of the audit  
There are several limitations to this audit that need to be addressed; mainly 
concerned with conducting a new method to assess the early effect of bariatric 
surgery on sexual and urological functions.  
The small sample size of the audit groups might have overestimated the 
significant correlations between variables. Another important consideration is 
that the audit patients may not be a random sample of the male morbidly obese 
population due to the lack of randomisation. However, the groups (ED and NO-
ED) were well matched for pre-operative patient characteristics.  
In addition, bariatric surgery is more common in women (5,047 hospital 
incidents between 2009 to 2010) than in men (1,473 hospital incidents in the 
same years), and all the audit patients were male (National Obesity 
Observatory 2010).  Most patients who listed for bariatric surgery in the UK are 
aged between 40 and 54 years, followed by those aged between 25 and 39 
years (National Obesity Observatory 2010); while the age range of the audit 
participants was mostly patients with the age between 40 and 49 years, 
followed by those with the age between 50 and 59 years. 
This audit was a small-scale single centre study set up at the UCLH. While 
single centre trials provide the flexibility of approach necessary for healthcare 
providers, using only a small number of participants carries a considerable risk 
of failing to demonstrate a treatment difference when one is really present, for 
example type II errors. While multicentre studies are an accepted way of 
evaluating a new intervention, a large number of participants and a multi-
investigator design would provide a better basis for the success of the research 
and would give better clinical judgement regarding the value of the research 
(Copeland 2005).  Since the audit was established in a single -centre with 
prospective experience, it represents a high number of tertiary care hospital 
patients who may not be representative of those in the general community. 
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Moreover, the audit results were limited to six months follow-up and based on a 
small number of participants. The evidence at longer than six months follow-up, 
in particular on the adverse events of bariatric surgery and mortality, remains 
unclear (Gloy et al. 2013). 
Since urogenital function was assessed by using self-administered 
questionnaires, the data could have been influenced by patient recall bias due 
to the nature of self-administered questionnaires, and also regarding the time 
elapsed and amount of weight loss when reporting the post-operative severity of 
sexual and urological function.  
The audit might have under estimated the severity of urinary dusfunction by 
substituting the answers in the IPSS questionnaire with those from the IIEF, and 
the length of the questionnaires might have contributed towards the poor 
response rate as there were two sets of questionnaires to complete. Therefore, 
it is important that urodynamic studies17 are undertaken as a part of this audit 
(NICE 2015).  
The audit also could not investigate the effect of bariatric surgery on 
cardiovascular morbidity and mortality, and did not analyse the severity or 
duration of diseases, such as cardiovascular disease, hypertension or diabetes 
as a function of domain scores.  
No information was available on ethnicities and marital status, but the results 
might be different for specific subgroups. However, the limited number of 
published studies prohibited researchers from finding out differential effects due 
to sex or age (Gloy et al. 2013).   
                                            
 
17
 Urodynamic studies assess the function of the bladder and urethra and are often useful in the 
assessment and diagnosis of patients presenting with lower urinary tract symptoms (LUTS) 
(NICE 2015). 
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Although no medical history was included to identify any medication or surgery 
that might affect urinary or sexual function, there may be other factors that 
affected the results such as parity and hormone levels. 
A number of participants expressed (but did not report) some previous history of 
tobacco abuse, but control of this important variable is difficult. Patients often 
stopped (pre-operative) and restarted (post-operative over a two month period) 
tobacco use. Some were active tobacco users; others had remote histories. The 
amount of tobacco products consumed over time also varied within patients (but 
this was not reported). Some participants were successful at post-operative 
smoking cessation; others renewed tobacco use at variable times after surgery. 
Because of the lack of documentation and the complexity of tobacco 
consumption and limitations in the statistical calculation, the researcher chose 
not to include this important predictor variable in the statistical results.  
Of note is the fact that waist circumference was not used to assess central 
obesity in the audit participants. According to NICE recommendations, the use 
of BMI in combination with waist circumference as a method for measuring 
overweight and obesity and determining health risks is important; specifically, 
the guidance currently states that assessment of health risks associated with 
being overweight and obese should be based on both BMI and waist 
circumference for those with a BMI of less than 35 kg/m2 (NHS Information 
Centre 2014).  
Additionally, testosterone has not been examined to assess sexual function or 
other hormone levels such as SHBG before and after weight loss. This is 
because testosterone is not part of the routine check for patients who are listed 
for bariatric surgery, the same as other hormones which are very important in 
this audit and have a significant role with regard to obesity (Esposito et al. 
2005). Pasquali et al., (1991) examined 52 obese men and found decreased 
free and total serum testosterone concentrations and a decrease in SHBG 
levels (Pasquali et al. 1991). Also, Reis et al., (2009) noted the levels of these 
hormones increased significantly with BMI reduction (Reis et al. 2010). 
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Another important limitation that was not measured is bile acids. Studies 
suggested there is a link between bile acids and blood glucose level and these 
studies showed an improvement, especially with T2DM. Gastric bypass surgery 
is being used as a treatment for T2DM, although the mechanism of action 
remains unclear (Pournaras et al. 2010, Pournaras et al. 2012). 
Also, aromatase enzyme levels were not measured in the audit. Aromatase is 
the enzyme responsible for converting androgens to oestrogens, and is widely 
distributed in several tissues such as testicular Ley-dig cells, adipose tissue, 
liver and reproductive tissue (Ho 2004).  In men, oestrogen production occurs 
mainly by extra testicular aromatization of androstenedione to oestrone and 
testosterone to oestradiol (Ho 2004).  Moreover, morbidly obese males have 
demonstrated the presence of decreased free and total testosterone levels with 
increased aromatase (Cohen 1999).  Since waist circumference is shown to be 
an accurate predictor and abdominal fat contains aromatase, including this 
variable in future work would be beneficial.   
Furthermore, it is well recognised that bariatric surgery is effective in improving 
insulin resistance and T2DM (Wickremesekera et al. 2005, Pournaras et al. 
2010, Pournaras et al. 2012). These findings should be confirmed in the audit 
by measuring HOMA-IR and fasting insulin. The previous studies suggest these 
improvements can be achieved within one week post operation before any 
apparent weight loss and the suggested mechanisms are due to caloric 
restriction (Pournaras et al. 2010, Isbell et al. 2010). Another suggestion is that 
the instant improvements in insulin sensitivity after bariatric surgery could have 
been a result of the associated stress or inflammatory responses to surgery, 
thus masking a greater improvement in insulin sensitivity with RYGB than with 
caloric restriction (Isbell et al. 2010). Moreover, the majority of these limitations 
were expected from the beginning of the audit and will be addressed in future 
work.  
The results presented in this thesis were obtained from two ongoning audits 
which aimed to increase the patient care quality and improve the outcomes and 
it was also used to confirm improvement in healthcare delivery. Although a plan 
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was made with the audits there was still a need for assistance in the 
implementation to reach a higher research level. The audits aimed to provide 
future assistance, by providing an initial practical overview to the structures and 
processes necessary to deliver a clinical audit at a higher research level. 
Additionally the parameters and blood tests measured were all useful to enrich 
the audit. However, they were inconclusive and the recommendation is to add 
the following testes; renal function, liver function, thyroid function, prolactin, 
SHBG, free and total testosterone level, aromatase levels, HOMA-IR and 
fasting insulin.  Also, waist circumference is needed to assess central obesity. 
Notably, results of the audit recommend that the questionnaires (IIEF and IPSS) 
should be a standard for all patients undergoing bariatric surgery.  
Generally, one of the possible benefits of the audit is to improve hospital cost-
efficiencies (Gordon et al. 2010). The aim of these audits as described before 
was to evaluate the baseline characteristics of patients with erectile dysfunction 
and to determine the impact of bariatric surgery on erectile and urological 
function in morbidly obese men. Moreover, more aims will be added in future 
work to estimate the possible cost-savings for a study at certain medical centers 
from improved surgical performance for bariatric surgery in presence of 
urological dysfunction. The current audits were limited to the availability of data 
estimated for each test and measures were used in the audits. The published 
studies for example provids estimates on weight measuring techniques were 
inconsistent in the use of standard definitions and methods used to measure the 
weight loss (Ariyarathenam et al. 2012). This appears to be a common problem 
internationally as confirmed in a large UK review on the topic of monitoring 
weight (Ariyarathenam et al. 2012). The lack of evidence on the effectiveness 
level of the audit parameters for surgery and urological function was also a 
limitation for measuring the cost. This is possibly due to, the challenging nature 
of the topic, the possible legal and social difficulties and lack of time. 
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5 CONCLUSION 
The aim of this study, as set out in section  1.5.2, was to evaluate the baseline 
characteristics of patients with erectile dysfunction and to determine the impact 
of bariatric surgery on erectile and urological function in morbidly obese men by 
conducting two separate clinical audits. This evaluation has then been used to 
investigate the hypothesis that surgical weight reduction is the hidden 
mechanism responsible for the association between obesity and erectile 
dysfunction. The impact of bariatric surgery was also used to investigate that 
effect on urological function. 
These objectives were proposed to achieve the aim of the study:  
1. To conduct an audit to investigate the baseline characteristics of men 
over 18 years of age and attending the urological clinic at UCLH using 
IIEF and IPSS questionnaires (results covered in section  3.1and 
discussed in section  4.1); 
2. Perform an audit the effect of BMI on urogenital function in men over 18 
years of age and attending the urological clinic at UCLH using IIEF and 
IPSS questionnaires (results covered in sections  3.1.7.1,  3.1.7.2 and 
discussed in sections  4.1.1); 
3. To collate and analyse other baseline characteristics such as age, 
smoking status, and medical history (results covered in section  3.1.7 and 
discussed in sections  4.1.1); 
4. To conduct a second audit to investigate the effect of bariatric surgery on 
the urogenital function and BMI of morbidly obese men over 30 years of 
age and BMI of 35 and over (results covered in section  3.2 and 
discussed in section  4.2); 
5. To analyse the urogenital function and biomarker data acquired in the 
second audit to assess the effect of bariatric surgery on urogenital 
function and recommend further work based on these analyses (results 
covered in section  3.2.8 and discussed in section  4.2.4 and  4.2.5); 
(results covered in Chapter  3 and discussed in sections  4.1.2 and  4.2.6). 
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The results presented in section  3.1 and discussed in section  4.1 show that the 
methods used in selecting, recruiting and collecting information from the audit 
participants have successfully been established, which is reflected in the 
amount of data gained compared to the data from the literature review 
(according to Objective 1). Furthermore, this information has revealed an 
important database model of patient characteristics which can be used in future 
studies.    
The results presented in section  3.1.7.1 and discussed in section  4.1.1 suggest, 
in parallel with other epidemiological studies, that obesity could be one of the 
causes of sexual dysfunction in men. However, the results presented in 
section  3.1.7.2 and discussed in section  4.1.1 demonstrate dissimilarities with 
other studies in that no correlation has been detected between obesity and 
LUTS (Objective 2).  
The results presented in section  3.1.7 and discussed in sections  4.1.1 show that 
age has a negative influence on sexual function, and many significant 
correlations were presented between biomarkers, ED and LUTS, that were 
compatible with previous studies (Objective 3). 
The results presented in section  3.2 and discussed in section  4.1 have shown 
that the method used in selecting, recruiting, observing and  collecting 
information from audit participants has successfully been established, which is 
reflected in the observed effect of bariatric surgery for the ED group compared 
to the NO-ED group (Objective 4).  Moreover, the present audit model has 
created an important initial database to be used in future studies. 
The results presented in section  3.2.8 and discussed in section  4.2.5 show a 
significant improvement within one month post-operative for fasting blood 
glucose and HbA1c. Furthermore, the results reveal prolonged improvements 
(six month post-operative) in fasting blood glucose levels and HbA1c. The 
results presented in Chapter  3 and discussed in sections  4.1.2 and  4.2.6 
highlight the limitations of the audits and addressing these difficulties in future 
work (Objective 5).  
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In summary, these audits have successfully achieved all the stated objectives, 
and a huge area for further research and development has arisen from the 
results gained.  
5.1 Future works 
In The work will be divided into two phases; phase one will consist of using 
baseline characteristics to help improve the decision making for male patients 
with obesity and urological dysfunction.  
In addition, it will include using baseline factors that allow the assessment of 
specific patient risks for clinical development and the benefits of medical 
therapy.  
A novel clinical decision tool based on these analyses will permit clinicians to 
evaluate specific patient benefits against possible risks from adverse effects on 
a given patient.  
There is a need for more studies, such as longitudinal, cross-sectional studies 
to investigate the associations between baseline characteristics. For example, a 
cross-sectional study of sexual function, and a longitudinal study exploring the 
associations between changes in LUTS and sexual function among men with 
obesity and of different ethnicities. Phase two will consist of the following:   
1. Creating a better understanding of the mechanisms of action for each 
variable to enable optimum information gathering from the surgery and 
follow up. 
2. Patient data management should be a mandatory item. Bariatric surgical 
procedures should be incorporated into local and national clinical 
registries to enable objective assessment of the risks and benefits across 
the community. This does not apply in the UK, but does in other 
countries such as Saudi Arabia. 
3. There is a need for more studies such as randomised controlled trials 
with a large sample size and different ethnicities to define the benefits of 
weight loss on the comorbidities of obesity.  
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4. Further randomised control studies are needed specifically for patients 
with ED, LUTS, T2DM, hypertension, non-alcoholic fatty liver, liver 
transplant, psychological disorders and obstructive sleep apnoea. 
5. Additional essential information is needed to find out more about the 
most safe and efficient pathways for assessment, surgery and follow up 
of ED patients. 
6. Further knowledge is needed to cost-effectively evaluate the bariatric 
surgical approach to disease management for ED and LUTS in 
comparison with current options.  
However, as previously noted, bariatric surgery could be one of the most 
significant treatments for obesity, sexual and urological dysfunctions. This 
approach has been realised through good science, wide-ranging data 
management and high quality clinical care.  
Specifically, the future work will be designed to be applied in one of the biggest 
hospitals in Saudi Arabia- King Faisal Specialist Hospital and Research Centre.   
There are some considerations that need to be addressed based on the thesis 
audits recommendations.  
First, as urinary incontinence is common in the morbidly obese population, an 
appropriate questionnaire to assess urinary incontinence such as the 
International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) 
(Gotoh et al. 2009) should be added to the IPSS and IIEF questionnaires to be 
completed by the participants.  
 
Second, there is a need to consider a large sample size from the study 
population to enhance the reliability of the findings and enhance the power of 
the results. This can be done by using different approaches to increase patient 
recruitment, including private and governmental sectors, and involving more 
bariatric surgeons from different hospitals.  
 
Third, the work will include a comprehensive history of the lifestyle, 
psychological condition and medical status of the participants and their 
partners. Focusing on lifestyle, the psychological condition of the partners will 
be examined by giving them, for example, a quality of life questionnaire. This 
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will provide a broad and clear view of the indirect factors affecting the lifestyle, 
physical and psychological well-being of the participants.   
 
Fourth, a detailed history of PDE5 inhibitor use as prescribed or non-prescribed 
(personal use of PDE5 inhibitors with no medical direction) should be included 
for each participant. Oral PDE5-Is are considered as the first-line treatment for 
erectile dysfunction (Costabile et al. 2003, Konstantinos et al. 2009). The daily 
administration of PDE5 inhibitors produced desirable effects in previous clinical 
studies (Corbin 2004, McMahon 2006, Bella et al. 2007). Both daily and on-
demand PDE5-Is improved efficacy outcomes and were well-tolerated 
(McMahon 2006). However, the change in the IIEF domain score and the 
successful completion of sexual intercourse were higher with daily dosing 
(McMahon 2006). The improvement in the erectile response proposed most 
likely related to improved endothelial function (Corbin 2004, McMahon 2006, 
Bella et al. 2007) and the higher satisfaction in the daily use of PDE5-Is were 
described by the patient and his partner. The primary outcome measures 
included changes from baseline (first visit) in the erectile function domain of the 
International Index of Erectile Function (IIEF) and the proportion of “yes” 
responses to questions 2 (successful penetration) and 3 (successful completion 
of intercourse) (McMahon 2006). This information can be retrieved through 
adequate and comprehensive sexual history taking from the patient and his 
partner and also, through the Ministry of Health (MOH) database in Saudi 
Arabia.  
Fifth, certain biomarkers should be measured such as testosterone, prolactin 
and aromatase enzyme at each time point of the research. Meanwhile, prolactin 
levels have been neglected in the hormonal studies of morbidly obese patients 
(Reis et al. 2010). Reis et al. (2010) highlighted an association between weight 
loss and prolactin levels decrease. Also, aromatase enzyme is concentrated in 
fat cells and decreases testosterone levels (Cohen 1999, Cohen 2001). 
Furthermore, the exact molecular mechanism of androgen action in EF remains 
unknown and testosterone imbalance recovery in morbidly obese men after 
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surgical weight loss could justify the erectile function improvement 
independently by acting at different sites (Reis et al. 2010).  
Sixth, waist circumference measurements combined with BMI will be used as a 
measure of the central obesity; this can be done by the clinic nurse at each visit 
to the participants. Also, waist circumference may represent an easy diagnostic 
tool to elucidate the presence of occult voiding dysfunction. Waist 
circumference has shown to be an accurate predictor and abdominal fat 
contains aromatase and is needed to assess central obesity (Lee et al. 2012). 
According to NICE recommendations; the guidance currently states that 
assessment of health risks associated with being overweight and obese should 
be based on both BMI and waist circumference for those with a BMI of less than 
35 kg/m2 (NICE 2014). Furthermore, waist circumference being heavily linked to 
various prostate related problems and associated with worsened voiding 
function and pelvic dysfunction (Lee et al. 2012).  
Finally, to strengthen the study, there should be a short term post-operative 
follow-up within one week and a long term follow-up period of up to two years. A 
short term post-operative follow-up should differentiate if the recovery of erectile 
function occurs early before weight loss in parallel with normalised blood 
glucose. The measurement of the long term effectiveness of weight loss 
surgeries on sexual function and the long term complications once patients 
have maintained a plateau weight for several months. 
 
To conclude, there are only a few studies focusing on EF in morbidly obese 
patient, and very few are focusing on EF after weight loss. The underlying 
mechanism of obesity-related sexual dysfunction is probably multi-factorial. ED 
should be considered one of the numerous potentially reversible complications 
of obesity (Reis et al. 2010). There is still an excessive need for more effective 
studies that can provide long-lasting improvement for urogenital dysfunction in 
morbidly obese men following bariatric surgery. 
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APPENDICES  
This section provides relevant supplementary information to project, including 
questionnaires used in audits, additional data not presented in the main body of 
this report and all information relating to the ethical approval of this project.  
 
Appendix A: Supplementary information to Chapter 2 – 
Methods.  
This appendix section presents the questionnaires that were used to obtain the 
majority of the data presented in chapter ‎3, as well as chapter 1and 2.  
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A.1 IIEF questionnaire 
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A.2 IPSS questionnaire  
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A.3 UCLH biochemistry and haematology request 
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Appendix B: Documentation relating to the ethical 
approval of this project.  
B.1 Baseline characteristics of urogenital function audit 
protocol submitted for ethics board approval.  
 
STUDY PROTOCOL 
Version 1, 3rd April 2014 
Cranfield Investigator: 
Dr Selim Cellek, Reader in Translational Medicine,  
Cranfield University, Bedfordshire, MK43 0AL 
Phone: 01234 758319 
E-mail: s.cellek@cranfield.ac.uk   
 
 
Clinical investigators: 
Mr David Ralph and Mr Asif Muneer      
Urology Department 
University College Hospital 
Ground Floor Central   
250 Euston Road  
London, NW1 2PG  
Phone: 020 3447 9280 
E-mail:  
dralph@andrology.co.uk 
asif.muneer@uclh.nhs.uk  
 
Estimated start date: 1st May 2014 
Estimate duration: 1 year 
 
1. Study Title: Audit of baseline characteristics of  urogenital function 
 
2. Project Background:  
Erectile dysfunction (ED) is a disease that affects generally men aged 40 years or more. 
Lower urinary tract symptoms, diabetes mellitus, obesity, inactive lifestyle and 
hypertension are the risk factors for ED. ED is a strong predictor for cardiovascular and 
coronary artery diseases.  
ED is one of the multifactorial aetiology diseases, many organs interact in the erection 
process. Generally, ED can be of psychogenic and organic origin. And because of this 
multifactorial aetiology it may be hard to define the factors involved in the problem. 
Although the baseline characteristics of patients with ED are well characterised, 
particularly the effect of obesity on the incidence of ED has not been clarified. Therefore 
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our aim is to investigate the effect of BMI on urogenital function of men over 30 years of 
age and to collate and analyse other baseline characteristics (age, smoking, medical 
history etc.). The erectile function and urological function will be evaluated using 
validated and widely used questionnaires (International Index of Erectile Function [IIEF] 
and International Prostate Symptom Score [IPSS]). If successful, this study will be the 
first assess the baseline characteristics of patients with ED at UCLH. The 
questionnaires will be totally anonymised. There will no additional intervention or 
change to the surgical procedure/patient care.  
  
3. Study Aims: 
Aim:  
To assess the baseline characteristics of patients with erectile dysfunction  
Objectives:  
o To investigate the effect of BMI on urogenital function of men over 30 years of 
age and attending urological clinic using IIEF and IPSS questionnaires. 
o To collate and analyse other baseline characteristics (age, smoking, medical 
history etc.)  
o Analyse and present the above data. 
o Recommend further work based on the above analysis. 
 
4. Recruitment and Consent: 
a. Study population: Prospective study of patients who have been listed to attend 
urological clinic for treatment of ED.  We are hoping to recruit 30 patients within this 
audit.  
 
b. Specific Inclusion and Exclusion Criteria: 
i. Inclusion criteria:  
a. Age 30 years old and above.   
b. Listed for attending urological clinic at UCLH 
c. No other serious illness for example cancer or neurodegenerative 
disease.  
ii. Exclusion criteria: 
a. Age  less than 30 years old 
b. Not listed for attending urological clinic at UCLH 
c. Other serious illness such as cancer or neurodegenerative disease 
a. Recruitment: 
Those patients who have been seen or listed for attending UCLH urological and 
meet the inclusion and exclusion criteria will be given included in the audit. Mr Asif 
Muneer and Mr David Ralph will be responsible for the recruitment process. 
 
b. Anonymisation: 
The patients will be asked not to put their names or any other personal information 
on the questionnaires. The study will be totally anonymised. The only data that will 
be transferred to Cranfield University are:  two completed questionnaires (IIEF, 
IPSS), age, BMI, smoking, medical history and blood chemistry values. No subject 
identifiable data will be transferred. 
 
c. Sponsorship: 
This study is sponsored by UCLH.  
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5. Study Methodology 
This study will not change the surgical or medical care the patients receive in anyway. 
No additional tests or procedures are required.  
As soon as collected at the clinic, the questionnaire will be placed in a folder and kept in 
the secured drawer at the Urology Department, Ground Floor, University College 
London Hospital. Each questionnaire will be accompanied by a brief note with date, 
age, BMI, IIEF and IPSS scores, blood chemistry values (see Appendix I). The 
questionnaires will then be transferred to Cranfield University within 24 hours. On arrival 
at Cranfield University, the questionnaire will be given a unique subject number and the 
data on the accompanying note will be recorded electronically.  
The questionnaires will be processed for data analysis by using statistical tests that will 
be performed by using SPSS version 19. The questionnaires will be destroyed at the 
completion of the study. 
Dr Selim Cellek will be responsible for recording of the data on the accompanying note, 
the questionnaires storage and disposal at Cranfield University. 
 
6. Data analysis: 
Appropriate statistical tests which we commonly use for these types of experiments will 
be utilised throughout the study. When/if necessary, professional statistician will be 
consulted. 
 
7. Dissemination of information: 
The results of the study will be disseminated by: 
a. Presentation at international meetings such as, but not limited to European 
Society for Sexual Medicine, European Association of Urology and American 
Urological Association. 
b. Publication in peer reviewed journals such as but not limited to Journal of 
Sexual Medicine, Journal of Urology and British Journal of Urology. 
The only patient-related data that will be used in these publications are patient’s age, 
BMI, scores of IPSS and IIEF. No subject identifiable data will be published.  
8. Ethical Issues Arising: 
Since this is an audit, patient consent is not required. Therefore the patients will be 
given an information sheet but they will not be asked for their consent. 
Based on our previous experience with the use of questionnaires in basic research, we 
do not envisage any ethical issues arising. In previous similar studies, we have 
observed that the majority of the patients are comfortable in giving consent to such 
studies since no extra test will be taken and the study is totally anonymised. We will 
exclude patients who do not understand the information sheet which is based again on 
our previous experience with patients who had difficulty comprehending the information 
sheet usually due to language barriers. 
 
9. Data Protection: 
No subject identifiable information will be transferred with the questionnaires. Only data 
that will be transferred are (see Appendix I): 
a. Date of the questionnaire 
b. Age of the patient 
c. BMI of the patient 
d. Questionnaires (IIEF, IPSS) scores 
e. Testosterone level 
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f. Prolactin level 
g. Fasting blood glucose level 
h. Thyroid function 
i. Kidney function  
j. Liver function 
k. Full blood count (number of red cells, white cells and platelets) 
l. HbA1c level  
m. Diabetes status 
n. Medical History 
o. Smoking 
These data will be recorded and kept electronically in a password-protected computer 
at Cranfield University. Dr Selim Cellek will be responsible for these data. 
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B.2 Patient information sheet of baseline characteristics of 
urogenital function audit  
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B.3 Copy of approval letter from ethics board (Cranfield 
University Health Research Ethics Committee; CUHREC)  
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B.4 Urogenital function following bariatric surgery audit 
protocol submitted for ethics board approval   
STUDY PROTOCOL 
Version 1, 23rd February 2013 
Cranfield Investigator: 
Dr Selim Cellek, Reader in Translational Medicine,  
Cranfield Health, Cranfield University, Bedfordshire, MK43 0AL 
Phone: 01234 758319 
E-mail: s.cellek@cranfield.ac.uk  
 
Clinical investigators: 
Mr Majid Hashemi 
University College Hospital  
250 Euston Central 
London, NW1 2PG  
Phone: 0203 447 9202  
E-mail: majid.hashemi@uclh.nhs.uk   
 
Mr Asif Muneer      
Urology Department 
University College Hospital 
Ground Floor Central   
250 Euston Road  
London, NW1 2PG  
Phone: 020 3447 9280 
E-mail: asif.muneer@uclh.nhs.uk  
 
Estimated start date: 1
st
 April 2013 
Estimate duration: 2 years 
 
10. Study Title: Urogenital function in morbidly obese men following bariatric surgery 
 
11. Project Background:  
Bariatric surgery is a gastrointestinal surgery that is intended to achieve weight loss and 
has been shown to elicit remission in Type 2 diabetes mellitus. Recently it has been 
shown that insulin resistance is decreased dramatically within a week following the 
surgery much before the weight loss is observed. Although the mechanisms for this 
acute effect on insulin resistance of the bariatric surgery are unknown, this presents 
itself as an unprecedented opportunity as a model to study the effect of insulin 
resistance recovery on diabetic complications independent of weight loss. Therefore our 
aim is to investigate the effect of bariatric surgery on urogenital function in morbidly 
obese men with and without type 2 diabetes. The erectile and urological function will be 
evaluated before and after the surgery. The assessment will be performed using 
validated and widely used questionnaires (International Index of Erectile Function [IIEF] 
and International Prostate Symptom Score [IPSS]). The post-surgery assessment will 
be at 4 weeks, 3 and 6 months after the surgery to distinguish the effect of the weight 
loss. We are seeking approval to utilise these two questionnaires (IIEF, IPSS). 
Moreover, the questionnaires will be totally anonymised. There will no additional 
intervention or change to the surgical procedure/patient care.  
  
12. Study Aims: 
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Aim:  
To investigate the impact of bariatric surgery on urogenital function in morbidly obese 
men.   
 
Objective:  
o Utilise and mine urogenital function and biomarker data from the research 
project on morbidly obese men undergoing elective bariatric surgery. 
o Analyse and present the above data. 
o Recommend further work based on the above analysis. 
 
13. Recruitment and Consent: 
c. Study population: Prospectively study for patients who have been listed for 
bariatric surgery for treatment of obesity and the patients are morbidly obese men 
with BMI more than 35. The populations will be recruited among patients who have 
been seen by Mr Majid Hashemi or one of his surgical team members at University 
College London Hospitals. We are hoping to recruit 30 patients per year.  
 
d. Specific Inclusion and Exclusion Criteria: 
iii. Inclusion criteria:  
d. Age 30 years old and above.   
e. Body Mass Index BMI 35 and above   
f. Listed for bariatric surgery 
g. No other serious illness for example cancer or neurodegenerative 
disease.  
iv. Exclusion criteria: 
d. Age  less than 30 years old 
e. Body Mass Index BMI less than 35  
f. Not eligible for bariatric surgery 
g. Other serious illness such as cancer or neurodegenerative disease 
a. Recruitment and Consenting Process: 
Those patients who have been seen and listed for surgery by Mr Hashemi or one 
of his surgical team and meet the inclusion and exclusion criteria will be given the 
patient information sheet and the consent form 4 weeks prior to the surgery and 4 
weeks, 3 and 6 months after the surgery. After the pre-assessment clinics (4 weeks 
before the surgery), consent form will be collected from the patient, if unsigned. If it 
is signed, it will be countersigned by a member of the surgical team. A copy of the 
signed consent form will be kept in the patient’s medical records, a copy will be 
given to the patient and a copy will be kept by the surgeon. Mr Majid Hashemi will 
be responsible for the recruitment and consenting process. 
 
b. Anonymisation: 
The study will be totally anonymised: The only data that will be transferred to 
Cranfield University are:  two questionnaires (IIEF, IPSS), age of the patient, BMI 
of the patient and date of each questionnaire. No subject identifiable data will be 
transferred. 
 
c. Sponsorship: 
This study is sponsored by UCLH. 
 
14. Study Methodology 
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This study will not change the surgical or medical care the patients receive in anyway. 
No additional tests or procedures are required. The questionnaires that will be collected 
would have been discarded otherwise. 
As soon as collected at the clinic or the operating theatre, the questionnaire will be 
placed in a folder and kept in the secured drawer at urology department, ground floor 
central of university college hospital. Each questionnaire will be accompanied by a brief 
note with date, age, BMI, IIEF and IPSS scores, Testosterone level, C-peptide level, 
Fasting blood glucose, fasting insulin, HbA1c level and diagnosis of diabetes miletus 
(see Appendix I). The questionnaires will then be transferred to Cranfield University 
within 24 hours. On arrival at Cranfield Health, the questionnaire will be given a unique 
subject number and the data on the accompanying note will be recorded electronically.  
The questionnaires will be processed for data analysis by using statistical tests that will 
be performed by using SPSS version 10. The questionnaires will be destroyed at the 
completion of the study. 
All questionnaires at the end of the study will be discarded by using local procedures.  
Dr Selim Cellek will be responsible for recording of the data on the accompanying note, 
the questionnaires storage and disposal at Cranfield University. 
15. Data analysis: 
Appropriate statistical tests which we commonly use for these types of experiments will 
be utilised throughout the study. When/if necessary, professional statistician will be 
consulted. 
 
16. Dissemination of information: 
The results of the study will be disseminated by: 
a. Presentation at international meetings such as but not limited to European 
Society for Sexual Medicine, European Association of Urology and Americal 
Urological Association. 
b. Publication in peer reviewed journals such as but not limited to Journal of 
Sexual Medicine, Journal of Urology and British Journal of Urology. 
The only patient-related data that will be used in these publications are patient’s age, 
BMI, scores of IPSS and IIEF. No subject identifiable data will be published.  
17. Ethical Issues Arising: 
Based on our previous experience with the use of questionnaires in basic research, we 
do not envisage any ethical issues arising. In previous similar studies, we have 
observed that the majority of the patients are comfortable in giving consent to such 
studies since no extra test will be taken and the study is totally anonymised. We will 
exclude patients who do not understand the information sheet which is based again on 
our previous experience with patients who had difficulty comprehending the information 
sheet usually due to language barriers. 
 
18. Data Protection: 
Consent forms will be scanned and the electronic copies will be stored in Mr Asif 
Muneer’s password protected UCLH computer in his secure office. Mr Asif Muneer will 
be responsible for storage of the consent forms. 
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No subject identifiable information will be transferred with the questionnaires. Only data 
that will be transferred are (see Appendix I): 
a. Date of the questionnaire 
b. Age of the patient 
c. BMI of the patient 
d. Disease of the patient (Diabetic or not) 
e. Questionnaires (IIEF, IPSS) scores 
f. Testosterone level 
g. Fasting blood glucose level 
h. HbA1c level 
These data will be recorded and kept electronically in a password-protected computer 
at Cranfield Health, Cranfield University. Dr Selim Cellek will be responsible for these 
data. 
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B.5 UCLH patient information sheet of urogenital function 
following bariatric surgery audit 
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B.6 Copy of approval letter from ethics board (Cranfield 
University Health Research Ethics Committee; CUHREC)  
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B.7 Copy of approval letter from Surgical Specialties at 
University College London Hospital  
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B.8 Copy of honorary contract from Surgical Specialties at 
University College London Hospital (page1) 
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B.9 Copy of honorary contract first extension from Surgical 
Specialties at University College London Hospital (page1)  
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B.10 Copy of honorary contract of second extension from 
Surgical Specialties at University College London Hospital 
(page1)  
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B.11 Copy of honorary contract of third extension from Surgical 
Specialties at University College London Hospital   
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Appendix C Supplementary data to Chapter 3 – Results  
C.1 Supplementary data to Section  3.1.7  
Table  5-1: List of definitions of the numbers in Figure  5-1 
1 Age 22 Eosinophil 43 SHBG 64 Hydrocele testis 
2 Weight (kg) 23 Basophils 44 T2DM 65 Smoker 
3 Height (cm) 24 FSH 45 Psoriatic arthritis 66 Overweight BMI ≥25 
4 BMI 25 TSH 46 Obstructive sleep 
apnoea 
67 Morbidly Obese BMI 
≥30 
5 Fasting blood 
glucose 
26 Free T4 47 Hypercholesterole
mia 
68 IIEF-EF 
6 HbA1c level 27 Alkaline 
phosphate 
48 Anxiety 69 IIEF-OF 
7 Prolactin test 28 Alkaline 
transaminase 
49 Depression 70 IIEF-SD 
8 Testosterone 
level 
29 Bilirubin total 50 Non-alcoholic fatty 
liver 
71 IIEF- IS 
9 WBC 30 Albumin 51 Gout 72 IIEF- OS 
10 RBC 31 LH 52 Hyperlipidaemia 73 IPSS-Inc. emptying 
11 Haemoglobin 32 Sodium 53 Irritable bowel 
syndrome 
74 IPSS- Frequency 
12 HCT 33 Potassium 54 Peyronie's disease 75 IPSS- Intermittency 
13 MCV 34 Creatinine 55 Fertility problem 76 IPSS- Urgency 
14 MCH 35 ESR 56 Proteinuria 77 IPSS- Weak stream 
15 MCHC 36 Urea 57 Right testicular 
atrophy 
78 IPSS- Straining 
16 RDW 37 Estimated GFR 58 Left testicular 
atrophy 
79 IPSS- Nocturia 
17 Platelet count 38 Cholesterol 59 Klinefelter 
syndrome 
80 IPSS- QoL 
18 MPV 39 Triglyceride 60 AIDS 81 IPSS total score 
19 Neutrophils 40 HDL 61 Hypertension   
20 Lymphocytes 41 LDL 62 Coughlan’s 
syndrome 
  
21 Monocytes 42 Cholesterol HDL 
ratio 
63 Asthma   
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Figure  5-1: Table of correlations between variables of the baseline characteristics audit  
(All correlations between variables are presented as grey dots where the p<0.05 )  
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Pearson correlation coefficient between biochemistry tests and IIEF, IPSS (N=60)      
IIEF/IPSS domains Correlation Prolactin Bilirubin total Sodium Estimated GFR HDL 
IIEF- EF Pearson correlation  -0.05 0.27 0.03 0.11 0.00 
p 0.71 0.03
* 
0.84 0.41 0.98 
IIEF-Orgasmic 
function 
Pearson correlation  0.01 0.13 0.11 0.23 0.16 
p 0.96 0.31 0.41 0.07 0.24 
IIEF- Sexual desire Pearson correlation  0.00 0.24 0.14 0.15 -0.04 
p 0.97 0.07 0.29 0.24 0.79 
IIEF- Intercourse 
satisfaction 
Pearson correlation  -0.05 0.25 0.09 0.13 0.07 
p 0.73 0.05 0.51 0.31 0.62 
IIEF- Overall 
satisfaction 
Pearson correlation  0.09 0.23 0.11 0.12 -0.16 
p 0.51 0.08 0.42 0.36 0.22 
IPSS- Incomplete 
emptying 
Pearson correlation  0.16 0.14 -0.03 -0.17 -0.22 
p 0.23 0.30 0.79 0.20 0.09 
IPSS- Frequency Pearson correlation  0.11 0.01 0.04 -0.17 -0.02 
p 0.41 0.94 0.77 0.19 0.91 
IPSS- Urgency Pearson correlation  0.07 0.05 -0.12 -0.29 -0.07 
p 0.57 0.70 0.37 0.02* 0.57 
IPSS- Weak-stream Pearson correlation  0.19 0.08 -0.10 -0.35 -0.23 
p 0.14 0.55 0.44  0.01*  0.08 
IPSS- Nocturia Pearson correlation  0.01 0.22 -0.04 -0.08 0.02 
p 0.95 0.09 0.75 0.56 0.89 
IPSS- QoL Pearson correlation  0.15 -0.12 -0.11 -0.08 -0.02 
p 0.25 0.37 0.40 0.55 0.90 
IPSS total score Pearson correlation  0.17 0.13 -0.07 -0.22 -0.14 
p 0.21 0.33 0.59 0.10 0.29 
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IIEF/IPSS domains Correlation Prolactin Bilirubin total Sodium Estimated GFR HDL 
Intermittency 
 
Spearman’s rho 0.07 0.24 -0.09 -0.15 -0.10 
p 0.59 0.06 0.46 0.22 0.42 
Straining 
 
Spearman’s rho 0.21 0.12 -0.01 -0.09 -0.03 
p 0.10 0.35 0.91 0.47 0.81 
 
Spearman’s rho correlation coefficient between biochemistry tests and IIEF, IPSS (N=60)     
Variables  IIEF-
EF 
IIEF-
OF 
IIEF-
SD 
IIEF-
IS 
IIEF-
OS 
IPSS-
Incomplete 
emptying 
Frequency Intermittency Urgency Weak 
stream 
Straining Nocturia QoL IPSS 
total 
score 
Fasting blood 
glucose 
rho -0.14 -0.18 -0.19 -0.14 0.06 0.05 0.08 -0.02 -0.10 0.20 -0.01 0.11 0.13 0.05 
p 0.29 0.17 0.16 0.29 0.66 0.71 0.53 0.90 0.43 0.12 0.94 0.39 0.32 0.68 
HbA1c rho -0.24 -0.18 -0.06 -0.14 0.07 -0.12 -0.06 -0.19 -0.21 0.01 -0.12 -0.07 -0.03 -0.11 
p 0.07 0.18 0.65 0.28 0.58 0.36 0.63 0.15 0.11 0.93 0.34 0.59 0.80 0.38 
Testosterone rho 0.36 0.42 0.26 0.33 0.06 0.07 -0.08 0.09 0.17 0.00 0.08 -0.01 0.01 0.06 
p <0.001 <0.001 0.04 0.01 0.65 0.59 0.55 0.49 0.20 0.98 0.55 0.91 0.93 0.66 
Free 
testosterone 
P 0.34 0.40 0.99 0.33 0.84 0.86 0.33 0.24 0.10 0.50 0.40 0.60 0.37 0.41 
rho 0.13 0.11 0.002 0.13 0.03 0.02 0.13 0.16 0.22 0.09 0.11 -0.07 0.12 0.11 
Bioavailable 
testosterone 
P 0.54 0.39 0.76 0.54 0.67 0.92 0.89 0.22 0.57 0.80 0.25 0.35 0.43 0.76 
rho 0.08 0.11 0.04 0.08 -0.06 -0.01 0.02 0.16 0.07 0.04 0.15 -0.12 0.10 0.04 
FSH rho 0.00 -0.06 -0.07 0.03 0.03 0.02 0.10 0.06 0.24 0.02 0.09 0.11 0.01 0.11 
p 0.97 0.64 0.57 0.83 0.85 0.91 0.46 0.67 0.06 0.86 0.49 0.40 0.97 0.41 
TSH rho -0.11 0.01 -0.05 -0.08 0.04 -0.10 0.07 0.10 0.03 0.01 0.01 0.02 -0.14 0.01 
p 0.42 0.92 0.72 0.55 0.77 0.45 0.58 0.44 0.83 0.95 0.93 0.88 0.30 0.96 
Free T4 rho 0.15 0.06 0.10 0.09 -0.06 0.21 0.00 0.25 0.14 0.05 0.20 0.06 0.31 0.14 
p 0.25 0.68 0.43 0.51 0.67 0.10 0.99 0.05 0.27 0.73 0.13 0.63 0.02 0.29 
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Variables  IIEF-
EF 
IIEF-
OF 
IIEF-
SD 
IIEF-
IS 
IIEF-
OS 
IPSS-
Incomplete 
emptying 
Frequency Intermittency Urgency Weak 
stream 
Straining Nocturia QoL IPSS 
total 
score 
Alkaline 
phosphate 
rho 0.01 0.04 -0.07 -0.01 0.09 0.16 0.23 0.06 0.24 0.11 0.02 0.14 0.05 0.17 
p 0.93 0.74 0.57 0.93 0.51 0.21 0.07 0.65 0.07 0.41 0.87 0.30 0.70 0.20 
Alkaline 
transaminase 
rho -0.12 -0.10 -0.05 -0.19 0.11 0.21 0.06 0.12 0.05 0.20 0.14 -0.06 -0.09 0.13 
p 0.37 0.45 0.68 0.14 0.41 0.11 0.66 0.36 0.73 0.13 0.29 0.63 0.49 0.34 
Albumin rho -0.02 -0.23 0.00 0.05 -0.07 -0.13 -0.07 -0.13 -0.14 -0.24 -0.10 -0.14 0.03 -0.16 
p 0.87 0.08 0.99 0.70 0.57 0.33 0.58 0.33 0.30 0.06 0.46 0.28 0.82 0.22 
LH rho 0.19 0.08 0.29 0.19 0.10 -0.13 -0.08 0.04 0.06 -0.05 0.19 -0.11 -0.01 -0.02 
p 0.14 0.52 0.02 0.15 0.45 0.33 0.53 0.76 0.66 0.68 0.16 0.40 0.92 0.88 
Potassium rho -0.02 0.05 0.09 -0.07 0.23 -0.17 -0.16 -0.31 -0.37 -0.07 -0.24 -0.25 -0.03 -0.25 
p 0.89 0.70 0.49 0.60 0.08 0.20 0.22 0.01 <0.001 0.60 0.07 0.05 0.83 0.06 
Creatinine rho 0.14 0.04 0.12 0.08 0.11 0.21 0.20 0.15 0.24 0.17 0.17 0.01 0.04 0.22 
p 0.28 0.78 0.38 0.55 0.42 0.11 0.13 0.24 0.07 0.18 0.20 0.92 0.76 0.09 
ESR rho -0.26 -0.29 -0.21 -0.28 -0.01 -0.01 -0.05 0.04 -0.10 0.27 0.05 0.12 0.07 0.08 
p 0.04 0.03 0.11 0.03 0.91 0.94 0.70 0.74 0.44 0.03 0.69 0.36 0.57 0.53 
Urea rho -0.11 -0.14 -0.02 -0.12 -0.06 -0.10 -0.02 -0.09 -0.14 0.01 -0.13 -0.20 -0.02 -0.11 
p 0.38 0.27 0.90 0.34 0.63 0.45 0.86 0.48 0.28 0.91 0.33 0.13 0.85 0.38 
Cholesterol rho -0.12 -0.20 0.08 -0.11 -0.20 -0.10 -0.13 -0.23 -0.24 -0.20 -0.25 -0.03 0.01 -0.20 
p 0.35 0.13 0.55 0.40 0.12 0.44 0.34 0.07 0.06 0.12 0.06 0.82 0.92 0.13 
Triglyceride rho -0.08 -0.02 -0.04 -0.11 0.21 0.03 -0.01 -0.12 0.02 0.14 -0.05 0.05 -0.03 0.02 
p 0.54 0.87 0.76 0.40 0.10 0.80 0.94 0.37 0.87 0.29 0.71 0.72 0.83 0.89 
LDL rho -0.06 -0.22 0.11 -0.09 -0.19 0.03 -0.04 -0.23 -0.16 -0.07 -0.26 -0.05 -0.01 -0.11 
p 0.62 0.09 0.39 0.50 0.15 0.84 0.78 0.08 0.21 0.59 0.05 0.69 0.95 0.38 
Cholesterol 
HDL ratio 
rho -0.02 -0.12 0.13 -0.05 0.05 0.13 0.01 -0.04 0.00 0.08 -0.14 0.05 0.00 0.04 
p 0.89 0.38 0.33 0.68 0.73 0.32 0.91 0.78 1.00 0.57 0.27 0.71 1.00 0.76 
SHBG rho -0.03 0.09 -0.05 0.10 -0.10 -0.18 -0.15 0.01 -0.01 -0.17 0.17 -0.04 0.00 -0.09 
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Variables  IIEF-
EF 
IIEF-
OF 
IIEF-
SD 
IIEF-
IS 
IIEF-
OS 
IPSS-
Incomplete 
emptying 
Frequency Intermittency Urgency Weak 
stream 
Straining Nocturia QoL IPSS 
total 
score 
p 0.82 0.48 0.73 0.45 0.47 0.18 0.26 0.95 0.93 0.20 0.20 0.75 0.98 0.48 
 
Spearman’s rho correlation coefficient between haematology tests and IIEF, IPSS (N=60)     
Variables IIEF-
EF 
IIEF-
OF 
IIEF-
SD 
IIEF-IS IIEF-
OS 
IPSS-Inc. 
emptying 
Frequency Intermittency Urgency Weak 
stream 
Straining Nocturia QoL IPSS 
total 
score 
WBC rho -0.21 -0.09 -0.20 -0.13 0.02 0.02 0.17 -0.04 -0.02 0.01 -0.01 0.04 -0.13 0.06 
p 0.11 0.51 0.13 0.34 0.90 0.86 0.21 0.75 0.91 0.92 0.97 0.76 0.33 0.66 
RBC rho 0.06 0.08 0.14 0.04 0.01 0.16 0.13 0.05 0.07 -0.06 0.07 0.00 0.00 0.05 
p 0.66 0.54 0.27 0.77 0.95 0.22 0.31 0.69 0.60 0.65 0.58 0.98 1.00 0.73 
Haemoglobin rho 0.07 0.11 0.12 0.03 0.01 0.13 0.11 -0.02 0.05 -0.15 -0.01 -0.13 -0.02 -0.02 
p 0.61 0.40 0.35 0.84 0.95 0.33 0.39 0.87 0.73 0.25 0.93 0.32 0.90 0.89 
HCT rho 0.00 0.16 0.09 -0.01 -0.05 0.02 0.09 -0.12 0.03 -0.18 -0.15 -0.10 -0.08 -0.08 
p 0.97 0.22 0.47 0.92 0.70 0.87 0.49 0.35 0.82 0.16 0.27 0.43 0.56 0.52 
MCV rho -0.21 -0.09 -0.23 -0.18 -0.19 -0.33 -0.07 -0.32 -0.06 -0.21 -0.38 -0.17 -0.18 -0.25 
p 0.10 0.51 0.08 0.18 0.15 0.01 0.61 0.01 0.63 0.10 <0.001 0.21 0.17 0.06 
MCH rho -0.18 -0.17 -0.15 -0.15 -0.13 -0.20 -0.06 -0.27 -0.09 -0.17 -0.29 -0.25 -0.10 -0.22 
p 0.18 0.20 0.27 0.24 0.32 0.12 0.65 0.04 0.50 0.20 0.02 0.06 0.44 0.09 
MCHC rho 0.12 0.08 0.30 0.07 0.14 0.29 0.08 0.06 -0.02 0.04 0.01 -0.20 -0.01 0.06 
p 0.36 0.56 0.02 0.59 0.29 0.03 0.55 0.67 0.90 0.76 0.93 0.14 0.92 0.65 
RDW rho -0.20 -0.03 -0.22 -0.23 -0.23 0.21 0.15 0.11 0.09 0.38 0.23 0.15 0.17 0.22 
p 0.12 0.80 0.09 0.08 0.08 0.10 0.24 0.38 0.50 <0.001 0.08 0.25 0.20 0.09 
Platelet rho 0.11 0.24 0.12 0.05 0.09 -0.09 -0.03 -0.19 -0.18 -0.05 -0.15 -0.06 0.01 -0.11 
p 0.42 0.07 0.37 0.68 0.47 0.50 0.80 0.14 0.16 0.73 0.24 0.67 0.92 0.40 
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Variables IIEF-
EF 
IIEF-
OF 
IIEF-
SD 
IIEF-IS IIEF-
OS 
IPSS-Inc. 
emptying 
Frequency Intermittency Urgency Weak 
stream 
Straining Nocturia QoL IPSS 
total 
score 
MPV rho 0.23 0.15 0.02 0.17 0.11 0.22 0.06 0.17 0.19 0.22 0.17 0.09 0.00 0.18 
p 0.08 0.26 0.90 0.19 0.41 0.09 0.67 0.19 0.15 0.08 0.18 0.50 0.97 0.16 
Neutrophils rho -0.17 0.09 -0.29 -0.20 -0.14 0.12 0.27 -0.01 0.24 0.05 -0.07 0.14 0.03 0.14 
p 0.19 0.51 0.02 0.13 0.30 0.38 0.04 0.97 0.06 0.71 0.60 0.29 0.84 0.27 
                                                                                                                          
Lymphocytes 
rho 0.12 0.21 0.02 0.01 0.09 0.14 0.28 0.09 0.09 0.09 0.06 0.01 -0.24 0.16 
p 0.37 0.10 0.89 0.93 0.48 0.27 0.03 0.48 0.48 0.51 0.67 0.93 0.06 0.22 
Monocytes rho 0.09 0.03 0.08 0.05 0.11 0.03 0.08 -0.03 -0.03 -0.09 -0.09 -0.07 -0.14 0.01 
p 0.52 0.84 0.55 0.72 0.40 0.80 0.56 0.80 0.81 0.49 0.52 0.59 0.29 0.97 
Eosinophil rho 0.26 0.07 0.11 0.27 0.17 0.05 0.10 0.16 0.12 0.02 0.12 -0.05 -0.21 0.09 
p 0.04 0.59 0.40 0.03 0.20 0.72 0.45 0.22 0.37 0.88 0.36 0.69 0.10 0.51 
Basophils rho 0.06 -0.18 -0.17 0.16 0.12 0.02 0.16 0.05 0.17 0.07 0.11 0.00 -0.12 0.08 
p 0.63 0.17 0.19 0.22 0.37 0.88 0.23 0.70 0.18 0.57 0.38 0.97 0.35 0.53 
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The correlations between smoker and IIEF, IPSS (N=60)      
Variables Correlation 
IIEF -Erectile function r -0.05 
p  0.72 
IIEF Orgasmic function r -0.04 
p  0.74 
IIEF Sexual desire r -0.06 
p  0.65 
IIEF Intercourse satisfaction r -0.07 
p  0.57 
IIEF Overall satisfaction r -0.03 
p  0.82 
Incomplete emptying r 0.00 
p  1.00 
Frequency r 0.26 
p  0.04
* 
Intermittency rho 0.01 
p  0.87 
Urgency r 0.06 
p  0.63 
Weak stream r 0.01 
p  0.95 
Straining rho -0.05 
p  0.71 
Nocturia r 0.02 
p  0.89 
QoL r -0.10 
p  0.43 
IPSS total score r 0.06 
p  0.66 
*
 Pearson correlation was significant at the 0.05 level 
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C.2 Supplementary data to section  3.2 
Examples of normality checking by histogram of BMI and EWL 
 Example of BMI distributions with IPSS- frequency over time 
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 Example of EWL distributions with IPSS- frequency over time 
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Changes in variables of ED and NO-ED groups across time  
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Variables at all time points 
ED No ED
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C.3 Supplement figures to section  3.2.8.  
 Time 1 (baseline)   
Table  5-2: Mann Whitney U test of all variables at baseline  
 Variable/Time Mean rank  Mann Whitney 
U test 
p 
ED NO-ED 
Erectile function  9.5 24.5 0.0 <0.001 
Orgasmic function 12.6 19.6 58.5 0.03 
Sexual desire 11.9 20.9 42.5 0.005 
Intercourse satisfaction 11.2 21.9 31.0 0.001 
Overall Satisfaction 11.4 21.6 35.0 0.002 
IPSS (total) 18.9 10.3 45.5 0.008 
BMI(Dos) 16.4 14.1 91.0 0.47 
BMI  15.9 14.8 100.0 0.73 
Blood glucose level 15.0 16.2 99.5 0.71 
HbA1c 15.2 15.9 102.5 0.81 
%EWL (Dos) 14.0 17.7 81.0 0.25 
 
 
Figure  5-2: Differences between variables of ED and NO-ED 
groups at time 1 (baseline)  
** 
Significant (p<0.01), 
* 
significant (p<0.05)  
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* ** 
** ** 
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 Time 2 (one month post-op)  
Table  5-3: Mann Whitney U test of all variables at time 2 
 Variable/Time Mean rank  Mann Whitney 
U test 
p 
ED NO-ED 
Erectile function 10.9 22.3 26.0 0.001 
Orgasmic function  11.8 21 42.0 0.004 
Sexual desire 12.7 19.5 59.0 0.035 
Intercourse satisfaction 12.1 20.4 48.5 0.011 
Overall satisfaction 12.0 20.7 45.5 0.007 
IPSS 18.0 11.6 61.5 0.048 
BMI 17.2 12.8 76.0 0.176 
Blood glucose level 14.5 16.9 90.5 0.457 
HbA1c 14.2 17.4 85.0 0.328 
%EWL 12.6 19.8 56.0 0.028 
 
 
Figure  5-3: Differences between variables of ED and NO-ED 
groups at time 2 
** 
Significant (p<0.01), 
* 
significant (p<0.05) 
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 Time 3 (three month post-op)  
Table  5-4: Mann Whitney U test of all variables at time 3 
 Variable/Time Mean rank  Mann Whitney 
U test 
p 
ED NO-ED 
Erectile function  11.6 21.3 38.5 0.003
 
Orgasmic function 11.8 20.9 43.0 0.003 
Sexual desire  13.5 18.4 73.0 0.131 
Intercourse satisfaction  13.3 18.6 70.0 .104 
Overall satisfaction 12.5 20.0 54.0 0.018 
IPSS (total) 16.4 14.1 91.5 0.483 
BMI 15.1 16.2 100.0 0.735 
Blood glucose level 15.7 15.2 104.0 0.865 
HbA1 14.7 16.7 93.5 0.537 
%EWL 17.2 12.9 77.0 0.189 
 
 
Figure  5-4: Differences between variables of ED and NO-ED 
groups at time 3 
* Significant (p<0.02)  
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 Time 4 (four month post-op)  
Table  5-5: Mann Whitney U test of all variables at time 4 
 Variable/Time Mean rank  Mann Whitney 
U test 
p 
ED NO-ED 
Erectile function 11.7 21.2 39.5 0.003 
Orgasmic function 14.1 17.5 83.0 0.25 
Sexual desire 14.1 17.5 83.0 0.25 
Intercourse satisfaction 13.7 18.2 75.0 0.14 
Overall satisfaction 13.8 18.0 77.5 0.17 
IPSS (total) 16.8 13.5 84.5 0.31 
BMI 14.6 16.8 92.0 0.50 
Blood glucose level 15.8 15.1 103.5 0.85 
HbA1c 13.9 17.9 78.5 0.21 
%EWL 17.3 12.8 76.0 0.18 
 
 
Figure  5-5: Differences between variables of ED and NO-ED 
groups at time 4 
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